Updated on 2023/06/21

写真a

 
NAKASHIMA Yasuhiro
 
Organization
Graduate School of Medicine Department of Clinical Medical Science Lecturer
School of Medicine Department of Medical Science
Title
Lecturer
Affiliation
Institute of Medicine

Position

  • Graduate School of Medicine Department of Clinical Medical Science 

    Lecturer  2022.04 - Now

  • School of Medicine Department of Medical Science 

    Lecturer  2022.04 - Now

Degree

  • 博士（医学） （ Osaka City University ）

Research Areas

  • Life Science / Hematology and medical oncology

  • Life Science / Hematology and medical oncology

Research Interests

  • 造血幹細胞移植、免疫監視機構

  • 造血幹細胞移植、免疫監視機構

  • leukemia

  • immunosenescence

Research subject summary

  • 造血幹細胞移植
    移植後免疫再構築

Research Career

  • 移植後エンドキサンを用いた造血幹細胞移植後の免疫再構築

    Individual

    2015.04 - 2020.03 

Professional Memberships

  • 日本免疫学会

      Domestic

  • 日本造血細胞移植学会

      Domestic

  • 日本血液学会

      Domestic

  • 日本内科学会

      Domestic

  • 日本造血細胞移植学会

  • 日本血液学会

  • 日本内科学会

  • 日本免疫学会

▼display all

Job Career (off-campus)

  • Osaka City University   Graduate School of Medicine Clinical Medicine Course

    2014.07 - Now

  • Osaka City University

    2012

Papers

  • Sinusoidal obstruction syndrome associated with disseminated toxoplasmosis involving the liver after allogeneic hematopoietic stem cell transplantation: A case report.

    Makuuchi Y, Tanaka S, Koh H, Niki M, Norose K, Nakaya Y, Ido K, Sakatoku K, Kuno M, Harada N, Takakuwa T, Hirose A, Okamura H, Nishimoto M, Nakashima Y, Nakamae M, Hikosaka K, Kakeya H, Ohsawa M, Hino M, Nakamae H

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   2023.05（ ISSN:1341-321X ）

    　More details

  • Effect of graft cell dose on second transplantation from a haploidentical donor with post-transplantation cyclophosphamide for relapsed/refractory acute leukemia.

    Nakaya Y, Nakamae H, Harada N, Okamura H, Sakatoku K, Ido K, Makuuchi Y, Kuno M, Takakuwa T, Hirose A, Nakamae M, Nishimoto M, Nakashima Y, Koh H, Hino M

    Bone marrow transplantation   2023.04（ ISSN:0268-3369 ）

    　More details

  • Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.

    Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y

    British journal of haematology   2023.04（ ISSN:0007-1048 ）

    　More details

  • Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.

    Makuuchi Y, Nakashima Y, Nishimoto M, Koh H, Hino M, Nakamae H

    Experimental hematology   2023.04（ ISSN:0301-472X ）

    　More details

  • Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.

    Makuuchi Y, Nakashima Y, Nishimoto M, Koh H, Hino M, Nakamae H

    Experimental hematology   2023.04（ ISSN:0301-472X ）

    　More details

  • Two cases of eosinophilic gastrointestinal disorder due to newly appearing food allergies after cord blood transplantation.

    Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nishimoto M, Nakashima Y, Koh H, Sakaida M, Tanaka S, Kuwae Y, Higashimori A, Tanaka F, Ohsawa M, Fujiwara Y, Hino M, Nakamae H

    Transplant immunology   77   101781   2023.04（ ISSN:0966-3274 ）

    　More details

  • Rhinovirus/enterovirus identification by electron microscopy in lower respiratory tract infection in a patient with relapsed myelodysplastic syndrome after allogeneic hematopoietic cell transplantation and donor lymphocyte infusion.

    Harada N, Nakashima Y, Sakaida M, Mukai D, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nishimoto M, Koh H, Ohsawa M, Hino M, Nakamae H

    Transplant immunology   77   101792   2023.04（ ISSN:0966-3274 ）

    　More details

  • Fulminant Metastatic Cellulitis Caused by Stenotrophomonas Maltophilia Infection and Subsequent Candida Parapsilosis Fungemia After Cord Blood Transplantation.

    Takagi I, Harada N, Niki M, Yamada K, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nishimoto M, Nakashima Y, Koh H, Kakeya H, Hino M, Nakamae H

    Transplantation proceedings   55 ( 3 )   706 - 710   2023.04（ ISSN:0041-1345 ）

    　More details

  • Ibrutinib Induces a Dramatic Improvement for Idiopathic Refractory Ascites Following Allogeneic Hematopoietic Cell Transplantation

    Tazoe Kumiyo, Nishimoto Mitsutaka, Yamamoto Akira, Makuuchi Yosuke, Kuno Masatomo, Okamura Hiroshi, Nakashima Yasuhiro, Tanaka Sayaka, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    Internal Medicine   advpub ( 0 )   2023.02（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    <p>We herein report a case of idiopathic refractory ascites following allogeneic hematopoietic cell transplantation that was successfully treated with ibrutinib. A 39-year-old man presented with massive transudative ascites. Despite a high portal venous pressure, the liver histology showed traces of alloreactivity inconsistent with veno-occlusive disease/sinusoidal obstructive syndrome. Ibrutinib was administered for ascites possibly secondary to portal hypertension associated with the alloreactivity. The ascites dramatically improved, and the portal venous pressure was reduced. This case may help clarify the mechanism through which refractory ascites develops after allogeneic hematopoietic cell transplantation and establish appropriate treatment protocols. </p>

    DOI： 10.2169/internalmedicine.1139-22

    PubMed

  • Ibrutinib Induces a Dramatic Improvement for Idiopathic Refractory Ascites Following Allogeneic Hematopoietic Cell Transplantation

    Tazoe Kumiyo, Nishimoto Mitsutaka, Yamamoto Akira, Makuuchi Yosuke, Kuno Masatomo, Okamura Hiroshi, Nakashima Yasuhiro, Tanaka Sayaka, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    Internal Medicine   advpub ( 0 )   2023.02（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    <p>We herein report a case of idiopathic refractory ascites following allogeneic hematopoietic cell transplantation that was successfully treated with ibrutinib. A 39-year-old man presented with massive transudative ascites. Despite a high portal venous pressure, the liver histology showed traces of alloreactivity inconsistent with veno-occlusive disease/sinusoidal obstructive syndrome. Ibrutinib was administered for ascites possibly secondary to portal hypertension associated with the alloreactivity. The ascites dramatically improved, and the portal venous pressure was reduced. This case may help clarify the mechanism through which refractory ascites develops after allogeneic hematopoietic cell transplantation and establish appropriate treatment protocols. </p>

    DOI： 10.2169/internalmedicine.1139-22

    PubMed

  • Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation(タイトル和訳中)

    Nakaya Yosuke, Nakashima Yasuhiro, Harada Naonori, Yamada Koichi, Makuuchi Yosuke, Kuno Masatomo, Takakuwa Teruhito, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Koh Hideo, Nakagama Yu, Kido Yasutoshi, Kanno Takayuki, Suzuki Tadaki, Nakamae Hirohisa, Kakeya Hiroshi, Hino Masayuki

    Journal of Infection and Chemotherapy   29 ( 2 )   223 - 227   2023.02（ ISSN:1341-321X ）

  • Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

    Nakaya Y, Nakashima Y, Harada N, Yamada K, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nanno S, Nishimoto M, Koh H, Nakagama Y, Kido Y, Kanno T, Suzuki T, Nakamae H, Kakeya H, Hino M

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   29 ( 2 )   223 - 227   2023.02（ ISSN:1341-321X ）

    　More details

  • Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation.

    Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nishimoto M, Nakashima Y, Koh H, Bingo M, Higashimori A, Fujiwara Y, Hino M, Nakamae H

    Annals of hematology   101 ( 11 )   2567 - 2569   2022.11（ ISSN:0939-5555 ）

    　More details

  • Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation.

    Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nishimoto M, Nakashima Y, Koh H, Bingo M, Higashimori A, Fujiwara Y, Hino M, Nakamae H

    Annals of hematology   101 ( 11 )   2567 - 2569   2022.11（ ISSN:0939-5555 ）

    　More details

  • BNT162b2 COVID-19ワクチン接種後に温式自己免疫性溶血性貧血とIgM-M蛋白血症を発症した脾辺縁帯リンパ腫

    曽我部 信広, 久野 雅智, 中釜 悠, 幕内 陽介, 原田 尚憲, 高桑 輝人, 岡村 浩史, 廣瀬 朝生, 西本 光孝, 中嶋 康博, 康 秀男, 中前 美佳, 城戸 康年, 中前 博久, 日野 雅之

    臨床血液   63 ( 10 )   1379 - 1385   2022.10（ ISSN:0485-1439 ）

    　More details

    新型コロナウイルス(SARS-CoV-2)に対するmRNA COVID-19ワクチン接種後に自己免疫性血球減少を発症することが知られているが,成熟B細胞腫瘍患者のワクチン接種が腫瘍随伴症状へ与える影響を調べた報告はない。症例は71歳男性。数年前に成熟B細胞腫瘍を疑う症状があったが自然軽快し経過観察されていた。BNT162b2 mRNA COVID-19ワクチン2回目接種10日後に温式自己免疫性溶血性貧血を発症した。貧血はステロイドで改善したが,脾腫,IgM-M蛋白血症,腎障害が増悪した。診断・治療目的に脾臓摘出術を施行し,脾辺縁帯リンパ腫と診断され,M蛋白血症,腎障害は改善した。本症例でSARS-CoV-2特異的抗体の獲得は障害されていた。ワクチン接種後の非特異的な免疫賦活が,成熟B細胞腫瘍の腫瘍随伴症状を増悪させる可能性が示唆されたが,病態解明のためにさらなる症例集積が必要である。(著者抄録)

  • 白血病マウスモデルにおけるロペグインターフェロンα-2bの癌細胞に対する免疫調節活性と直接活性(Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia)

    Sakatoku Kazuki, Nakashima Yasuhiro, Nagasaki Joji, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    Cancer Science   113 ( 7 )   2246 - 2257   2022.07（ ISSN:1347-9032 ）

    　More details

    マウスB細胞白血病細胞株BA-1を用いたマウス白血病モデルに対するモノPEG化αインターフェロンであるロペグインターフェロンα-2b(ropeg)の抗腫瘍効果を検討した。ropeg療法は、白血病マウスでは生存期間を有意に延長し、一部のマウスでは長期寛解をもたらした。従来のインターフェロンα治療では、生存期間が僅かに延長しただけで、全てのマウスが死亡した。腫瘍に対する直接的な効果を確認するために、白血病発症後のインターフェロンα受容体1ノックアウトマウスにropegを投与したところ、マウスの生存期間は僅かに延長したが、全てのマウスが死亡した。In vivoにおけるCD4+またはCD8+T-細胞の枯渇がropegの治療効果を著しく低下させたことから、ropegの宿主養子免疫刺激作用が腫瘍細胞抑制の主要なメカニズムであることが示唆された。長期寛解状態にあるマウスは、腫瘍の再チャレンジ後でも白血病を発症することはなかった。再チャレンジ腫瘍の拒絶反応は、CD4+とCD8+の両方のT細胞を生体内で除去した場合にのみキャンセルされたことから、免疫学的記憶においてそれぞれのT細胞群が独立して機能することが示唆された。

  • Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.

    Takakuwa T, Okayama Y, Nakamae H, Kuno M, Makuuchi Y, Harada N, Okamura H, Nishimoto M, Nakashima Y, Koh H, Hino M

    Annals of hematology   101 ( 7 )   1609 - 1610   2022.07（ ISSN:0939-5555 ）

    　More details

  • Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia.

    Sakatoku K, Nakashima Y, Nagasaki J, Nishimoto M, Hirose A, Nakamae M, Koh H, Hino M, Nakamae H

    Cancer science   113 ( 7 )   2246 - 2257   2022.07（ ISSN:1347-9032 ）

    　More details

  • Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.

    Takakuwa T, Okayama Y, Nakamae H, Kuno M, Makuuchi Y, Harada N, Okamura H, Nishimoto M, Nakashima Y, Koh H, Hino M

    Annals of hematology   101 ( 7 )   1609 - 1610   2022.07（ ISSN:0939-5555 ）

    　More details

  • Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia.

    Sakatoku K, Nakashima Y, Nagasaki J, Nishimoto M, Hirose A, Nakamae M, Koh H, Hino M, Nakamae H

    Cancer science   113 ( 7 )   2246 - 2257   2022.07（ ISSN:1347-9032 ）

    　More details

  • Phagocytosis of Mature Granulocytes by Bone Marrow Macrophages in an Elderly Man with Adult-Onset Primary Autoimmune Neutropenia.

    Nishimoto M, Nakane T, Koh H, Nakashima Y, Yamamura R, Nakamae H, Hino M, Ohta K

    Hematology reports   14 ( 2 )   165 - 171   2022.05（ ISSN:2038-8322 ）

    　More details

  • Phagocytosis of Mature Granulocytes by Bone Marrow Macrophages in an Elderly Man with Adult-Onset Primary Autoimmune Neutropenia.

    Nishimoto M, Nakane T, Koh H, Nakashima Y, Yamamura R, Nakamae H, Hino M, Ohta K

    Hematology reports   14 ( 2 )   165 - 171   2022.05（ ISSN:2038-8322 ）

    　More details

  • チロシンキナーゼ阻害薬を用いた慢性骨髄性白血病治療下での心血管有害事象に対し、臨床検査パラメータによる予測能(Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors)

    Nakamae Mika, Nakamae Hirohisa, Hashimoto Mika, Koh Hideo, Nakashima Yasuhiro, Hirose Asao, Hino Masayuki

    International Journal of Hematology   115 ( 3 )   329 - 335   2022.03（ ISSN:0925-5710 ）

    　More details

    慢性骨髄性白血病(CML)の治療に用いられる、チロシンキナーゼ阻害薬(TKI)のオフターゲット効果により生じる心血管有害事象(CAE)に対し、最適なモニタリング法について検討した。TKI投与を受けているCML患者74例(男性46例、女性28例、年齢21～91歳)を対象に、足関節上腕血圧比(ABI)、心臓足首血管指数(CAVI)、頸動脈エコー、心電図等の様々な心血管パラメータを包括的に評価することで、CAEのモニタリングと予測を試みた。その結果、C統計量により、ABIとCAVIを追加することで、確立されたリスク因子モデルの予測能が有意に上昇し、高血圧と喫煙歴および脂質異常症のモデル1では0.680と0.817、高血圧と脂質異常症および糖尿病のモデル2では0.685と.0.830、年齢と高血圧および脂質異常症と糖尿病のモデル3では0.737と0.818であることが確認された。だが、単独の心血管パラメータを用いて確立したリスク因子モデルの予測能に関しては、改善することは出来なかった。以上より、確立されたリスク因子モデルにABIとCAVIを併用した評価を追加することにより、CAE予測が改善され、TKI治療下にあるCML患者の臨床管理に有用な指標となり得ることが示唆された。

  • Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.

    Nakamae M, Nakamae H, Hashimoto M, Koh H, Nakashima Y, Hirose A, Hino M

    International journal of hematology   115 ( 3 )   329 - 335   2022.03（ ISSN:0925-5710 ）

    　More details

  • Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.

    Nakamae M, Nakamae H, Hashimoto M, Koh H, Nakashima Y, Hirose A, Hino M

    International journal of hematology   115 ( 3 )   329 - 335   2022.03（ ISSN:0925-5710 ）

    　More details

  • Delayed immune-related neutropenia with hepatitis by pembrolizumab.

    Nakako S, Nakashima Y, Okamura H, Tani Y, Ueda T, Makuuchi Y, Kuno M, Takakuwa T, Nishimoto M, Koh H, Nakamae H, Hino M

    Immunotherapy   14 ( 2 )   101 - 105   2022.02（ ISSN:1750-743X ）

    　More details

  • Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

    Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I

    Japanese journal of clinical oncology   52 ( 1 )   29 - 38   2022.01（ ISSN:0368-2811 ）

    　More details

  • 急速にMGUSから多発性骨髄腫に進行し多臓器不全を呈した原発性アミロイドーシス

    田添 久実代, 高桑 輝人, 幕内 陽介, 久野 雅智, 原田 尚憲, 岡村 浩史, 西本 光孝, 康 秀男, 中嶋 康博, 中前 博久, 日野 雅之

    臨床血液   63 ( 1 )   31 - 36   2022.01（ ISSN:0485-1439 ）

    　More details

    意義不明の単クローン性免疫グロブリン血症(MGUS)は通常無症候性であり無治療経過観察が標準治療であるが,年に1.5%の頻度で骨髄腫関連腫瘍に進行する。病勢進行の判断が一般的な検査では困難な場合もあり,今回長期間無症状で,突然の腎機能障害を契機に多発性骨髄腫への病勢進行が判明したMGUSの症例を報告する。症例は66歳女性。IgA-κ型のMGUSの診断に至ってから8年後,急激な腎機能障害を認めて持続的血液濾過透析を要した。精査の結果IgA-κ型の多発性骨髄腫の診断に至り,化学療法が奏効せず,敗血症を合併して第19病日に死亡した。その後,病理解剖で全身アミロイドーシスおよび黄色ブドウ球菌による多発膿瘍の合併が判明した。MGUSの病勢進行のリスクとして遊離軽鎖κ/λ比の異常やM蛋白がIgG以外であることが報告されている。これらのリスクを有する症例では早期診断のために常に病勢進行の可能性を念頭において注意深く観察を行うことが重要である。(著者抄録)

  • 寛解導入療法に非適応である日本人の未治療急性骨髄性白血病患者におけるベネトクラクス+アザシチジン併用療法(Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy)

    Yamamoto Kazuhito, Shinagawa Atsushi, DiNardo Courtney D., Pratz Keith W., Ishizawa Kenichi, Miyamoto Toshihiro, Komatsu Norio, Nakashima Yasuhiro, Yoshida Chikashi, Fukuhara Noriko, Usuki Kensuke, Yamauchi Takahiro, Asada Noboru, Asou Norio, Choi Ilseung, Miyazaki Yasushi, Honda Hideyuki, Okubo Sumiko, Kurokawa Misaki, Zhou Ying, Zha Jiuhong, Potluri Jalaja, Matsumura Itaru

    Japanese Journal of Clinical Oncology   52 ( 1 )   29 - 38   2022.01（ ISSN:0368-2811 ）

    　More details

    強力な寛解導入療法の適応とならない未治療の急性骨髄性白血病(AML)患者を対象に、ベネトクラクス(VEN)+アザシチジン(AZA)の併用療法を評価した国際共同第3相試験(VIALE-A試験)における日本人患者のサブグループ解析を行った。日本人AML患者をVEN+AZA群24例(年齢68～85歳)またはプラセボ-AZA群13例(年齢67～86歳)に無作為に割り付けた。追跡期間の中央値は16.3ヵ月(範囲1.0～20.3)であった。全生存期間中央値は、VEN+AZA群では未到達であった(ハザード比0.409、95%CI 0.151～1.109)。全生存推定値は、VEN+AZA群でプラセボ-AZA群に比べて、12ヵ月(67%と46%)および18ヵ月(57%と31%)の時点で高かった。複合完全寛解率(完全寛解[CR]+血球数回復が不完全な完全寛解[CRi])は、VEN+AZA群で67%、プラセボ-AZA群で15%であった。主な有害事象として、VEN+AZA群とプラセボ-AZA群で、発熱性好中球減少症(79%と39%)、血小板減少症(54%と77%)、便秘(54%と54%)、食欲減退(54%と38%)が認められた。VEN+AZA群の1例が投与中止に至ったグレード4の発熱性好中球減少症を発症した。以上より、VIALE-A試験の日本人サブグループで試験全体と同等の安全性および有効性が示された。

  • HLA一致血縁/非血縁同種造血幹細胞移植後のGVHD予防を目的とした移植後シクロホスファミドとタクロリムスの併用療法に関する第II相臨床試験(A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation)

    Nakamae Hirohisa, Nakane Takahiko, Okamura Hiroshi, Koh Hideo, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nishimoto Mitsutaka, Kuno Masatomo, Makuuchi Yosuke, Harada Naonori, Takakuwa Teruhito, Hino Masayuki

    International Journal of Hematology   115 ( 1 )   77 - 86   2022.01（ ISSN:0925-5710 ）

    　More details

    HLA一致血縁/非血縁同種造血幹細胞移植後の移植片対宿主病(GVHD)予防のためのシクロホスファミド(PTCy)とカルシニューリン阻害剤であるタクロリムス(TAC)の併用の安全性と有効性を前向きに検討した。血液悪性腫瘍患者39例は、HLA一致血縁ドナー(MRD)(年齢30～65歳)またはHLA一致非血縁ドナー(MUD)(年齢29～66歳)から同種造血幹細胞移植を受けた。移植後100日目におけるグレードII～IVおよびIII～IVの急性GVHDの累積発生率は、MRD群でそれぞれ18%および5.9%、MUD群でそれぞれ18%および9.1%であった。1年後の中等度または重度の慢性GVHDの累積発生率は、MRD群、MUD群でそれぞれ12%、9.1%であった。MRD群とMUD群の1年全生存率はそれぞれ88%と64%で、1年GVHDがない無再発生存率はそれぞれ59%と50%であった。以上より、HLA一致造血幹細胞移植後に、より強度の低い2剤併用(PT/CyとTAC)によるGVHD予防が実行可能である可能性が示唆された。

  • High-Dose Chemotherapy With Autologous Stem Cell Transplantation in a Case of Refractory Peripheral T Cell Lymphoma With Tracheoesophageal Fistula: A Case Report.

    Hayashi T, Nakashima Y, Nishimoto M, Nanno S, Naka R, Gyobu K, Lee S, Okamoto S, Hino M, Nakamae H

    Transplantation proceedings   54 ( 1 )   189 - 192   2022.01（ ISSN:0041-1345 ）

    　More details

  • HLA一致血縁/非血縁同種造血幹細胞移植後のGVHD予防を目的とした移植後シクロホスファミドとタクロリムスの併用療法に関する第II相臨床試験(A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation)

    Nakamae Hirohisa, Nakane Takahiko, Okamura Hiroshi, Koh Hideo, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nishimoto Mitsutaka, Kuno Masatomo, Makuuchi Yosuke, Harada Naonori, Takakuwa Teruhito, Hino Masayuki

    International Journal of Hematology   115 ( 1 )   77 - 86   2022.01（ ISSN:0925-5710 ）

    　More details

    HLA一致血縁/非血縁同種造血幹細胞移植後の移植片対宿主病(GVHD)予防のためのシクロホスファミド(PTCy)とカルシニューリン阻害剤であるタクロリムス(TAC)の併用の安全性と有効性を前向きに検討した。血液悪性腫瘍患者39例は、HLA一致血縁ドナー(MRD)(年齢30～65歳)またはHLA一致非血縁ドナー(MUD)(年齢29～66歳)から同種造血幹細胞移植を受けた。移植後100日目におけるグレードII～IVおよびIII～IVの急性GVHDの累積発生率は、MRD群でそれぞれ18%および5.9%、MUD群でそれぞれ18%および9.1%であった。1年後の中等度または重度の慢性GVHDの累積発生率は、MRD群、MUD群でそれぞれ12%、9.1%であった。MRD群とMUD群の1年全生存率はそれぞれ88%と64%で、1年GVHDがない無再発生存率はそれぞれ59%と50%であった。以上より、HLA一致造血幹細胞移植後に、より強度の低い2剤併用(PT/CyとTAC)によるGVHD予防が実行可能である可能性が示唆された。

  • High-Dose Chemotherapy With Autologous Stem Cell Transplantation in a Case of Refractory Peripheral T Cell Lymphoma With Tracheoesophageal Fistula: A Case Report.

    Hayashi T, Nakashima Y, Nishimoto M, Nanno S, Naka R, Gyobu K, Lee S, Okamoto S, Hino M, Nakamae H

    Transplantation proceedings   54 ( 1 )   189 - 192   2022.01（ ISSN:0041-1345 ）

    　More details

  • Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.

    Ido K, Koh H, Hirose A, Seto T, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nanno S, Nakamae M, Nishimoto M, Nakashima Y, Hino M, Nakamae H

    Transplantation and cellular therapy   28 ( 1 )   20.e1 - 20.e10   2022.01（ ISSN:26666367 ）

    　More details

  • Correction to: A phase II study of post‑transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA‑matched related/unrelated allogeneic hematopoietic stem cell transplantation.

    Nakamae H, Nakane T, Okamura H, Koh H, Nakashima Y, Hirose A, Nakamae M, Nishimoto M, Kuno M, Makuuchi Y, Harada N, Takakuwa T, Hino M

    International journal of hematology   115 ( 1 )   146   2022.01（ ISSN:0925-5710 ）

    　More details

  • A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies.

    Nakamae H, Okamura H, Hirose A, Koh H, Nakashima Y, Nakamae M, Nishimoto M, Makuuchi Y, Kuno M, Harada N, Takakuwa T, Hino M

    Cell transplantation   31   9636897221112098   2022.01（ ISSN:0963-6897 ）

    　More details

  • A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.

    Nakamae H, Nakane T, Okamura H, Koh H, Nakashima Y, Hirose A, Nakamae M, Nishimoto M, Kuno M, Makuuchi Y, Harada N, Takakuwa T, Hino M

    International journal of hematology   115 ( 1 )   77 - 86   2022.01（ ISSN:0925-5710 ）

    　More details

  • Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort.

    Goto H, Ogawa C, Iida H, Horibe K, Oh I, Takada S, Maeda Y, Minami H, Nakashima Y, Morris JD, Kormany W, Chen Y, Miyamoto T

    Acta haematologica   145 ( 6 )   592 - 602   2022（ ISSN:0001-5792 ）

    　More details

  • Warm autoimmune hemolytic anemia and IgM-monoclonal gammopathy following BNT162b2 COVID-19 vaccine in a patient with splenic marginal zone lymphoma

    SOGABE Nobuhiro, KUNO Masatomo, NAKAGAMA Yu, MAKUUCHI Yosuke, HARADA Naonori, TAKAKUWA Teruhito, OKAMURA Hiroshi, HIROSE Asao, NISHIMOTO Mitsutaka, NAKASHIMA Yasuhiro, KOH Hideo, NAKAMAE Mika, KIDO Yasutoshi, NAKAMAE Hirohisa, HINO Masayuki

    Rinsho Ketsueki   63 ( 10 )   1379 - 1385   2022（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    <p>There is currently no evidence that a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine might be associated with the development of autoimmune hemolytic anemia or disease progression in patients with mature B-cell neoplasm. Our patient was a 71-year-old man with indolent mature B-cell neoplasm who had been monitored for many years without treatment. After receiving the second dose of the BNT162b2 mRNA COVID-19 vaccine, he developed severe warm autoimmune hemolytic anemia. Although steroid therapy improved his anemia, he continued to develop IgM-monoclonal gammopathy, renal insufficiency, and splenomegaly. He was diagnosed with splenic marginal zone lymphoma after undergoing splenectomy. The splenectomy improved the patient’s symptoms. We assessed his SARS-CoV-2 specific antibody response, but the patient’s serologic response to the vaccine was impaired. In patients with mature B-cell neoplasm, a non-specific immune response after vaccination might be associated with paraneoplastic syndromes.</p>

    DOI： 10.11406/rinketsu.63.1379

    PubMed

  • AL amyloidosis presenting with fluminant multiorgan failure accompanied by rapid progression from MGUS to multiple myeloma

    TAZOE Kumiyo, TAKAKUWA Teruhito, MAKUUCHI Yosuke, KUNO Masatomo, HARADA Naonori, OKAMURA Hiroshi, NISHIMOTO Mitsutaka, KOH Hideo, NAKASHIMA Yasuhiro, NAKAMAE Hirohisa, HINO Masayuki

    Rinsho Ketsueki   63 ( 1 )   31 - 36   2022（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    <p>Monoclonal gammopathy of undermined significance (MGUS) is usually asymptomatic, and untreated follow-up is the standard treatment. However, MGUS progresses to multiple myeloma or related malignancy at a frequency of 1.5% per year. It is sometimes difficult to diagnose the progression of the disease via usual examinations. We herein report a case wherein rapid renal dysfunction led to a diagnosis of disease progression to multiple myeloma in a patient with MGUS that was asymptomatic for a long time. A 66-year-old woman developed rapid renal dysfunction requiring continuous hemodiafiltration 8 years after the diagnosis of IgA-κ type MGUS. A complete examination led to the diagnosis of IgA-κ type multiple myeloma. Chemotherapy was not effective, and she died due to sepsis on the 19th day of admission. A pathological autopsy revealed systemic amyloidosis and multiple abscesses positive for <i>Staphylococcus aureus</i>. An abnormal free light chain κ/λ ratio and M protein other than IgG are reportedly risk factors of disease progression of MGUS. In cases with these risk factors, it is important to always keep in mind the possibility of disease progression and to monitor the patient carefully for an early diagnosis.</p>

    DOI： 10.11406/rinketsu.63.31

    PubMed

    CiNii Article

  • 未治療の免疫性血小板減少症患者におけるCD19+ CD24high CD38high制御性B細胞およびプレ胚中心B細胞の増加は、活性化した自己免疫を反映し、将来の治療反応を予測する(Increasing numbers of CD19+CD24high CD38high regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia)

    Hayashi Tetsuya, Nakamae Hirohisa, Takeda Shinichi, Nakashima Yasuhiro, Koh Hideo, Nishimoto Mitsutaka, Okamura Hiroshi, Nanno Satoru, Makuuchi Yosuke, Kuno Masatomo, Nakamae Mika, Hirose Asao, Hino Masayuki

    International Journal of Hematology   114 ( 5 )   580 - 590   2021.11（ ISSN:0925-5710 ）

    　More details

    免疫性血小板減少症(ITP)の病態をさらに解明するため、未治療ITP患者の末梢血中のリンパ球サブセットとサイトカイン血清レベルや血小板関連IgG(PAIgG)抗体価との関連を検討した。ITP患者では、健常対照者と比較して、CD19+ CD24high CD38high制御性B細胞、プレ胚中心B細胞、およびプラズマブラスト様B細胞の割合が有意に高かった。制御性B細胞およびプレ胚中心B細胞の絶対数は、二次治療が必要なITP患者で有意に高かった。さらに、血清中の腫瘍壊死因子ファミリーに属するB細胞活性化因子腫瘍壊死因子(BAFF)レベルおよび血小板関連免疫グロブリンG抗体価は、制御性B細胞、プレ胚中心B細胞、および自己応答性B細胞の細胞数と正の相関があった。血清インターフェロンα(IFNα)レベルは、自己応答性B細胞数の多いITP患者4例で上昇していた。以上より、制御性B細胞とプレ胚中心B細胞の増加は、BAFFやIFNαによって活性化される自己免疫を反映している可能性があり、未治療ITP患者におけるB細胞サブセットの評価は治療効果を予測する可能性が示唆された。

  • Increasing numbers of CD19 + CD24(high)CD38(high) regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia.

    Hayashi T, Nakamae H, Takeda S, Nakashima Y, Koh H, Nishimoto M, Okamura H, Nanno S, Makuuchi Y, Kuno M, Nakamae M, Hirose A, Hino M

    International journal of hematology   114 ( 5 )   580 - 590   2021.11（ ISSN:0925-5710 ）

    　More details

  • Increasing numbers of CD19 + CD24(high)CD38(high) regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia.

    Hayashi T, Nakamae H, Takeda S, Nakashima Y, Koh H, Nishimoto M, Okamura H, Nanno S, Makuuchi Y, Kuno M, Nakamae M, Hirose A, Hino M

    International journal of hematology   114 ( 5 )   580 - 590   2021.11（ ISSN:0925-5710 ）

    　More details

  • Kinetics of IgG subclasses and their effects on the incidence of infection after allogeneic hematopoietic stem cell transplantation.

    Koh S, Koh H, Nanno S, Okamura H, Nakashima Y, Nakamae M, Hirose A, Hino M, Nakamae H

    Transplant immunology   67   101413   2021.08（ ISSN:0966-3274 ）

    　More details

  • Kinetics of IgG subclasses and their effects on the incidence of infection after allogeneic hematopoietic stem cell transplantation.

    Koh S, Koh H, Nanno S, Okamura H, Nakashima Y, Nakamae M, Hirose A, Hino M, Nakamae H

    Transplant immunology   67   101413   2021.08（ ISSN:0966-3274 ）

    　More details

  • Acute fibrinous and organizing pneumonia following hemophagocytic syndrome in two adult patients with hematological malignancies

    Nanno Satoru, Koh Hideo, Okamura Hiroshi, Nishimoto Mitsutaka, Nakashima Yasuhiro, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    Journal of Clinical and Experimental Hematopathology   61 ( 2 )   93 - 96   2021.06（ ISSN:1346-4280 ） （ eISSN:18809952 ）

    　More details

    <p>Acute fibrinous and organizing pneumonia (AFOP) is a rare acute lung injury featuring pathological intra-alveolar fibrin balls and organizing pneumonia without hyaline membranes or eosinophils. AFOP forms acute and subacute patterns; the former often has a poor prognosis, whereas the latter has better survival. Secondary hemophagocytic syndrome (HPS) is a cytokine-related and potentially lethal disorder induced by various diseases, and pulmonary involvement in HPS is not rare. However, to our knowledge, no report has addressed the association between secondary HPS and AFOP development. We report two cases of subacute AFOP following HPS in hematological malignancies.</p>

    DOI： 10.3960/jslrt.20042

    PubMed

    CiNii Article

  • Pretransplant plasma brain natriuretic peptide and N-terminal probrain natriuretic peptide are more useful prognostic markers of overall survival after allogeneic hematopoietic cell transplantation than echocardiography.

    Harada N, Okamura H, Nakane T, Koh S, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Koh H, Hino M, Nakamae H

    Bone marrow transplantation   56 ( 6 )   1467 - 1470   2021.06（ ISSN:0268-3369 ）

    　More details

  • 成人血液悪性腫瘍患者2例に発症した血球貪食症候群に続く急性線維素性器質化肺炎(Acute fibrinous and organizing pneumonia following hemophagocytic syndrome in two adult patients with hematological malignancies)

    Nanno Satoru, Koh Hideo, Okamura Hiroshi, Nishimoto Mitsutaka, Nakashima Yasuhiro, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    Journal of Clinical and Experimental Hematopathology   61 ( 2 )   93 - 96   2021.06（ ISSN:1346-4280 ）

    　More details

    症例1は63歳男性で、トリソミー8に起因する骨髄異形成症候群であった。その1年半後、輸血依存症となり、低用量プレドニゾロン(PSL)とメテノロンの投与を開始した。その4ヵ月後に汎血球減少、脾腫、高フェリチン血症を呈した。骨髄は低形成で、芽球が22.4%、血球が5.2%であった。また、染色体分析により、5q欠失とトリソミー8を含む複雑な核型が認められた。血球貪食症候群(HPS)と診断した。さらに、右中葉への浸潤と両肺への多発性微小結節が確認された。アムホテリシンBリポソーム製剤(LAMB)とメロペネムの投与では症状は改善しなかった。経気管支肺生検により、急性線維素性器質化肺炎(AFOP)と診断した。メチルプレドニゾロンのパルス療法を行い、その後PSLの維持療法を行った。浸潤性陰影はすぐに消失したが、微小結節は大きくなっていった。その後、ボリコナゾール投与により、病変は徐々に小さくなり消失した。症例2は38歳女性で、縦隔原発B細胞リンパ腫であった。リンパ腫に対する各種薬物療法と放射線照射により、初回の完全奏効が得られた。その1ヵ月後に再発し、2回目のサルベージ化学療法の1クール目で部分奏効が達成された。しかし、発熱性好中球減少症を発症し、左肺にすりガラス様陰影(GGO)を伴う浸潤影が認められた。イミペネム+シラスタチンとカスポファンギンをタゾバクタム+ピペラシリンとLAMBに変更した。発熱を伴う重度の汎血球減少が残ったため、骨髄穿刺を行った結果、血球貪食細胞を含む著しい骨髄低形成が認められた。染色体の核型は正常であった。HPSと診断した。その後、GGOを伴う浸潤影が拡大し、左肺に新たなGGOが発生した。経気管支生検により、AFOPと診断した。PSL投与により、浸潤影は徐々に消失した。

  • リンパ管造影により乳び胸水が著明に改善したびまん性大細胞型B細胞リンパ腫

    森口 慎, 高桑 輝人, 影山 健, 岡村 浩史, 南野 智, 西本 光孝, 中嶋 康博, 康 秀男, 中根 孝彦, 山本 晃, 中前 博久, 日野 雅之

    臨床血液   62 ( 6 )   554 - 559   2021.06（ ISSN:0485-1439 ）

    　More details

    乳び胸水はびまん性大細胞型B細胞リンパ腫(DLBCL)の症例にまれに認められる臨床徴候であるが,管理に難渋する場合が多く予後不良である。症例は59歳の女性で,DLBCLの診断時に右胸水貯留を認めた。化学療法に反応してリンパ腫病変は縮小したが胸水の増悪を認めた。胸水穿刺にて乳び胸水と診断し,絶食・中心静脈栄養管理を行うも効果は不良であった。乳び胸水の原因精査のため超音波ガイド下で鼠径リンパ節穿刺によるリンパ管造影検査を行った。乳びの漏出部位は特定できなかったが,検査翌日に胸水の著明な改善を認め,2ヵ月で胸水は完全に消失した。リンパ管造影検査は低侵襲で合併症が少ない検査であり,乳びの漏出部位の特定だけではなく乳び胸水の改善・消失にも寄与する可能性があるため,化学療法や栄養管理に反応しない難治性乳び胸水に対し検討すべき検査と考えられる。(著者抄録)

  • Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil.

    Nakako S, Takakuwa T, Ichimura H, Okamura H, Nanno S, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H

    Clinical case reports   9 ( 6 )   e04298   2021.06（ ISSN:2050-0904 ）

    　More details

  • Pretransplant plasma brain natriuretic peptide and N-terminal probrain natriuretic peptide are more useful prognostic markers of overall survival after allogeneic hematopoietic cell transplantation than echocardiography.

    Harada N, Okamura H, Nakane T, Koh S, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Koh H, Hino M, Nakamae H

    Bone marrow transplantation   56 ( 6 )   1467 - 1470   2021.06（ ISSN:0268-3369 ）

    　More details

  • Interactive Web Application for Plotting Personalized Prognosis Prediction Curves in Allogeneic Hematopoietic Cell Transplantation Using Machine Learning.

    Okamura H, Nakamae M, Koh S, Nanno S, Nakashima Y, Koh H, Nakane T, Hirose A, Hino M, Nakamae H

    Transplantation   105 ( 5 )   1090 - 1096   2021.05（ ISSN:0041-1337 ）

    　More details

  • Interactive Web Application for Plotting Personalized Prognosis Prediction Curves in Allogeneic Hematopoietic Cell Transplantation Using Machine Learning.

    Okamura H, Nakamae M, Koh S, Nanno S, Nakashima Y, Koh H, Nakane T, Hirose A, Hino M, Nakamae H

    Transplantation   105 ( 5 )   1090 - 1096   2021.05（ ISSN:0041-1337 ）

    　More details

  • Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation.

    Tanizawa N, Koh H, Okamura H, Yamamoto K, Makuuchi Y, Kuno M, Takakuwa T, Koh S, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H

    Transplantation and cellular therapy   27 ( 5 )   437.e1 - 437.e9   2021.05（ ISSN:26666367 ）

    　More details

  • Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis. Reviewed

    Harada N, Nishimoto M, Ikemoto A, Okamura H, Koh S, Nanno S, Nakashima Y, Koh H, Nakane T, Kuwae Y, Ohsawa M, Hino M, Nakamae H

    一般社団法人 日本内科学会　Internal medicine (Tokyo, Japan)   60 ( 7 )   1083 - 1088   2021.04（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence of acute lymphoblastic leukemia (ALL) accompanied by BMN. After re-induction therapy, bone marrow aspiration (BMA) and biopsy from the iliac bone showed necrotic cells and eosinophilic debris, respectively. Magnetic resonance imaging (MRI) showed heterogeneous signals in the bilateral iliac bone, possibly reflecting various stages of BMN. BMA from the sternum eventually revealed the recurrence of ALL after a few weeks. Comprehensive assessments, including MRI and repeated bone marrow tests, are required when evaluating the underlying hematological malignancies of patients with BMN. </p>

    DOI： 10.2169/internalmedicine.5815-20

    PubMed

    CiNii Article

  • Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis

    Harada Naonori, Nishimoto Mitsutaka, Ikemoto Aya, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Kuwae Yuko, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    Internal Medicine   60 ( 7 )   1083 - 1088   2021.04（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    <p>Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence of acute lymphoblastic leukemia (ALL) accompanied by BMN. After re-induction therapy, bone marrow aspiration (BMA) and biopsy from the iliac bone showed necrotic cells and eosinophilic debris, respectively. Magnetic resonance imaging (MRI) showed heterogeneous signals in the bilateral iliac bone, possibly reflecting various stages of BMN. BMA from the sternum eventually revealed the recurrence of ALL after a few weeks. Comprehensive assessments, including MRI and repeated bone marrow tests, are required when evaluating the underlying hematological malignancies of patients with BMN. </p>

    DOI： 10.2169/internalmedicine.5815-20

    PubMed

    CiNii Article

  • 骨髄壊死を伴う急性リンパ性白血病の再発　1症例報告と骨髄壊死のMRI所見についての文献レビュー(Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis)

    Harada Naonori, Nishimoto Mitsutaka, Ikemoto Aya, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Kuwae Yuko, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    Internal Medicine   60 ( 7 )   1083 - 1088   2021.04（ ISSN:0918-2918 ）

    　More details

    症例は52歳男性で、フィラデルフィア染色体陽性急性リンパ性白血病(ALL)に対して臍帯血移植を行った。1年後、重度骨痛を伴うALL再発と診断され、再導入療法のために入院した。再導入療法前の骨髄生検では、多数の芽細胞が認められた。入院時には高熱を認め、迅速診断検査でインフルエンザAが陽性であったため、MEC療法(ミトキサントロン、エトポシド、中間用量シタラビン)と静注ペラミビルによる治療を行った。高熱は一時的に改善したが、MEC療法の16日目に再発した。この時点でAspergillus fumigatusが検出されたため、静注ボリコナゾールを開始した。右腸骨からの骨髄穿刺では壊死細胞、骨髄生検では好酸球デブリが認められた。高熱が改善しなかったため、MEC療法の35日目にボリコナゾールをリポソーマルアンホテリシンBに変更した。MEC療法の45日目、腰痛と下肢痛が徐々に悪化した。MRIでは両側腸骨に不均一シグナルが認められ、様々なステージの骨髄壊死を反映していると考えられた。MEC療法の50日目、骨痛が著明に悪化し、51日目に胸骨から行った骨髄穿刺でALL再発が判明した。

  • High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib Reviewed

    Takakuwa Teruhito, Sakai Ryota, Koh Shiro, Okamura Hiroshi, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    CLINICAL CASE REPORTS   9 ( 3 )   1344 - 1349   2021.03（ ISSN:2050-0904 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/ccr3.3770

    PubMed

  • High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib.

    Takakuwa T, Sakai R, Koh S, Okamura H, Nanno S, Nakashima Y, Nakane T, Koh H, Hino M, Nakamae H

    Clinical case reports   9 ( 3 )   1344 - 1349   2021.03（ ISSN:2050-0904 ）

    　More details

  • High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib.

    Takakuwa T, Sakai R, Koh S, Okamura H, Nanno S, Nakashima Y, Nakane T, Koh H, Hino M, Nakamae H

    Clinical case reports   9 ( 3 )   1344 - 1349   2021.03（ ISSN:2050-0904 ）

    　More details

  • Pretransplant plasma brain natriuretic peptide and N-terminal probrain natriuretic peptide are more useful prognostic markers of overall survival after allogeneic hematopoietic cell transplantation than echocardiography Reviewed

    Harada Naonori, Okamura Hiroshi, Nakane Takahiko, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    BONE MARROW TRANSPLANTATION   2021.02（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-021-01224-x

    PubMed

  • Clonal hematopoiesis in adult pure red cell aplasia. Reviewed

    Fujishima N, Kohmaru J, Koyota S, Kuba K, Saga T, Omokawa A, Moritoki Y, Ueki S, Ishida F, Nakao S, Matsuda A, Ohta A, Tohyama K, Yamasaki H, Usuki K, Nakashima Y, Sato S, Miyazaki Y, Nannya Y, Ogawa S, Sawada K, Mitani K, Hirokawa M

    Scientific reports   11 ( 1 )   2253   2021.01

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-021-81890-5

    PubMed

  • 後縦隔脂肪腫を呈した胸腔内に嵌入した大網膜ヘルニア(Intrathoracic omental herniation mimics posterior mediastinal lipomatous tumor)

    Nakashima Yasuhiro, Kobayashi Masashi, Sueyoshi Kuniyo, Mori Erika, Asakawa Ayaka, Ishibashi Hironori, Sugishita Tetsuo, Yamaguchi Kazuya, Hoshino Akihiro, Okubo Kenichi

    General Thoracic and Cardiovascular Surgery   69 ( 1 )   155 - 159   2021.01（ ISSN:1863-6705 ）

    　More details

    症例は72歳男性で、胸部X線検査で異常陰影を指摘され、精査を目的に当院へ紹介された。受診時のCT検査で後縦隔に腫瘤を認めた。無症候性で、5年前のCT検査で腫瘤は見られなかった。身体所見および臨床検査値に異常はなかった。胸部X線検査で境界明瞭な腫瘤を後縦隔に認め、横隔膜右側にシルエットサインを認めた。CT検査で後縦隔に径70×50×80mmの低濃度腫瘤を認めた。腫瘤の上部は右下肺静脈に接しており、腫瘤の下部は食道穿孔部を介して胸腔から腹腔に連続していた。造影MRI検査で腹腔内脂肪に進展する巨大な腫瘤を認めたが、腫瘤部への血流は見られなかった。当初は脂肪性腫瘍を疑ったが、以上の所見から胸腔内食道裂孔ヘルニアと診断した。しかし5年前には腫瘍を認めず、縦隔脂肪腫を否定し得なかったことから、腹腔鏡下手術を施行した。その結果、大網膜が食道裂孔を介して胸腔内に嵌入しており、折れ曲がった小網が大網膜とヘルニア嚢に挟まれていた。癒着は見られなかった。ヘルニア嚢を腹腔内へ還納し、食道穿孔を縫合した。摘出標本は脂肪組織で、大網膜として矛盾しなかった。術後経過は良好で、3日目に摂食可能となり、5日目に退院に至った。

  • Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma.

    Takakuwa T, Ohta K, Sogabe N, Nishimoto M, Kuno M, Makuuchi Y, Okamura H, Nakashima Y, Koh H, Nakamae H, Hino M

    Chemotherapy   66 ( 5-6 )   192 - 195   2021（ ISSN:0009-3157 ）

    　More details

  • Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma.

    Takakuwa T, Ohta K, Sogabe N, Nishimoto M, Kuno M, Makuuchi Y, Okamura H, Nakashima Y, Koh H, Nakamae H, Hino M

    Chemotherapy   66 ( 5-6 )   192 - 195   2021（ ISSN:0009-3157 ）

    　More details

  • Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy.

    Okamura H, Nakamae H, Shindo T, Ohtani K, Hidaka Y, Ohtsuka Y, Makuuchi Y, Kuno M, Takakuwa T, Harada N, Nishimoto M, Nakashima Y, Koh H, Hirose A, Nakamae M, Wakamiya N, Hino M, Inoue N

    Frontiers in immunology   12   695037   2021

    　More details

  • Diffuse large B-cell lymphoma with markedly improved chylothorax by lymphangiography

    MORIGUCHI Makoto, TAKAKUWA Teruhito, KAGEYAMA Ken, OKAMURA Hiroshi, NANNO Satoru, NISHIMOTO Mitsutaka, NAKASHIMA Yasuhiro, KOH Hideo, NAKANE Takahiko, YAMAMOTO Akira, NAKAMAE Hirohisa, HINO Masayuki

    Rinsho Ketsueki   62 ( 6 )   554 - 559   2021（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    <p>Chylothorax is a rare clinical sign in patients with diffuse large B-cell lymphoma (DLBCL), which is often challenging to manage and has a poor prognosis. We report the case of a 59-year-old woman who presented with right pleural effusion at the time of DLBCL diagnosis. Lymphadenopathy rapidly improved in response to chemotherapy. However, the pleural effusion progressed and was identified as chylothorax by thoracentesis. Because attempts to manage the condition with fasting and central venous nutrition were unsuccessful, we performed ultrasound-guided intranodal lipiodol lymphangiography from the inguinal lymph node. Although leak sites were not detected, the pleural effusion markedly improved on the day after the examination and resolved after 2 months. Lymphangiography is a minimally invasive examination with few complications. It contributes not only to the identification of leak sites but also to the improvement and resolution of chylothorax. Therefore, lymphangiography should be considered for refractory chylothorax that is unresponsive to chemotherapy or nutritional management.</p>

    DOI： 10.11406/rinketsu.62.554

    PubMed

    CiNii Article

  • Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Reviewed

    Nanno Satoru, Matsumoto Kana, Nakamae Mika, Okamura Hiroshi, Nishimoto Mitsutaka, Hirose Asao, Koh Hideo, Nakashima Yasuhiro, Nakane Takahiko, Morita Kunihiko, Hino Masayuki, Nakamae Hirohisa

    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA   20 ( 12 )   813 - +   2020.12（ ISSN:2152-2650 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.clml.2020.07.005

    PubMed

  • Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.

    Nanno S, Matsumoto K, Nakamae M, Okamura H, Nishimoto M, Hirose A, Koh H, Nakashima Y, Nakane T, Morita K, Hino M, Nakamae H

    Clinical lymphoma, myeloma & leukemia   20 ( 12 )   813 - 819.e1   2020.12（ ISSN:21522650 ）

    　More details

  • Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis

    Ido Kentaro, Nakane Takahiko, Tanizawa Nao, Makuuchi Yosuke, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    Internal Medicine   59 ( 21 )   2751 - 2756   2020.11（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    <p>A 53-year-old man presented with uncontrolled bleeding caused by acquired platelet dysfunction accompanied by calreticulin-mutated primary myelofibrosis. Based on the detection of abnormal platelets, including large gray platelets, under light microscopy and the loss of the second wave of aggregation observed by light transmission aggregometry, the patient was diagnosed with platelet dysfunction accompanied by myeloproliferative neoplasms (MPNs). In addition, the absence of platelet α-granules was confirmed by electron microscopy. Therefore, this condition may be termed "acquired gray platelet syndrome." Acquired platelet dysfunction must be ruled out when abnormal platelets are observed in patients with MPNs. </p>

    DOI： 10.2169/internalmedicine.4912-20

    PubMed

    CiNii Article

  • Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis(和訳中) Reviewed

    Ido Kentaro, Nakane Takahiko, Tanizawa Nao, Makuuchi Yosuke, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    (一社)日本内科学会　Internal Medicine   59 ( 21 )   2751 - 2756   2020.11（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 原発性骨髄線維症に伴う後天性灰色血小板症候群(Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis)

    Ido Kentaro, Nakane Takahiko, Tanizawa Nao, Makuuchi Yosuke, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    Internal Medicine   59 ( 21 )   2751 - 2756   2020.11（ ISSN:0918-2918 ）

    　More details

    症例は53歳男性で、2年前にカルレティキュリン変異原発性骨髄線維症(PMF)と診断され、無治療で経過観察とされていた。PMFが増悪し、触知可能な脾腫も認めるようになったため、同種造血細胞移植(allo-HCT)の適応となった。増悪コントロールのために3ヵ月前にルキソリチニブとヒドロキシカルバミドの投与を開始したが、大量の腹水が出現して入院した。入院時の評価では出血リスクは低いと考え、入院当日と入院5日目に腹膜穿刺を行った。入院7日目、重度貧血となり、腹壁のコントロール不良出血が判明した。入院12日目、中心静脈カテーテルを挿入したが、挿入部にコントロール不良の出血が出現した。止血または凝固障害が疑われ、精査の結果、PMFに伴う後天性血小板機能障害と診断した。電子顕微鏡で血小板α顆粒の欠如が確認され、病態は後天性灰色血小板症候群であると考えられた。入院の1ヵ月後、allo-HCTを行った。移植後46日目に好中球生着を達成したが、血小板生着は達成せず、移植後112日目に特発性肺炎症候群により死亡した。

  • 同種造血幹細胞移植後にみられた赤血球増加症 Reviewed

    川原 宏惠, 高桑 輝人, 中前 美佳, 久保田 浩, 岡村 浩史, 南野 智, 中嶋 康博, 中根 孝彦, 康 秀男, 廣瀬 朝生, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局　臨床血液   61 ( 10 )   1492 - 1496   2020.10（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    移植後赤血球増加症(PTE)が同種造血幹細胞移植後に生じることは稀であり,臨床的特徴は不明な部分が多い。当院で1992年1月〜2011年12月の間に同種造血幹細胞移植を行った321例のうち3例のPTE患者の臨床的特徴について検討を行った。3例はいずれもヘモグロビン最大時の白血球数および血小板数は正常範囲内であった。エリスロポエチンは2例で測定され,ともに正常範囲内であった。3例ともに細胞減少療法や抗血小板薬投与は行わずに血栓症や出血のイベントはなかった。3例はいずれもJAK2V617F変異陰性であったが,2例はJAK/STAT経路の上流シグナルであるIL-13が高値を示した。真性多血症ではJAK2遺伝子の変異が病態に大きく寄与していることが知られているが,PTEでは病態が異なる可能性がある。今後の症例集積により同種移植後PTEの適切なマネジメントを構築する必要があると考える。(著者抄録)

  • Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia(和訳中) Reviewed

    Moriguchi Makoto, Koh Hideo, Hayashi Tetsuya, Okamura Hiroshi, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Imoto Waki, Yamada Koichi, Kakeya Hiroshi, Hino Masayuki, Nakamae Hirohisa

    エルゼビア・ジャパン(株)　Journal of Infection and Chemotherapy   26 ( 10 )   1054 - 1057   2020.10（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia Reviewed

    Moriguchi Makoto, Koh Hideo, Hayashi Tetsuya, Okamura Hiroshi, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Imoto Waki, Yamada Koichi, Kakeya Hiroshi, Hino Masayuki, Nakamae Hirohisa

    JOURNAL OF INFECTION AND CHEMOTHERAPY   26 ( 10 )   1054 - 1057   2020.10（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jiac.2020.05.001

    PubMed

  • 慢性骨髄性白血病患者の結核性腹膜炎検出目的において、非常に高値である血中可溶性インターロイキン2受容体の臨床的有用性(Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia)

    Moriguchi Makoto, Koh Hideo, Hayashi Tetsuya, Okamura Hiroshi, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Imoto Waki, Yamada Koichi, Kakeya Hiroshi, Hino Masayuki, Nakamae Hirohisa

    Journal of Infection and Chemotherapy   26 ( 10 )   1054 - 1057   2020.10（ ISSN:1341-321X ）

    　More details

    症例は59歳女性で、白血球増加と血小板増加を主訴とした。入院初日(HD1)、白血球・血小板増加、LDH、CRP、AST、ALT値上昇が認められた。HD4に実施したIGRAとT-SPOT.TB試験は陰性であった。骨髄生検により有意な線維症を伴う骨髄球過形成、巨核球過形成が認められた。蛍光in situハイブリダイゼーションによりフィラデルフィア転座が検出された。造影CTにより大量の腹水と肝脾腫大が認められた。HD9に血中のMajor BCR/ABL1 mRNA(IS)の陽性所見に基づいて慢性骨髄性白血病と診断した。HD22の腹腔穿刺により半透明の黄色い液体が認められ、アデノシンデアミナーゼ値はカットオフ値以上であった。HD18に、血清中に極めて高値の可溶性インターロイキン2受容体(sIL-2R)値が観察された。心肺機能低下のため悪性リンパ腫を疑い、HD29にメチルプレドニゾロンパルス療法を開始したが、結核の家族歴があったことからHD32にレボフロキサシン、イソニアジド、ストレプトマイシンを静脈内投与した。腹水の培養検査結果に基づき、HD39に結核性腹膜炎と診断した。抗結核治療により血清中のsIL-2R値は顕著に低下し、腹水量も改善した。

  • 同種造血幹細胞移植後にみられた赤血球増加症

    川原 宏惠, 高桑 輝人, 中前 美佳, 久保田 浩, 岡村 浩史, 南野 智, 中嶋 康博, 中根 孝彦, 康 秀男, 廣瀬 朝生, 日野 雅之, 中前 博久

    臨床血液   61 ( 10 )   1492 - 1496   2020.10（ ISSN:0485-1439 ）

    　More details

    移植後赤血球増加症(PTE)が同種造血幹細胞移植後に生じることは稀であり,臨床的特徴は不明な部分が多い。当院で1992年1月～2011年12月の間に同種造血幹細胞移植を行った321例のうち3例のPTE患者の臨床的特徴について検討を行った。3例はいずれもヘモグロビン最大時の白血球数および血小板数は正常範囲内であった。エリスロポエチンは2例で測定され,ともに正常範囲内であった。3例ともに細胞減少療法や抗血小板薬投与は行わずに血栓症や出血のイベントはなかった。3例はいずれもJAK2V617F変異陰性であったが,2例はJAK/STAT経路の上流シグナルであるIL-13が高値を示した。真性多血症ではJAK2遺伝子の変異が病態に大きく寄与していることが知られているが,PTEでは病態が異なる可能性がある。今後の症例集積により同種移植後PTEの適切なマネジメントを構築する必要があると考える。(著者抄録)

  • Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia.

    Moriguchi M, Koh H, Hayashi T, Okamura H, Nanno S, Nakashima Y, Nakane T, Imoto W, Yamada K, Kakeya H, Hino M, Nakamae H

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   26 ( 10 )   1054 - 1057   2020.10（ ISSN:1341-321X ）

    　More details

  • Mosquito allergy: a novel strong prognostic symptom of outcome after allogeneic hematopoietic transplantation. Reviewed

    Koh S, Nakamae H, Nanno S, Nakane T, Nakashima Y, Koh H, Nakamae M, Hirose A, Hino M

    Bone marrow transplantation   55 ( 7 )   1509 - 1511   2020.07（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-019-0759-y

    PubMed

  • Mosquito allergy: a novel strong prognostic symptom of outcome after allogeneic hematopoietic transplantation. Reviewed

    Koh S, Nakamae H, Nanno S, Nakane T, Nakashima Y, Koh H, Nakamae M, Hirose A, Hino M

    Bone marrow transplantation   55 ( 7 )   1509 - 1511   2020.07（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-019-0759-y

    PubMed

  • Interactive web application for plotting personalized prognosis prediction curves in allogeneic hematopoietic cell transplantation using machine learning. Reviewed

    Okamura H, Nakamae M, Koh S, Nanno S, Nakashima Y, Koh H, Nakane T, Hirose A, Hino M, Nakamae H

    Transplantation   2020.06（ ISSN:0041-1337 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/TP.0000000000003357

    PubMed

  • 再発/難治性の急性リンパ芽球性白血病に罹患した日本人成人を対象としたブリナツモマブの第1b/2相試験(Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia) Reviewed

    Kiyoi Hitoshi, Morris Joan D., Oh Iekuni, Maeda Yoshinobu, Minami Hironobu, Miyamoto Toshihiro, Sakura Toru, Iida Hiroatsu, Tuglus Catherine A., Chen Yuqi, Dos Santos Cedric, Kalabus James, Anderson Abraham, Hata Tomoko, Nakashima Yasuhiro, Kobayashi Yukio

    John Wiley & Sons Australia, Ltd　Cancer Science   111 ( 4 )   1314 - 1323   2020.04（ ISSN:1347-9032 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    再発/難治性の前駆B細胞急性リンパ芽球性白血病の日本人成人患者を対象に、CD19とCD3の両者に対する二重特異性T細胞誘導抗体であるブリナツモマブの安全性、薬物動態、有効性、推奨用量を決定する非盲検第1b/2試験を施行した。ブリナツモマブの用量は1週目には9μg/日、2〜4週目には28μg/日とし、2週間の休薬期間を加え計6週間のサイクルで投与を行った。以後のサイクルでは用量を28μg/日に設定した。第1b相試験での主要評価項目は用量制限毒性(DLT)の発現率に、第2相では初期2サイクル内の完全寛解(CR)/血液学的部分回復(CRh)達成に設定した。総計で26名の患者が組み入れられ、うち25名(96%)でグレード3以上の有害事象が報告されたが、その多くは血球減少症であった。DLT報告例は無かった。初期2サイクル内のCR/CRhは、第1b相では5名中4名(80%)、第2相では21名中8名(38%)で達成された。第2相でCR/CRhを達成していた8名における無再発生存期間の中央値は5ヵ月(95%CI 3.5〜6.4ヵ月)で、全生存期間の中央値に関しては推定不可であった。本試験では再発/難治性の前駆B細胞急性リンパ芽球性白血病に罹患した日本人成人に対しブリナツモマブが安全かつ有効であると思われる結果が得られたが、このことは世界各国で行われた研究の結果と合致していた。

  • Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Reviewed

    Ido K, Koh H, Hirose A, Okamura H, Koh S, Nanno S, Nishimoto M, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   26 ( 4 )   723 - 733   2020.04（ ISSN:1083-8791 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbmt.2019.12.765

    PubMed

  • 再発/難治性の急性リンパ芽球性白血病に罹患した日本人成人を対象としたブリナツモマブの第1b/2相試験(Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia)

    Kiyoi Hitoshi, Morris Joan D., Oh Iekuni, Maeda Yoshinobu, Minami Hironobu, Miyamoto Toshihiro, Sakura Toru, Iida Hiroatsu, Tuglus Catherine A., Chen Yuqi, Dos Santos Cedric, Kalabus James, Anderson Abraham, Hata Tomoko, Nakashima Yasuhiro, Kobayashi Yukio

    Cancer Science   111 ( 4 )   1314 - 1323   2020.04（ ISSN:1347-9032 ）

    　More details

    再発/難治性の前駆B細胞急性リンパ芽球性白血病の日本人成人患者を対象に、CD19とCD3の両者に対する二重特異性T細胞誘導抗体であるブリナツモマブの安全性、薬物動態、有効性、推奨用量を決定する非盲検第1b/2試験を施行した。ブリナツモマブの用量は1週目には9μg/日、2～4週目には28μg/日とし、2週間の休薬期間を加え計6週間のサイクルで投与を行った。以後のサイクルでは用量を28μg/日に設定した。第1b相試験での主要評価項目は用量制限毒性(DLT)の発現率に、第2相では初期2サイクル内の完全寛解(CR)/血液学的部分回復(CRh)達成に設定した。総計で26名の患者が組み入れられ、うち25名(96%)でグレード3以上の有害事象が報告されたが、その多くは血球減少症であった。DLT報告例は無かった。初期2サイクル内のCR/CRhは、第1b相では5名中4名(80%)、第2相では21名中8名(38%)で達成された。第2相でCR/CRhを達成していた8名における無再発生存期間の中央値は5ヵ月(95%CI 3.5～6.4ヵ月)で、全生存期間の中央値に関しては推定不可であった。本試験では再発/難治性の前駆B細胞急性リンパ芽球性白血病に罹患した日本人成人に対しブリナツモマブが安全かつ有効であると思われる結果が得られたが、このことは世界各国で行われた研究の結果と合致していた。

  • Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study Reviewed

    Harada Naonori, Nakane Takahiko, Nakamae Mika, Hashimoto Yoshinori, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    TRANSPLANT INTERNATIONAL   33 ( 4 )   391 - 401   2020.04（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tri.13564

    PubMed

  • Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Reviewed

    Hitoshi Kiyoi, Joan D Morris, Iekuni Oh, Yoshinobu Maeda, Hironobu Minami, Toshihiro Miyamoto, Toru Sakura, Hiroatsu Iida, Catherine A Tuglus, Yuqi Chen, Cedric Dos Santos, James Kalabus, Abraham Anderson, Tomoko Hata, Yasuhiro Nakashima, Yukio Kobayashi

    Cancer science   111 ( 4 )   1314 - 1323   2020.04（ ISSN:1347-9032 ）

    　More details

    Publishing type：Research paper (scientific journal)   International / domestic magazine：International journal  

    Adult patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) have a poor prognosis. Blinatumomab is a bispecific T-cell engager (BiTE) immuno-oncology therapy with dual specificity for CD19 and CD3 that redirects patients' CD3-positive cytotoxic T cells to lyse malignant and normal B cells. We conducted an open-label, phase 1b/2 study to determine the safety, pharmacokinetics, efficacy and recommended dose of blinatumomab in Japanese adults with R/R B-precursor ALL. Patients received 9 μg/day blinatumomab during week 1 and 28 μg/day during weeks 2-4, with a 2-week treatment-free interval (6-week cycle); patients received 28 μg/day blinatumomab in subsequent cycles. Primary endpoints were the incidence of dose-limiting toxicities (DLT) in phase 1b and complete remission (CR)/CR with partial hematologic recovery (CRh) within the first two cycles in phase 2. A total of 26 patients enrolled and 25 (96%) reported grade ≥3 adverse events (mostly cytopenias). There were no DLT. CR/CRh within two cycles was achieved by 4 of 5 patients (80%) in phase 1b and 8 of 21 patients (38%) in phase 2. Among patients with evaluable minimal residual disease, 4 (100%) in phase 1b and 3 (38%) in phase 2 had a complete MRD response. Median RFS for 8 patients who achieved CR/CRh in phase 2 was 5 (95% CI: 3.5-6.4) months; median OS was not estimable. There were no significant associations between maximum cytokine levels or percentage of specific cell types during cycle 1 and response. Consistent with global studies, blinatumomab appeared to be safe and efficacious in Japanese adults with R/R ALL.

    DOI： 10.1111/cas.14322

    PubMed

  • Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study Reviewed

    Harada Naonori, Nakane Takahiko, Nakamae Mika, Hashimoto Yoshinori, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    TRANSPLANT INTERNATIONAL   33 ( 4 )   391 - 401   2020.04（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tri.13564

    PubMed

  • Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Reviewed

    Hitoshi Kiyoi, Joan D Morris, Iekuni Oh, Yoshinobu Maeda, Hironobu Minami, Toshihiro Miyamoto, Toru Sakura, Hiroatsu Iida, Catherine A Tuglus, Yuqi Chen, Cedric Dos Santos, James Kalabus, Abraham Anderson, Tomoko Hata, Yasuhiro Nakashima, Yukio Kobayashi

    Cancer science   111 ( 4 )   1314 - 1323   2020.04（ ISSN:1347-9032 ）

    　More details

    Publishing type：Research paper (scientific journal)   International / domestic magazine：International journal  

    Adult patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) have a poor prognosis. Blinatumomab is a bispecific T-cell engager (BiTE) immuno-oncology therapy with dual specificity for CD19 and CD3 that redirects patients' CD3-positive cytotoxic T cells to lyse malignant and normal B cells. We conducted an open-label, phase 1b/2 study to determine the safety, pharmacokinetics, efficacy and recommended dose of blinatumomab in Japanese adults with R/R B-precursor ALL. Patients received 9 μg/day blinatumomab during week 1 and 28 μg/day during weeks 2-4, with a 2-week treatment-free interval (6-week cycle); patients received 28 μg/day blinatumomab in subsequent cycles. Primary endpoints were the incidence of dose-limiting toxicities (DLT) in phase 1b and complete remission (CR)/CR with partial hematologic recovery (CRh) within the first two cycles in phase 2. A total of 26 patients enrolled and 25 (96%) reported grade ≥3 adverse events (mostly cytopenias). There were no DLT. CR/CRh within two cycles was achieved by 4 of 5 patients (80%) in phase 1b and 8 of 21 patients (38%) in phase 2. Among patients with evaluable minimal residual disease, 4 (100%) in phase 1b and 3 (38%) in phase 2 had a complete MRD response. Median RFS for 8 patients who achieved CR/CRh in phase 2 was 5 (95% CI: 3.5-6.4) months; median OS was not estimable. There were no significant associations between maximum cytokine levels or percentage of specific cell types during cycle 1 and response. Consistent with global studies, blinatumomab appeared to be safe and efficacious in Japanese adults with R/R ALL.

    DOI： 10.1111/cas.14322

    PubMed

  • 同種造血細胞移植後難治性ウイルス血症・感染症に対する高用量polyclonal intravenous immunoglobulin Reviewed

    井戸 健太郎, 中根 孝彦, 岡村 浩史, 南野 智, 西本 光孝, 廣瀬 朝生, 中前 美佳, 中嶋 康博, 康 秀男, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局　臨床血液   61 ( 3 )   215 - 222   2020.03（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    我々は致死的合併症の一つである同種造血細胞移植後難治性ウイルス血症・感染症に対するpolyclonal intravenous immunoglobulin(polyclonal IVIG)400mg/kg/日連続5日間投与の有効性・安全性を評価するためにこの前向きパイロット試験を計画した。14例の試験参加者は全例介入を受けた。Human parvovirus B19血症あるいは高リスクrespiratory syncytial virus肺炎/気管支炎といった外因性ウイルス血症・感染症に対して投与された3例は全例complete responseに到達した。1例でIVIG開始後2日に心不全が観察された。結論として,本研究は高用量polyclonal IVIGが同種造血細胞移植後のとくに,難治性外因性ウイルス感染症に対して有効である可能性を示唆している。(著者抄録)

  • 同種造血細胞移植後難治性ウイルス血症・感染症に対する高用量polyclonal intravenous immunoglobulin

    井戸 健太郎, 中根 孝彦, 岡村 浩史, 南野 智, 西本 光孝, 廣瀬 朝生, 中前 美佳, 中嶋 康博, 康 秀男, 日野 雅之, 中前 博久

    臨床血液   61 ( 3 )   215 - 222   2020.03（ ISSN:0485-1439 ）

    　More details

    我々は致死的合併症の一つである同種造血細胞移植後難治性ウイルス血症・感染症に対するpolyclonal intravenous immunoglobulin(polyclonal IVIG)400mg/kg/日連続5日間投与の有効性・安全性を評価するためにこの前向きパイロット試験を計画した。14例の試験参加者は全例介入を受けた。Human parvovirus B19血症あるいは高リスクrespiratory syncytial virus肺炎/気管支炎といった外因性ウイルス血症・感染症に対して投与された3例は全例complete responseに到達した。1例でIVIG開始後2日に心不全が観察された。結論として,本研究は高用量polyclonal IVIGが同種造血細胞移植後のとくに,難治性外因性ウイルス感染症に対して有効である可能性を示唆している。(著者抄録)

  • Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia Reviewed

    Kiyoi Hitoshi, Morris Joan D., Oh Lekuni, Maeda Yoshinobu, Minami Hironobu, Miyamoto Toshihiro, Sakura Toru, Iida Hiroatsu, Tuglus Catherine A., Chen Yuqi, Dos Santos Cedric, Kalabus James, Anderson Abraham, Hata Tomoko, Nakashima Yasuhiro, Kobayashi Yukio

    CANCER SCIENCE   2020.02（ ISSN:1347-9032 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.14322

    PubMed

  • A noninvasive diagnostic approach using per-rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Reviewed

    Okamura H, Koh H, Takakuwa T, Ido K, Makuuchi Y, Ine S, Nanno S, Nakashima Y, Nakane T, Jogo A, Yamamoto A, Hamuro M, Kotani K, Kawabe J, Higashiyama S, Yoshida A, Shiomi S, Ohsawa M, Hino M, Nakamae H

    Bone marrow transplantation   55 ( 2 )   470 - 472   2020.02（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-019-0537-x

    PubMed

  • 経気管支肺胞生検で診断できた肺浸潤を伴う急性単球性白血病 Reviewed

    原田 尚憲, 中根 孝彦, 岡村 浩史, 南野 智, 中嶋 康博, 康 秀男, 田中 さやか, 大澤 政彦, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局　臨床血液   61 ( 1 )   27 - 32   2020.01（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 経気管支肺胞生検で診断できた肺浸潤を伴う急性単球性白血病 Reviewed

    原田 尚憲, 中根 孝彦, 岡村 浩史, 南野 智, 中嶋 康博, 康 秀男, 田中 さやか, 大澤 政彦, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局 臨床血液   61 ( 1 )   27 - 32   2020.01（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 経気管支肺胞生検で診断できた肺浸潤を伴う急性単球性白血病

    原田 尚憲, 中根 孝彦, 岡村 浩史, 南野 智, 中嶋 康博, 康 秀男, 田中 さやか, 大澤 政彦, 日野 雅之, 中前 博久

    臨床血液   61 ( 1 )   27 - 32   2020.01（ ISSN:0485-1439 ）

    　More details

    65歳女性。2017年10月より抗菌薬不応性の発熱を認め,当院緊急入院となった。入院時白血球54,400/μl(芽球様細胞90%),経皮的動脈血酸素飽和度は97%(酸素3l/分鼻カニューレ)であった。骨髄検査にて急性単球性白血病と診断,胸部CTで小葉間隔壁肥厚,中枢側優位のスリガラス陰影,左下葉結節影を認め,感染症や心不全合併を考慮し各治療を行うも有効性に乏しく入院後第7病日にTBLBを施行し,白血病肺浸潤と診断,最終的に強化化学療法を行う方針を選択し寛解を得た。急性骨髄性白血病は初発時肺浸潤合併が多い一方でほかの肺合併症との鑑別に苦慮することも少なくないが,実地診療では臨床診断に基づき化学療法の開始が決定されることが多い。今回,生前に病理学的に病態を確認し,良好な経過を得られた貴重な症例と考えられることから,文献的考察を加え報告する。(著者抄録)

  • 経気管支肺胞生検で診断できた肺浸潤を伴う急性単球性白血病 Reviewed

    原田 尚憲, 中根 孝彦, 岡村 浩史, 南野 智, 中嶋 康博, 康 秀男, 田中 さやか, 大澤 政彦, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局 臨床血液   61 ( 1 )   27 - 32   2020.01（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Pulmonary infiltration of acute monoblastic leukemia diagnosed by transbronchial lung biopsy Reviewed

    HARADA Naonori, NAKAMAE Hirohisa, NAKANE Takahiko, OKAMURA Hiroshi, NANNO Satoru, NAKASHIMA Yasuhiro, KOH Hideo, TANAKA Sayaka, OHSAWA Masahiko, HINO Masayuki

    The Japanese Society of Hematology, Rinsho Ketsueki   61 ( 1 )   27 - 32   2020（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>A 65-year-old woman was urgently admitted to our hospital for antibiotic-resistant fever, hypoxemia, and hyperleukocytosis and was diagnosed with acute monoblastic leukemia. Chest computed tomography revealed interlobular septal thickening, central ground-glass opacity, and a nodular shadow in the left lower lobe. Although several treatments for infectious disease and acute heart failure were administered, they were less effective. Transbronchial lung biopsy was performed on day 7 of hospitalization, and subsequently, pulmonary leukemic infiltration was confirmed. Based on the diagnosis, we decided to start intensive chemotherapy. Consequently, the abnormal lung shadow on computed tomography vanished, and complete hematological remission was achieved. Although acute myeloid leukemia is frequently associated with lung infiltration during onset, it is often difficult to distinguish it from other pulmonary complications. In clinical practice, intensive chemotherapy is often initiated based on the clinical evaluation without pathological confirmation of the lung disease. Our patient was accurately diagnosed based on the pulmonary leukemic infiltration observed pathologically and recovered well. Here we report our case along with a discussion of the relevant literature.</p>

    DOI： 10.11406/rinketsu.61.27

    PubMed

    CiNii Article

  • Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis Reviewed

    Ido Kentaro, Nakane Takahiko, Tanizawa Nao, Makuuchi Yosuke, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    一般社団法人 日本内科学会　INTERNAL MEDICINE   59 ( 21 )   2751 - 2756   2020（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>A 53-year-old man presented with uncontrolled bleeding caused by acquired platelet dysfunction accompanied by calreticulin-mutated primary myelofibrosis. Based on the detection of abnormal platelets, including large gray platelets, under light microscopy and the loss of the second wave of aggregation observed by light transmission aggregometry, the patient was diagnosed with platelet dysfunction accompanied by myeloproliferative neoplasms (MPNs). In addition, the absence of platelet α-granules was confirmed by electron microscopy. Therefore, this condition may be termed "acquired gray platelet syndrome." Acquired platelet dysfunction must be ruled out when abnormal platelets are observed in patients with MPNs. </p>

    DOI： 10.2169/internalmedicine.4912-20

    PubMed

    CiNii Article

  • High-dose polyclonal intravenous immunoglobulin therapy for refractory viral infections including viremia after allogeneic hematopoietic cell transplantation Reviewed

    IDO Kentaro, HINO Masayuki, NAKAMAE Hirohisa, NAKANE Takahiko, OKAMURA Hiroshi, NANNO Satoru, NISHIMOTO Mitsutaka, HIROSE Asao, NAKAMAE Mika, NAKASHIMA Yasuhiro, KOH Hideo

    The Japanese Society of Hematology, Rinsho Ketsueki   61 ( 3 )   215 - 222   2020（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Refractory viremia/viral disease is a major life-threatening complication that may arise among patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This study aimed to clarify the therapeutic effect of high-dose polyclonal intravenous immunoglobulin (IVIG) against viremia/viral diseases after allo-HCT. We conducted a pilot study to investigate the therapeutic effect of 400 mg/kg of IVIG given for 5 consecutive days against refractory viremia/viral disease after allo-HCT. Overall, 7 patients were drug-resistant and the other 7 had not previously received any drug for their viremia/viral disease. All patients completed the 5-day therapy regimen of IVIG. A complete response at Day 56 was observed for 8 of 14 patients (57.1%). Additionally, 10 of 14 patients (71.4%) were alive at Day 56, although only one death occurred due to the viremia/viral disease. Remarkably, all 3 cases who developed exogenous viremia/viral diseases including respiratory syncytial virus pneumonia/bronchitis and human parvovirus B19 viremia achieved a complete response, suggesting that high-dose polyclonal IVIG may be more effective against exogenous viruses rather than endogenous ones. Congestive heart failure was observed in 1 patient. High-dose polyclonal IVIG could be an effective and feasible therapy for refractory viremia/viral disease after allo-HCT.</p>

    DOI： 10.11406/rinketsu.61.215

    PubMed

    CiNii Article

  • Erythrocytosis following allogeneic hematopoietic stem cell transplantation Reviewed

    KAWAHARA Hiroe, HIROSE Asao, HINO Masayuki, NAKAMAE Hirohisa, TAKAKUWA Teruhito, NAKAMAE Mika, KUBOTA Hiroshi, OKAMURA Hiroshi, NANNO Satoru, NAKASHIMA Yasuhiro, NAKANE Takahiko, KOH Hideo

    The Japanese Society of Hematology, Rinsho Ketsueki   61 ( 10 )   1492 - 1496   2020（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Post-transplant erythrocytosis (PTE) following allogeneic hematopoietic stem cell transplantation (alloHSCT) is rare, and the clinical characteristics of this condition remain unknown. In this study, we examined the clinical characteristics of three PTE cases among 321 patients who received allo HSCT from January 1992 to December 2011 at our institution. All three patients exhibited normal levels of white blood cell and platelet counts when their hemoglobin levels reached their peak. Two patients exhibited normal levels of erythropoietin. No thrombosis or hemorrhage was observed in any of the three patients without cytoreductive therapy or an antiplatelet agent. All three patients tested negative for JAK2V617F mutations. Two patients had high levels of IL-13, an upstream signal for the JAK/STAT pathway. JAK2 is known to significantly contribute to the pathology of polycythemia vera; however, this pathology may differ from that of PTE. We believe that it is necessary to construct a more appropriate management structure for PTE by analyzing more case data in the future.</p>

    DOI： 10.11406/rinketsu.61.1492

    PubMed

    CiNii Article

  • 同種造血細胞移植後早期の補体Ba上昇は移植関連血栓性微小血管症の発症予測マーカーになり得る

    岡村 浩史, 中前 博久, 進藤 岳郎, 大谷 克城, 日高 義彦, 大塚 泰史, 南野 智, 中嶋 康博, 康 秀男, 廣瀬 朝生, 中前 美佳, 日野 雅之, 若宮 伸隆, 井上 徳光

    移植   55 ( Supplement )   232_2 - 232_2   2020（ ISSN:05787947 ） （ eISSN:21880034 ）

    　More details

    <p><背景>同種造血細胞移植後の移植関連血栓性微小血管症（TA-TMA）発症に補体の関与が示唆されているがその動態の詳細は不明である。我々はTA-TMAにおける補体動態を網羅的に検討した。<方法>2012年から2016年の間、当院で同種造血細胞移植を施行した患者の移植前、day7、28、60の血漿を用いて補体蛋白検査（sC5b-9、Ba、CFH、CFH-IgG、CFI、C5a、 C3、C4、CH50）を行い、TA-TMA群と対照群の経時的推移を比較した。傾向スコアを用いてマッチングした非TA-TMA症例を対照群とした。<結果>174例の移植例からTA-TMA15例、非TA-TMA15例を解析対象とした。最も移植後早期に有意差を示した補体蛋白は移植後day7のBaであり、TA-TMA群で異常高値を示した（p=0.02）。<結論>移植後早期のBa上昇は、TA-TMAの発症予測マーカーとなり得る。</p>

    DOI： 10.11386/jst.55.supplement_232_2

    CiNii Article

  • Pulmonary infiltration of acute monoblastic leukemia diagnosed by transbronchial lung biopsy Reviewed

    HARADA Naonori, NAKANE Takahiko, OKAMURA Hiroshi, NANNO Satoru, NAKASHIMA Yasuhiro, KOH Hideo, TANAKA Sayaka, OHSAWA Masahiko, HINO Masayuki, NAKAMAE Hirohisa

    Rinsho Ketsueki   61 ( 1 )   27 - 32   2020（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>A 65-year-old woman was urgently admitted to our hospital for antibiotic-resistant fever, hypoxemia, and hyperleukocytosis and was diagnosed with acute monoblastic leukemia. Chest computed tomography revealed interlobular septal thickening, central ground-glass opacity, and a nodular shadow in the left lower lobe. Although several treatments for infectious disease and acute heart failure were administered, they were less effective. Transbronchial lung biopsy was performed on day 7 of hospitalization, and subsequently, pulmonary leukemic infiltration was confirmed. Based on the diagnosis, we decided to start intensive chemotherapy. Consequently, the abnormal lung shadow on computed tomography vanished, and complete hematological remission was achieved. Although acute myeloid leukemia is frequently associated with lung infiltration during onset, it is often difficult to distinguish it from other pulmonary complications. In clinical practice, intensive chemotherapy is often initiated based on the clinical evaluation without pathological confirmation of the lung disease. Our patient was accurately diagnosed based on the pulmonary leukemic infiltration observed pathologically and recovered well. Here we report our case along with a discussion of the relevant literature.</p>

    DOI： 10.11406/rinketsu.61.27

    PubMed

    CiNii Article

  • High-dose polyclonal intravenous immunoglobulin therapy for refractory viral infections including viremia after allogeneic hematopoietic cell transplantation

    IDO Kentaro, NAKANE Takahiko, OKAMURA Hiroshi, NANNO Satoru, NISHIMOTO Mitsutaka, HIROSE Asao, NAKAMAE Mika, NAKASHIMA Yasuhiro, KOH Hideo, HINO Masayuki, NAKAMAE Hirohisa

    Rinsho Ketsueki   61 ( 3 )   215 - 222   2020（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    <p>Refractory viremia/viral disease is a major life-threatening complication that may arise among patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This study aimed to clarify the therapeutic effect of high-dose polyclonal intravenous immunoglobulin (IVIG) against viremia/viral diseases after allo-HCT. We conducted a pilot study to investigate the therapeutic effect of 400 mg/kg of IVIG given for 5 consecutive days against refractory viremia/viral disease after allo-HCT. Overall, 7 patients were drug-resistant and the other 7 had not previously received any drug for their viremia/viral disease. All patients completed the 5-day therapy regimen of IVIG. A complete response at Day 56 was observed for 8 of 14 patients (57.1%). Additionally, 10 of 14 patients (71.4%) were alive at Day 56, although only one death occurred due to the viremia/viral disease. Remarkably, all 3 cases who developed exogenous viremia/viral diseases including respiratory syncytial virus pneumonia/bronchitis and human parvovirus B19 viremia achieved a complete response, suggesting that high-dose polyclonal IVIG may be more effective against exogenous viruses rather than endogenous ones. Congestive heart failure was observed in 1 patient. High-dose polyclonal IVIG could be an effective and feasible therapy for refractory viremia/viral disease after allo-HCT.</p>

    DOI： 10.11406/rinketsu.61.215

    PubMed

    CiNii Article

  • Erythrocytosis following allogeneic hematopoietic stem cell transplantation

    KAWAHARA Hiroe, TAKAKUWA Teruhito, NAKAMAE Mika, KUBOTA Hiroshi, OKAMURA Hiroshi, NANNO Satoru, NAKASHIMA Yasuhiro, NAKANE Takahiko, KOH Hideo, HIROSE Asao, HINO Masayuki, NAKAMAE Hirohisa

    Rinsho Ketsueki   61 ( 10 )   1492 - 1496   2020（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    <p>Post-transplant erythrocytosis (PTE) following allogeneic hematopoietic stem cell transplantation (alloHSCT) is rare, and the clinical characteristics of this condition remain unknown. In this study, we examined the clinical characteristics of three PTE cases among 321 patients who received allo HSCT from January 1992 to December 2011 at our institution. All three patients exhibited normal levels of white blood cell and platelet counts when their hemoglobin levels reached their peak. Two patients exhibited normal levels of erythropoietin. No thrombosis or hemorrhage was observed in any of the three patients without cytoreductive therapy or an antiplatelet agent. All three patients tested negative for JAK2V617F mutations. Two patients had high levels of IL-13, an upstream signal for the JAK/STAT pathway. JAK2 is known to significantly contribute to the pathology of polycythemia vera; however, this pathology may differ from that of PTE. We believe that it is necessary to construct a more appropriate management structure for PTE by analyzing more case data in the future.</p>

    DOI： 10.11406/rinketsu.61.1492

    PubMed

    CiNii Article

  • Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Reviewed

    Ido K, Koh H, Hirose A, Okamura H, Koh S, Nanno S, Nishimoto M, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   2019.12（ ISSN:1083-8791 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbmt.2019.12.765

    PubMed

  • Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study Reviewed

    Harada Naonori, Nakane Takahiko, Nakamae Mika, Hashimoto Yoshinori, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    TRANSPLANT INTERNATIONAL   33 ( 4 )   391 - 401   2019.12（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tri.13564

    PubMed

  • Mosquito allergy: a novel strong prognostic symptom of outcome after allogeneic hematopoietic transplantation. Reviewed

    Koh S, Nakamae H, Nanno S, Nakane T, Nakashima Y, Koh H, Nakamae M, Hirose A, Hino M

    Bone marrow transplantation   2019.12（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-019-0759-y

    PubMed

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-019-02743-6

    PubMed

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients(和訳中) Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    (一社)日本血液学会 International Journal of Hematology   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients(和訳中) Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    (一社)日本血液学会　International Journal of Hematology   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 日本人患者に対する一つまたは二つのHLA不一致非血縁ドナーからの同種造血幹細胞移植におけるボルテゾミブを用いた移植片対宿主病予防に関する第1相試験(Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients)

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    International Journal of Hematology   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    日本におけるHLA不一致非血縁ドナーからの同種造血幹細胞移植(HCT)におけるボルテゾミブによる移植片対宿主病(GVHD)予防の安全性を調べるため、第1相試験を実施した。2012年10月～2018年10月に6例(年齢38～64歳)が試験に参加した。6例に対しボルテゾミブ1.3mg/m2が投与され、用量制限毒性が発生した場合に用量を調節した。初回投与に参加した6例のうち5例が骨髄ドナーであった。全例が好中球生着と完全ドナーキメラ化を達成した。3例がグレードIIの急性GVHDを呈した。第100日までにグレードIII-IVのGVHDまたはボルテゾミブ起因性の用量制限毒性は認めなかった。2例に遅発性急性GVHD、2例に慢性GVHDを認めたが、全症例とも管理可能であった。全患者が追跡期間中央値52ヵ月に再発なく生存した。ボルテゾミブの至適用量は1.3mg/m2であると決定された。HLA不一致非血縁同種HCTに対するボルテゾミブを含むレジメンを用いたGVHD予防は実施可能であると考えられた。

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-019-02743-6

    PubMed

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients(和訳中) Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    (一社)日本血液学会 International Journal of Hematology   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-019-02743-6

    PubMed

  • Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients(和訳中) Reviewed

    Nakane Takahiko, Okamura Hiroshi, Tagaito Yumi, Koh Shiro, Yoshimura Takuro, Makuuchi Yosuke, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    (一社)日本血液学会 International Journal of Hematology   110 ( 6 )   736 - 742   2019.12（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors Reviewed

    Nakamae Hirohisa, Fujii Kazuki, Nanno Satoru, Okamura Hiroshi, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Teshima Takanori, Hino Masayuki

    TRANSPLANT INTERNATIONAL   32 ( 12 )   1322 - 1332   2019.12（ ISSN:0934-0874 ） （ eISSN:1432-2277 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tri.13494

    PubMed

    Other URL： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/tri.13494

  • Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide Reviewed

    Ido Kentaro, Koh Hideo, Okamura Hiroshi, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   134   2019.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2019-125173

  • Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation Reviewed

    Tanizawa Nao, Koh Hideo, Okamura Hiroshi, Shiro Koh, Nanno Satoru, Nishimoto Mitsutaka, Hirose Asao, Nakamae Mika, Nakashima Yasuhiro, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   134   2019.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2019-124264

  • Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide Reviewed

    Nishimoto Mitsutaka, Hirose Asao, Koh Hideo, Nakamae Mika, Nanno Satoru, Okamura Hiroshi, Nakane Takahiko, Nakashima Yasuhiro, Hino Masayuki, Nakamae Hirohisa

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   25 ( 10 )   2061 - 2069   2019.10（ ISSN:1083-8791 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbmt.2019.06.003

    PubMed

  • The Proportional Relationship between Pre-transplant WT1 mRNA Levels and Risk of Mortality after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission. Reviewed

    Ido K, Nakamae M, Koh H, Okamura H, Nanno S, Nishimoto M, Takeoka Y, Hirose A, Nakashima Y, Hashimoto Y, Nakane T, Hino M, Nakamae H

    Transplantation   103 ( 10 )   2201 - 2210   2019.10（ ISSN:0041-1337 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/TP.0000000000002662

    PubMed

  • Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide Reviewed

    Nishimoto Mitsutaka, Hirose Asao, Koh Hideo, Nakamae Mika, Nanno Satoru, Okamura Hiroshi, Nakane Takahiko, Nakashima Yasuhiro, Hino Masayuki, Nakamae Hirohisa

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   25 ( 10 )   2061 - 2069   2019.10（ ISSN:1083-8791 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbmt.2019.06.003

    PubMed

  • A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors Reviewed

    Nakamae Hirohisa, Fujii Kazuki, Nanno Satoru, Okamura Hiroshi, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Teshima Takanori, Hino Masayuki

    TRANSPLANT INTERNATIONAL   32 ( 12 )   1322 - 1332   2019.09（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tri.13494

    PubMed

  • A noninvasive diagnostic approach using per-rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Reviewed

    Okamura H, Koh H, Takakuwa T, Ido K, Makuuchi Y, Ine S, Nanno S, Nakashima Y, Nakane T, Jogo A, Yamamoto A, Hamuro M, Kotani K, Kawabe J, Higashiyama S, Yoshida A, Shiomi S, Ohsawa M, Hino M, Nakamae H

    Bone marrow transplantation   2019.05（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41409-019-0537-x

    PubMed

  • Short-Term Fasting Induces Cell Cycle Arrest in Immature Hematopoietic Cells and Increases the Number of Naïve T Cells in the Bone Marrow of Mice. Reviewed

    Takakuwa T, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M

    Acta haematologica   141 ( 3 )   189 - 198   2019.03（ ISSN:0001-5792 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000496096

    PubMed

  • The Proportional Relationship between Pre-transplant WT1 mRNA Levels and Risk of Mortality after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission. Reviewed

    Ido K, Nakamae M, Koh H, Okamura H, Nanno S, Nishimoto M, Takeoka Y, Hirose A, Nakashima Y, Hashimoto Y, Nakane T, Hino M, Nakamae H

    Transplantation   2019.02（ ISSN:0041-1337 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/TP.0000000000002662

    PubMed

  • 同種造血幹細胞移植後にリンパ還流障害による難治性腹水をきたした急性骨髄性白血病 Reviewed

    高桑 輝人, 奥野 高裕, 西本 光孝, 南野 智, 武岡 康信, 中嶋 康博, 康 秀男, 中根 孝彦, 鰐渕 英機, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局　臨床血液   60 ( 1 )   12 - 16   2019.01（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 同種造血幹細胞移植後にリンパ還流障害による難治性腹水をきたした急性骨髄性白血病 Reviewed

    高桑 輝人, 奥野 高裕, 西本 光孝, 南野 智, 武岡 康信, 中嶋 康博, 康 秀男, 中根 孝彦, 鰐渕 英機, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局 臨床血液   60 ( 1 )   12 - 16   2019.01（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 同種造血幹細胞移植後にリンパ還流障害による難治性腹水をきたした急性骨髄性白血病

    高桑 輝人, 奥野 高裕, 西本 光孝, 南野 智, 武岡 康信, 中嶋 康博, 康 秀男, 中根 孝彦, 鰐渕 英機, 日野 雅之, 中前 博久

    臨床血液   60 ( 1 )   12 - 16   2019.01（ ISSN:0485-1439 ）

    　More details

    同種造血幹細胞移植後の難治性腹水の鑑別疾患としては類洞閉塞症候群、感染症、原疾患の再発および浸潤、低栄養などが知られているが、しばしば原因特定が困難な症例に遭遇する。症例は59歳の男性で、急性骨髄性白血病の血液学的再発に対して同種骨髄移植を施行された。移植後3ヵ月頃より乳び腹水が出現し、リンパ管シンチでは乳び槽レベルでのリンパ流停滞がみられたが、腹水に対する有効な治療は見いだせなかった。死後の病理組織から肝臓や消化管にGVHDはみられず、白血病細胞の残存も認めなかった。膵臓については急性膵炎の像に加え、膵実質の線維化や形質細胞の浸潤があり、慢性的な炎症が併存しており、膵炎によるリンパ還流障害が腹水を引き起こしていた可能性が示唆された。本症例は生前には膵炎の確定診断に至らなかった。移植後の無症候性膵炎は少なくない可能性があり、鑑別疾患として、留意する必要があると考えられた。(著者抄録)

  • 同種造血幹細胞移植後にリンパ還流障害による難治性腹水をきたした急性骨髄性白血病 Reviewed

    高桑 輝人, 奥野 高裕, 西本 光孝, 南野 智, 武岡 康信, 中嶋 康博, 康 秀男, 中根 孝彦, 鰐渕 英機, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局 臨床血液   60 ( 1 )   12 - 16   2019.01（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Refractory ascites caused by lymphatic flow disorder after stem cell transplantation for acute myeloid leukemia Reviewed

    TAKAKUWA Teruhito, HINO Masayuki, NAKAMAE Hirohisa, OKUNO Takahiro, NISHIMOTO Mitsutaka, NANNO Satoru, TAKEOKA Yasunobu, NAKASHIMA Yasuhiro, KOH Hideo, NAKANE Takahiko, WANIBUCHI Hideki

    The Japanese Society of Hematology, Rinsho Ketsueki   60 ( 1 )   12 - 16   2019（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>In allogeneic hematopoietic stem cell transplantation (HSCT), ascites may develop owing to several causes, including sinusoidal obstruction syndrome, infections, malignancies, and malnutrition. However, it is often difficult to determine its precise cause. Here, a 59-year-old male developed chylous ascites three months post allogeneic bone marrow transplantation for relapsed acute myeloid leukemia. None of the attempted treatments resulted in improvement. Lymphangioscintigraphy revealed a lymphatic flow disorder at the level of the cisterna chyli. Autopsy revealed no leukemic cell infiltration or graft-versus-host disease of the liver or pancreas. The pancreatic specimen revealed parenchymal fibrosis and infiltration of plasma cells, suggesting chronic inflammation in addition to pathological changes caused by acute pancreatitis. These findings indicate that acute or chronic pancreatitis caused a lymphatic flow disorder that developed into refractory ascites. Although we could not diagnose pancreatitis while the patient was alive, it is important to recognize that asymptomatic pancreatitis can develop after HSCT. Furthermore, one should attempt to make an accurate diagnosis as early as possible.</p>

    DOI： 10.11406/rinketsu.60.12

    PubMed

    CiNii Article

  • Refractory ascites caused by lymphatic flow disorder after stem cell transplantation for acute myeloid leukemia Reviewed

    TAKAKUWA Teruhito, OKUNO Takahiro, NISHIMOTO Mitsutaka, NANNO Satoru, TAKEOKA Yasunobu, NAKASHIMA Yasuhiro, KOH Hideo, NAKANE Takahiko, WANIBUCHI Hideki, HINO Masayuki, NAKAMAE Hirohisa

    Rinsho Ketsueki   60 ( 1 )   12 - 16   2019（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>In allogeneic hematopoietic stem cell transplantation (HSCT), ascites may develop owing to several causes, including sinusoidal obstruction syndrome, infections, malignancies, and malnutrition. However, it is often difficult to determine its precise cause. Here, a 59-year-old male developed chylous ascites three months post allogeneic bone marrow transplantation for relapsed acute myeloid leukemia. None of the attempted treatments resulted in improvement. Lymphangioscintigraphy revealed a lymphatic flow disorder at the level of the cisterna chyli. Autopsy revealed no leukemic cell infiltration or graft-versus-host disease of the liver or pancreas. The pancreatic specimen revealed parenchymal fibrosis and infiltration of plasma cells, suggesting chronic inflammation in addition to pathological changes caused by acute pancreatitis. These findings indicate that acute or chronic pancreatitis caused a lymphatic flow disorder that developed into refractory ascites. Although we could not diagnose pancreatitis while the patient was alive, it is important to recognize that asymptomatic pancreatitis can develop after HSCT. Furthermore, one should attempt to make an accurate diagnosis as early as possible.</p>

    DOI： 10.11406/rinketsu.60.12

    PubMed

    CiNii Article

  • Short-Term Fasting Induces Cell Cycle Arrest in Immature Hematopoietic Cells and Increases the Number of Naïve T Cells in the Bone Marrow of Mice. Reviewed

    Takakuwa T, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M

    Acta haematologica   141 ( 3 )   189 - 198   2019（ ISSN:0001-5792 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000496096

    PubMed

  • Rituximabが有効であったHLA半合致移植後の脊髄長大病変を伴う再発性急性散在性脳脊髄炎 Reviewed

    幕内 陽介, 西本 光孝, 山本 圭一, 高橋 利幸, 久野 雅智, 中嶋 康博, 康 秀男, 中根 孝彦, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局 臨床血液   59 ( 12 )   2588 - 2593   2018.12（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    同種造血幹細胞移植後の慢性移植片対宿主病(graft-versus-host disease、GVHD)に起因する中枢神経疾患は稀であり、その病態や治療法には不明な点が多い。我々は急性混合性白血病に対して移植後大量シクロフォスファミドを用いたHLA半合致同種末梢血幹細胞移植を行い、慢性GVHDに起因した脊髄長大病変を伴う再発性の急性散在性脳脊髄炎(acute disseminated encephalomyelitis、ADEM)を合併した1症例を経験した。ステロイド治療に抵抗性を認めたがrituximabの投与が有効であった。我々が知る限り、脊髄長大病変というADEMにおいては非典型的な病変形成に慢性GVHDが寄与し、またこの病態に対してrituximabが有効であった報告は他にない。同種造血細胞移植後の慢性GVHD患者に生じた神経症状の鑑別としてADEMの可能性を考慮するべきと考えられる。(著者抄録)

  • Rituximabが有効であったHLA半合致移植後の脊髄長大病変を伴う再発性急性散在性脳脊髄炎 Reviewed

    幕内 陽介, 西本 光孝, 山本 圭一, 高橋 利幸, 久野 雅智, 中嶋 康博, 康 秀男, 中根 孝彦, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局　臨床血液   59 ( 12 )   2588 - 2593   2018.12（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    同種造血幹細胞移植後の慢性移植片対宿主病(graft-versus-host disease、GVHD)に起因する中枢神経疾患は稀であり、その病態や治療法には不明な点が多い。我々は急性混合性白血病に対して移植後大量シクロフォスファミドを用いたHLA半合致同種末梢血幹細胞移植を行い、慢性GVHDに起因した脊髄長大病変を伴う再発性の急性散在性脳脊髄炎(acute disseminated encephalomyelitis、ADEM)を合併した1症例を経験した。ステロイド治療に抵抗性を認めたがrituximabの投与が有効であった。我々が知る限り、脊髄長大病変というADEMにおいては非典型的な病変形成に慢性GVHDが寄与し、またこの病態に対してrituximabが有効であった報告は他にない。同種造血細胞移植後の慢性GVHD患者に生じた神経症状の鑑別としてADEMの可能性を考慮するべきと考えられる。(著者抄録)

  • Rituximabが有効であったHLA半合致移植後の脊髄長大病変を伴う再発性急性散在性脳脊髄炎

    幕内 陽介, 西本 光孝, 山本 圭一, 高橋 利幸, 久野 雅智, 中嶋 康博, 康 秀男, 中根 孝彦, 日野 雅之, 中前 博久

    臨床血液   59 ( 12 )   2588 - 2593   2018.12（ ISSN:0485-1439 ）

    　More details

    同種造血幹細胞移植後の慢性移植片対宿主病(graft-versus-host disease、GVHD)に起因する中枢神経疾患は稀であり、その病態や治療法には不明な点が多い。我々は急性混合性白血病に対して移植後大量シクロフォスファミドを用いたHLA半合致同種末梢血幹細胞移植を行い、慢性GVHDに起因した脊髄長大病変を伴う再発性の急性散在性脳脊髄炎(acute disseminated encephalomyelitis、ADEM)を合併した1症例を経験した。ステロイド治療に抵抗性を認めたがrituximabの投与が有効であった。我々が知る限り、脊髄長大病変というADEMにおいては非典型的な病変形成に慢性GVHDが寄与し、またこの病態に対してrituximabが有効であった報告は他にない。同種造血細胞移植後の慢性GVHD患者に生じた神経症状の鑑別としてADEMの可能性を考慮するべきと考えられる。(著者抄録)

  • Rituximabが有効であったHLA半合致移植後の脊髄長大病変を伴う再発性急性散在性脳脊髄炎 Reviewed

    幕内 陽介, 西本 光孝, 山本 圭一, 高橋 利幸, 久野 雅智, 中嶋 康博, 康 秀男, 中根 孝彦, 日野 雅之, 中前 博久

    (一社)日本血液学会-東京事務局 臨床血液   59 ( 12 )   2588 - 2593   2018.12（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    同種造血幹細胞移植後の慢性移植片対宿主病(graft-versus-host disease、GVHD)に起因する中枢神経疾患は稀であり、その病態や治療法には不明な点が多い。我々は急性混合性白血病に対して移植後大量シクロフォスファミドを用いたHLA半合致同種末梢血幹細胞移植を行い、慢性GVHDに起因した脊髄長大病変を伴う再発性の急性散在性脳脊髄炎(acute disseminated encephalomyelitis、ADEM)を合併した1症例を経験した。ステロイド治療に抵抗性を認めたがrituximabの投与が有効であった。我々が知る限り、脊髄長大病変というADEMにおいては非典型的な病変形成に慢性GVHDが寄与し、またこの病態に対してrituximabが有効であった報告は他にない。同種造血細胞移植後の慢性GVHD患者に生じた神経症状の鑑別としてADEMの可能性を考慮するべきと考えられる。(著者抄録)

  • Noninvasive Diagnostic Approach By per Rectal Portal Scintigraphy for Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Okamura Hiroshi, Koh Hideo, Ido Kentaro, Makuuchi Yosuke, Takakuwa Teruhito, Ine Shoji, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Jogo Atsushi, Yamamoto Akira, Hamuro Masao, Yoshida Atsushi, Kotani Kohei, Higashiyama Shigeaki, Kawabe Joji, Shiomi Susumu, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-110517

  • The Proportional Association between WT1 mRNA Level in Peripheral Blood before Allogeneic Hematopoietic Cell Transplantation and Risk of Mortality in Acute Myeloid Leukemia Not in Remission Reviewed

    Ido Kentaro, Nakamae Mika, Koh Hideo, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Hashimoto Yoshinori, Takeoka Yasunobu, Hirose Asao, Nakashima Yasuhiro, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-111834

  • Pre-Transplant Serum Beta-2 Microglobulin Level Is a Potential Novel Prognostic Marker for Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Harada Naonori, Nakane Takahiko, Nakamae Mika, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Takeoka Yasunobu, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-111679

  • Noninvasive Diagnostic Approach By per Rectal Portal Scintigraphy for Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Okamura Hiroshi, Koh Hideo, Ido Kentaro, Makuuchi Yosuke, Takakuwa Teruhito, Ine Shoji, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Jogo Atsushi, Yamamoto Akira, Hamuro Masao, Yoshida Atsushi, Kotani Kohei, Higashiyama Shigeaki, Kawabe Joji, Shiomi Susumu, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-110517

  • The Proportional Association between WT1 mRNA Level in Peripheral Blood before Allogeneic Hematopoietic Cell Transplantation and Risk of Mortality in Acute Myeloid Leukemia Not in Remission Reviewed

    Ido Kentaro, Nakamae Mika, Koh Hideo, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Hashimoto Yoshinori, Takeoka Yasunobu, Hirose Asao, Nakashima Yasuhiro, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-111834

  • Pre-Transplant Serum Beta-2 Microglobulin Level Is a Potential Novel Prognostic Marker for Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Harada Naonori, Nakane Takahiko, Nakamae Mika, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Takeoka Yasunobu, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-111679

  • Noninvasive Diagnostic Approach By per Rectal Portal Scintigraphy for Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Okamura Hiroshi, Koh Hideo, Ido Kentaro, Makuuchi Yosuke, Takakuwa Teruhito, Ine Shoji, Nanno Satoru, Nakashima Yasuhiro, Nakane Takahiko, Jogo Atsushi, Yamamoto Akira, Hamuro Masao, Yoshida Atsushi, Kotani Kohei, Higashiyama Shigeaki, Kawabe Joji, Shiomi Susumu, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-110517

  • Pre-Transplant Serum Beta-2 Microglobulin Level Is a Potential Novel Prognostic Marker for Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Harada Naonori, Nakane Takahiko, Nakamae Mika, Okamura Hiroshi, Nanno Satoru, Nishimoto Mitsutaka, Takeoka Yasunobu, Hirose Asao, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

    BLOOD   132   2018.11（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-111679

  • Prophylactic Combined Use of Anticoagulant Agent and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation(和訳中) Reviewed

    Okamura Hiroshi, Koh Hideo, Nishimoto Mitsutaka, Nakane Takahiko, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会　Osaka City Medical Journal   64 ( 1 )   43 - 54   2018.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Prophylactic Combined Use of Anticoagulant Agent and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation(和訳中) Reviewed

    Okamura Hiroshi, Koh Hideo, Nishimoto Mitsutaka, Nakane Takahiko, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会 Osaka City Medical Journal   64 ( 1 )   43 - 54   2018.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Prophylactic Combined Use of Anticoagulant Agent and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation(和訳中) Reviewed

    Okamura Hiroshi, Koh Hideo, Nishimoto Mitsutaka, Nakane Takahiko, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会 Osaka City Medical Journal   64 ( 1 )   43 - 54   2018.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 同種造血幹細胞移植後の類洞閉塞症候群予防を目的とした抗凝固薬とウルソデオキシコール酸の併用投与(Prophylactic Combined Use of Anticoagulant Agent and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation)

    Okamura Hiroshi, Koh Hideo, Nishimoto Mitsutaka, Nakane Takahiko, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    Osaka City Medical Journal   64 ( 1 )   43 - 54   2018.06（ ISSN:0030-6096 ）

    　More details

    当施設で骨髄破壊的前処置による同種造血幹細胞移植(HSCT)を受けた患者において、類洞閉塞症候群(SOS)の予防目的で行った凝固薬とウルソデオキシコール酸(UDCA)の併用投与の有効性を後ろ向きに評価した。2000年6月～2014年5月にHSCT後のSOS予防のためUDCAとダルテパリンまたはダナパロイドのいずれかが併用投与された患者(I群)59例とUDCA単剤を投与された患者(II群)193例を対象とした。Seattle基準、Baltimore基準によるそれぞれのSOS発症率、および移植後30日、100日以内の出血イベント発症率を検討した。I群の59例中9例(15.3%)とII群の193例中28例(14.5%)がSOSを発症した。SOS発症率に関して両群間に有意差は認めなかった。移植後30日または100日以内の出血イベントの発症率においても、両群間で有意差を認めなかった。以上から、HSCT後のSOS予防にUDCAを使用する場合、抗凝固薬を併用投与することの意義は乏しいと考えられた。

  • Prophylactic Combined Use of Anticoagulant Agent and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation(和訳中) Reviewed

    Okamura Hiroshi, Koh Hideo, Nishimoto Mitsutaka, Nakane Takahiko, Nakashima Yasuhiro, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会 Osaka City Medical Journal   64 ( 1 )   43 - 54   2018.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Successful treatment with rituximab in acute disseminated encephalomyelitis with whole spinal cord involvement following HLA haploidentical transplantation Reviewed

    MAKUUCHI Yosuke, NAKAMAE Hirohisa, NISHIMOTO Mitsutaka, YAMAMOTO Keiichi, TAKAHASHI Toshiyuki, KUNO Masatomo, NAKASHIMA Yasuhiro, KOH Hideo, NAKANE Takahiko, HINO Masayuki

    The Japanese Society of Hematology, Rinsho Ketsueki   59 ( 12 )   2588 - 2593   2018（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Chronic graft versus host disease (cGVHD) of the central nervous system is a rare condition that could occur after allogeneic hematopoietic stem cell transplantation (SCT) but has been poorly documented. Here, we report a patient diagnosed with recurrent acute disseminated encephalomyelitis (ADEM) with longitudinal extensive transverse myelitis (LETM) as cGVHD after HLA haploidentical peripheral blood SCT using posttransplantation cyclophosphamide for mixed-phenotype acute leukemia. We observed clinical and radiological improvement after the rituximab treatment of the condition that had been refractory to steroids. To the best of our knowledge, no report of cGVHD presented recurrent ADEM with LETM after allogeneic SCT and successfully treated with rituximab. Hence, ADEM should be included in the differential diagnosis of neurological symptoms in posttransplant patients with cGVHD.</p>

    DOI： 10.11406/rinketsu.59.2588

    PubMed

    CiNii Article

  • Successful treatment with rituximab in acute disseminated encephalomyelitis with whole spinal cord involvement following HLA haploidentical transplantation Reviewed

    MAKUUCHI Yosuke, NISHIMOTO Mitsutaka, YAMAMOTO Keiichi, TAKAHASHI Toshiyuki, KUNO Masatomo, NAKASHIMA Yasuhiro, KOH Hideo, NAKANE Takahiko, HINO Masayuki, NAKAMAE Hirohisa

    Rinsho Ketsueki   59 ( 12 )   2588 - 2593   2018（ ISSN:0485-1439 ） （ eISSN:18820824 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Chronic graft versus host disease (cGVHD) of the central nervous system is a rare condition that could occur after allogeneic hematopoietic stem cell transplantation (SCT) but has been poorly documented. Here, we report a patient diagnosed with recurrent acute disseminated encephalomyelitis (ADEM) with longitudinal extensive transverse myelitis (LETM) as cGVHD after HLA haploidentical peripheral blood SCT using posttransplantation cyclophosphamide for mixed-phenotype acute leukemia. We observed clinical and radiological improvement after the rituximab treatment of the condition that had been refractory to steroids. To the best of our knowledge, no report of cGVHD presented recurrent ADEM with LETM after allogeneic SCT and successfully treated with rituximab. Hence, ADEM should be included in the differential diagnosis of neurological symptoms in posttransplant patients with cGVHD.</p>

    DOI： 10.11406/rinketsu.59.2588

    PubMed

    CiNii Article

  • Autonomic Nervous System Pretransplant Malfunction Is a Powerful Predictor of Survival After Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakane Takahiko, Nakamae Mika, Koh Hideo, Nishimoto Mitsutaka, Nakashima Yasuhiro, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    TRANSPLANTATION   101 ( 11 )   2801 - 2809   2017.11（ ISSN:0041-1337 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/TP.0000000000001813

    PubMed

  • Autonomic Nervous System Pretransplant Malfunction Is a Powerful Predictor of Survival After Allogeneic Hematopoietic Cell Transplantation Reviewed

    Takahiko Nakane, Mika Nakamae, Hideo Koh, Mitsutaka Nishimoto, Yasuhiro Nakashima, Asao Hirose, Masayuki Hino, Hirohisa Nakamae

    Transplantation   101 ( 11 )   2801 - 2809   2017.11（ ISSN:0041-1337 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Background: Autonomic nervous system function indexed by heart rate variability (HRV) has shown prognostic value for mortality in various cardiovascular and noncardiovascular diseases including cancer. The purpose of this study was to evaluate an association between HRV and outcomes of allogeneic hematopoietic cell transplantation (allo-HCT). Methods: We prospectively measured HRV as a surrogate pretransplant marker of autonomic nervous system activity in consecutive allo-HCTs with hematological diseases. Results: We analyzed 112 allo-HCTs performed between July 2011 and July 2013 in our center. Univariate analysis showed that increased values of HRV components (low-frequency [LF] and high-frequency [HF] spectral component), SD of normal-to-normal RR interval (SDNN), and squares of the differences between adjacent normal-to-normal RR intervals (r-MSSD) were significantly associated with decreased probability of overall mortality (hazard ratio = 0.3 for LF, P &lt
    0.001
    hazard ratio = 0.3 for HF, P = 0.001
    hazard ratio = 0.6 for SDNN, P = 0.004
    and hazard ratio = 0.5 for r-MSSD, P = 0.014). Among these 4 indicators, the LF-added pretransplantation assessment of mortality, hematopoietic cell transplantation-comorbidity index, and disease risk index models showed the highest values of ΔAkaike information criterion (16.5, 22.2, and 11.4, respectively). When stratified into quartiles of LF groups, 2-year overall survival was 92.9, 84.5, 59.7, and 33.2%, respectively (P &lt
    0.001). LF alone represented a better discriminating variable for the prediction of mortality when compared with pretransplantation assessment of mortality, hematopoietic cell transplantation-comorbidity index, and disease risk index. In addition, from bivariate analyses, decreased LF was an independent and significant factor for higher overall mortality in all models. Conclusions: Indicators reflective of autonomic nervous system function might be a powerful predictor of survival after allo-HCT.

    DOI： 10.1097/TP.0000000000001813

    PubMed

  • Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation Reviewed

    Nishimoto Mitsutaka, Koh Hideo, Tokuwame Atsushi, Makuuchi Yosuke, Kuno Masatomo, Takakuwa Teruhito, Okamura Hiroshi, Koh Shiro, Yoshimura Takuro, Nanno Satoru, Nakamae Mika, Hirose Asao, Nakashima Yasuhiro, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY   83 ( 9 )   2000 - 2007   2017.09（ ISSN:0306-5251 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/bcp.13303

    PubMed

  • Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation Reviewed

    Mitsutaka Nishimoto, Hideo Koh, Atsushi Tokuwame, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Shiro Koh, Takuro Yoshimura, Satoru Nanno, Mika Nakamae, Asao Hirose, Yasuhiro Nakashima, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae

    British Journal of Clinical Pharmacology   83 ( 9 )   2000 - 2007   2017.09（ ISSN:0306-5251 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Aim: Small-scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects
    however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo-HCT) patients. Methods: We retrospectively assessed the drug interactions and safety profiles in allo-HCT recipients treated concomitantly with CPFG and calcineurin inhibitors. Results: Ninety-one consecutive cases were evaluated. There were no statistically significant differences in the plasma concentration/dose (C/D) ratios of tacrolimus (TAC) in 34 patients before and after co-administration with CPFG (median: 575.6–672.4, P = 0.200). In contrast, the median C/D ratio of cyclosporin A (CsA) in 16 patients was significantly elevated after co-administration with CPFG (median: 62.8–74.9, P = 0.016). There were no serious adverse effects on liver or renal function associated with the therapy. Conclusions: Our data show that CPFG did not affect the pharmacokinetics of TAC and that it could mildly increase CsA blood concentrations in allo-HCT patients.

    DOI： 10.1111/bcp.13303

    PubMed

  • An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone

    Koh Shiro, Koh Hideo, Kubo Yuki, Kuroda Maiko, Nishimoto Mitsutaka, Yoshimura Takuro, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    Internal Medicine   56 ( 16 )   2199 - 2203   2017.08（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Although anti-neutrophil antibodies (ANAs) often exist and immunoreaction may be involved in agranulocytosis, few reports have so far described ANA-positive cases of agranulocytosis with an unknown etiology. We herein describe the case of a 69-year-old woman who presented with ANA-positive agranulocytosis. In this case, both the withdrawal of the drugs that had possibly caused neutropenia and the use of granulocyte-colony stimulating factor (G-CSF) were ineffective treatment measures. Approximately 2 weeks after the discontinuation of the suspected drugs, we initiated corticosteroid pulse therapy; the neutrophil count recovered by day 19 of steroid therapy. High-dose methylprednisolone therapy should thus be considered for patients demonstrating ANA-positive agranulocytosis with an unknown etiology that is refractory to G-CSF treatment. </p>

    DOI： 10.2169/internalmedicine.8268-16

    PubMed

    CiNii Article

  • 高用量メチルプレドニゾロン静注に応答した抗好中球抗体陽性無顆粒球症の高齢女性(An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone) Reviewed

    Koh Shiro, Koh Hideo, Kubo Yuki, Kuroda Maiko, Nishimoto Mitsutaka, Yoshimura Takuro, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    (一社)日本内科学会　Internal Medicine   56 ( 16 )   2199 - 2203   2017.08（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は69歳女性で、2ヵ月前に原因不明の皮疹が出現し、その後、高熱、咽喉痛、全身疲労がみられた。今回、進行性白血球減少症と持続性発熱のため入院となった。数年間にわたり降圧薬、抗脂質異常薬、血栓予防目的でアスピリンを服用しており、1年前からは非ウイルス性肝炎に対してウルソデオキシコール酸を処方していた。所見から薬剤誘導性無顆粒球症と仮診断し、全ての処方薬を中止した。4日目にG-CSF投与とラミナエアフロー隔離を行った。広域抗生物質投与により高熱と咽頭痛は改善したが、好中球数は回復しなかった。その後、重度肺炎を発症し、11日目のCTで前縦隔腫瘍が明らかになった。G-CSF投与を継続した上で、20日目から高用量メチルプレドニゾロン静注療法(1g/日を3日間)を開始し、その後プレドニゾロン(1mg/kg)を投与した。40日目には好中球数が次第に正常範囲に改善したが、アスペルギルス肺炎と脳出血により46日目に死亡した。

  • 高用量メチルプレドニゾロン静注に応答した抗好中球抗体陽性無顆粒球症の高齢女性(An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone) Reviewed

    Koh Shiro, Koh Hideo, Kubo Yuki, Kuroda Maiko, Nishimoto Mitsutaka, Yoshimura Takuro, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    (一社)日本内科学会 Internal Medicine   56 ( 16 )   2199 - 2203   2017.08（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は69歳女性で、2ヵ月前に原因不明の皮疹が出現し、その後、高熱、咽喉痛、全身疲労がみられた。今回、進行性白血球減少症と持続性発熱のため入院となった。数年間にわたり降圧薬、抗脂質異常薬、血栓予防目的でアスピリンを服用しており、1年前からは非ウイルス性肝炎に対してウルソデオキシコール酸を処方していた。所見から薬剤誘導性無顆粒球症と仮診断し、全ての処方薬を中止した。4日目にG-CSF投与とラミナエアフロー隔離を行った。広域抗生物質投与により高熱と咽頭痛は改善したが、好中球数は回復しなかった。その後、重度肺炎を発症し、11日目のCTで前縦隔腫瘍が明らかになった。G-CSF投与を継続した上で、20日目から高用量メチルプレドニゾロン静注療法(1g/日を3日間)を開始し、その後プレドニゾロン(1mg/kg)を投与した。40日目には好中球数が次第に正常範囲に改善したが、アスペルギルス肺炎と脳出血により46日目に死亡した。

  • 高用量メチルプレドニゾロン静注に応答した抗好中球抗体陽性無顆粒球症の高齢女性(An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone) Reviewed

    Koh Shiro, Koh Hideo, Kubo Yuki, Kuroda Maiko, Nishimoto Mitsutaka, Yoshimura Takuro, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    (一社)日本内科学会 Internal Medicine   56 ( 16 )   2199 - 2203   2017.08（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は69歳女性で、2ヵ月前に原因不明の皮疹が出現し、その後、高熱、咽喉痛、全身疲労がみられた。今回、進行性白血球減少症と持続性発熱のため入院となった。数年間にわたり降圧薬、抗脂質異常薬、血栓予防目的でアスピリンを服用しており、1年前からは非ウイルス性肝炎に対してウルソデオキシコール酸を処方していた。所見から薬剤誘導性無顆粒球症と仮診断し、全ての処方薬を中止した。4日目にG-CSF投与とラミナエアフロー隔離を行った。広域抗生物質投与により高熱と咽頭痛は改善したが、好中球数は回復しなかった。その後、重度肺炎を発症し、11日目のCTで前縦隔腫瘍が明らかになった。G-CSF投与を継続した上で、20日目から高用量メチルプレドニゾロン静注療法(1g/日を3日間)を開始し、その後プレドニゾロン(1mg/kg)を投与した。40日目には好中球数が次第に正常範囲に改善したが、アスペルギルス肺炎と脳出血により46日目に死亡した。

  • 高用量メチルプレドニゾロン静注に応答した抗好中球抗体陽性無顆粒球症の高齢女性(An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone)

    Koh Shiro, Koh Hideo, Kubo Yuki, Kuroda Maiko, Nishimoto Mitsutaka, Yoshimura Takuro, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    Internal Medicine   56 ( 16 )   2199 - 2203   2017.08（ ISSN:0918-2918 ）

    　More details

    症例は69歳女性で、2ヵ月前に原因不明の皮疹が出現し、その後、高熱、咽喉痛、全身疲労がみられた。今回、進行性白血球減少症と持続性発熱のため入院となった。数年間にわたり降圧薬、抗脂質異常薬、血栓予防目的でアスピリンを服用しており、1年前からは非ウイルス性肝炎に対してウルソデオキシコール酸を処方していた。所見から薬剤誘導性無顆粒球症と仮診断し、全ての処方薬を中止した。4日目にG-CSF投与とラミナエアフロー隔離を行った。広域抗生物質投与により高熱と咽頭痛は改善したが、好中球数は回復しなかった。その後、重度肺炎を発症し、11日目のCTで前縦隔腫瘍が明らかになった。G-CSF投与を継続した上で、20日目から高用量メチルプレドニゾロン静注療法(1g/日を3日間)を開始し、その後プレドニゾロン(1mg/kg)を投与した。40日目には好中球数が次第に正常範囲に改善したが、アスペルギルス肺炎と脳出血により46日目に死亡した。

  • Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation Reviewed

    Satoru Nanno, Hideo Koh, Yasuhiro Nakashima, Takako Katayama, Hiroshi Okamura, Shiro Koh, Takuro Yoshimura, Mitsutaka Nishimoto, Yoshiki Hayashi, Mika Nakamae, Asao Hirose, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae

    Leukemia and Lymphoma   58 ( 7 )   1664 - 1672   2017.07（ ISSN:1026-8022 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    To examine the diagnostic value of serum ferritin, the associated risk factors, and cytokine profiles of hemophagocytic syndrome (HPS) following allogeneic hematopoietic cell transplantation (allo-HCT), we retrospectively analyzed data from patients undergoing allo-HCT between 2006 and 2012. Of 223 eligible patients, 18 patients developed HPS. A serum ferritin level above 30,000 μg/l was highly specific for the detection of HPS (specificity, 93%). The one-year survival rate for HPS was significantly lower than that of non-HPS patients (37.5% vs. 72.9%, respectively, Log-rank p &lt
    .01). In multivariable Cox models, antigen mismatches in human leukocyte antigen (HLA) in both graft-versus-host (GVH) and host-versus-graft (HVG) directions were significantly associated with the incidence of HPS. We found a significant elevation of Th1 cytokine (IFN-γ), Th2 cytokines (IL-10), and chemokines (MCP-1 and IP-10), at the onset of HPS. Our results suggest that allo-reactivity, derived from HLA-mismatch, and possibly causing a cytokine storm, may be associated with HPS development.

    DOI： 10.1080/10428194.2016.1262034

    PubMed

  • Immunoprofile Changes during Dasatinib Treatment in Patients with Chronic Myeloid Leukemia: A Prospective Observational Study(和訳中) Reviewed

    Kuno Masatomo, Nakane Takahiko, Katayama Takako, Koh Hideo, Nakashima Yasuhiro, Nishimoto Mitsutaka, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会　Osaka City Medical Journal   63 ( 1 )   43 - 55   2017.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Immunoprofile Changes during Dasatinib Treatment in Patients with Chronic Myeloid Leukemia: A Prospective Observational Study(和訳中) Reviewed

    Kuno Masatomo, Nakane Takahiko, Katayama Takako, Koh Hideo, Nakashima Yasuhiro, Nishimoto Mitsutaka, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会 Osaka City Medical Journal   63 ( 1 )   43 - 55   2017.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Immunoprofile Changes during Dasatinib Treatment in Patients with Chronic Myeloid Leukemia: A Prospective Observational Study(和訳中) Reviewed

    Kuno Masatomo, Nakane Takahiko, Katayama Takako, Koh Hideo, Nakashima Yasuhiro, Nishimoto Mitsutaka, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会 Osaka City Medical Journal   63 ( 1 )   43 - 55   2017.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 慢性骨髄性白血病患者におけるダサチニブ治療中の免疫プロファイルの変化　前向き観察研究(Immunoprofile Changes during Dasatinib Treatment in Patients with Chronic Myeloid Leukemia: A Prospective Observational Study)

    Kuno Masatomo, Nakane Takahiko, Katayama Takako, Koh Hideo, Nakashima Yasuhiro, Nishimoto Mitsutaka, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    Osaka City Medical Journal   63 ( 1 )   43 - 55   2017.06（ ISSN:0030-6096 ）

    　More details

    ダサチニブ、イマチニブ、ニロチニブによる治療を行った慢性期の慢性骨髄性白血病(CML)患者30例を対象に、ダサチニブ治療中の免疫細胞数とナチュラルキラー(NK)細胞反応性の変化、免疫学的変化と治療奏効の関連性、大顆粒リンパ球(LGL)の抗CML作用を評価した。さらに、ダサチニブ治療中のLGLおよびNK細胞の拡大に関与する可溶性因子を特定し、LGLリンパ球増加を発症する患者の特性を検討した。NK細胞反応性とLGL数は、ダサチニブ治療中に有意に増強した。NK細胞反応性と制御性TNF細胞数は、ダサチニブ治療の奏効の程度と有意に相関した。ベースラインとダサチニブ治療開始後3、6ヵ月時のT-LGL数には有意な正の相関が認められた。ダサチニブ治療により増強したNK細胞の細胞毒性が抗CML作用の根拠であり、ダサチニブ治療前のT-LGL数はダサチニブ治療の予後的指標となりうることが示唆された。

  • Immunoprofile Changes during Dasatinib Treatment in Patients with Chronic Myeloid Leukemia: A Prospective Observational Study(和訳中) Reviewed

    Kuno Masatomo, Nakane Takahiko, Katayama Takako, Koh Hideo, Nakashima Yasuhiro, Nishimoto Mitsutaka, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    大阪市医学会 Osaka City Medical Journal   63 ( 1 )   43 - 55   2017.06（ ISSN:0030-6096 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Cidofovir Treatment for Adenovirus-Associated Hemorrhagic Cystitis in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Comparative Study Reviewed

    Yoshimura Takuro, Nishimoto Mitsutaka, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Takeoka Yasunobu, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   23 ( 3 )   S191 - S191   2017.03（ ISSN:1083-8791 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone Reviewed

    Koh Shiro, Koh Hideo, Kubo Yuki, Kuroda Maiko, Nishimoto Mitsutaka, Yoshimura Takuro, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    一般社団法人 日本内科学会　INTERNAL MEDICINE   56 ( 16 )   2199 - 2203   2017（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>Although anti-neutrophil antibodies (ANAs) often exist and immunoreaction may be involved in agranulocytosis, few reports have so far described ANA-positive cases of agranulocytosis with an unknown etiology. We herein describe the case of a 69-year-old woman who presented with ANA-positive agranulocytosis. In this case, both the withdrawal of the drugs that had possibly caused neutropenia and the use of granulocyte-colony stimulating factor (G-CSF) were ineffective treatment measures. Approximately 2 weeks after the discontinuation of the suspected drugs, we initiated corticosteroid pulse therapy; the neutrophil count recovered by day 19 of steroid therapy. High-dose methylprednisolone therapy should thus be considered for patients demonstrating ANA-positive agranulocytosis with an unknown etiology that is refractory to G-CSF treatment. </p>

    DOI： 10.2169/internalmedicine.8268-16

    PubMed

    CiNii Article

  • Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation Reviewed

    Nanno Satoru, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Okamura Hiroshi, Koh Shiro, Yoshimura Takuro, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakamae Mika, Hirose Asao, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    LEUKEMIA & LYMPHOMA   58 ( 7 )   1664 - 1672   2017（ ISSN:1042-8194 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428194.2016.1262034

    PubMed

  • Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation Reviewed

    Okamura Hiroshi, Nishimoto Mitsutaka, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Takeoka Yasunobu, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation Reviewed

    Okamura Hiroshi, Nishimoto Mitsutaka, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Takeoka Yasunobu, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Short-Term Fasting Induces Cell Cycle Arrest of Immature Hematopoietic Cells and Increases the Number of Naive T Cells in the Bone Marrow of Mice Reviewed

    Takakuwa Teruhito, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Nakamae Hirohisa, Hino Masayuki

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Short-Term Fasting Induces Cell Cycle Arrest of Immature Hematopoietic Cells and Increases the Number of Naive T Cells in the Bone Marrow of Mice Reviewed

    Takakuwa Teruhito, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Nakamae Hirohisa, Hino Masayuki

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation Reviewed

    Okamura Hiroshi, Nishimoto Mitsutaka, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Takeoka Yasunobu, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Short-Term Fasting Induces Cell Cycle Arrest of Immature Hematopoietic Cells and Increases the Number of Naive T Cells in the Bone Marrow of Mice Reviewed

    Takakuwa Teruhito, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Nakamae Hirohisa, Hino Masayuki

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation Reviewed

    Okamura Hiroshi, Nishimoto Mitsutaka, Nakane Takahiko, Koh Hideo, Nakashima Yasuhiro, Takeoka Yasunobu, Nakamae Mika, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    BLOOD   128 ( 22 )   2016.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 発熱を伴う好中球減少症患者の細菌同定に対する23SリボソームRNA遺伝子を標的とするin situハイブリダイゼーションと血液培養との組み合わせアプローチ(Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever) Reviewed

    Koh Hideo, Aimoto Mizuki, Matsuhisa Akio, Inoue Shin-ichi, Katayama Takako, Okamura Hiroshi, Yoshimura Takuro, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    エルゼビア・ジャパン(株)　Journal of Infection and Chemotherapy   22 ( 9-10 )   697 - 703   2016.10（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    化学療法施行中の発熱性好中球減少症(FN)患者において、global bacteria probe(GBプローブ)を用いた新たなin situハイブリダイゼーション法(ISH)の有用性を評価した。患者34例(男18例、女16例、年齢中央値42.5歳)を対象とした。50回の発熱事象を評価した。発熱時におけるISHによる原因菌の特定は原因不明の発熱事象24で21%、局所感染(血液培養陰性)による発熱事象15で13%であった。敗血症7名(血液培養陽性)では発熱時にISH陽性に達したのは71%であった。好中球数0/μLと171/μLの症例では陰性の結果が得られた。この新しいISH法は、化学療法後に好中球減少症と原因不明の発熱を有する血液培養陰性患者における、細菌の早期検出に有用であった。この方法と血液培養との併用は好中球数が極端に低い症例においてでも、FNの良好な管理に寄与する可能性があると考えられた。

  • 発熱を伴う好中球減少症患者の細菌同定に対する23SリボソームRNA遺伝子を標的とするin situハイブリダイゼーションと血液培養との組み合わせアプローチ(Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever) Reviewed

    Koh Hideo, Aimoto Mizuki, Matsuhisa Akio, Inoue Shin-ichi, Katayama Takako, Okamura Hiroshi, Yoshimura Takuro, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    エルゼビア・ジャパン(株) Journal of Infection and Chemotherapy   22 ( 9-10 )   697 - 703   2016.10（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    化学療法施行中の発熱性好中球減少症(FN)患者において、global bacteria probe(GBプローブ)を用いた新たなin situハイブリダイゼーション法(ISH)の有用性を評価した。患者34例(男18例、女16例、年齢中央値42.5歳)を対象とした。50回の発熱事象を評価した。発熱時におけるISHによる原因菌の特定は原因不明の発熱事象24で21%、局所感染(血液培養陰性)による発熱事象15で13%であった。敗血症7名(血液培養陽性)では発熱時にISH陽性に達したのは71%であった。好中球数0/μLと171/μLの症例では陰性の結果が得られた。この新しいISH法は、化学療法後に好中球減少症と原因不明の発熱を有する血液培養陰性患者における、細菌の早期検出に有用であった。この方法と血液培養との併用は好中球数が極端に低い症例においてでも、FNの良好な管理に寄与する可能性があると考えられた。

  • Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever Reviewed

    Hideo Koh, Mizuki Aimoto, Akio Matsuhisa, Shin-Ichi Inoue, Takako Katayama, Hiroshi Okamura, Takuro Yoshimura, Shiro Koh, Satoru Nanno, Mitsutaka Nishimoto, Yasuhiro Nakashima, Asao Hirose, Mika Nakamae, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae

    Journal of Infection and Chemotherapy   22 ( 10 )   697 - 703   2016.10（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Background A new 23S ribosomal RNA genes-targeted in situ hybridization (ISH) probe to detect global bacterial genomic DNA (59 species from 35 genera
    referred to as the GB probe) phagocytized in leukocytes was recently developed. This method provided early and direct evidence of bacterial infection with high sensitivity and specificity in spontaneous bacterial peritonitis ascites. However, the utility of this method in febrile neutropenia (FN) is unknown. Methods We prospectively evaluated the utility of the ISH approach using the GB probe and previously reported probes in patients with neutropenia and fever undergoing chemotherapy at our institution between June 2011 and July 2013. Blood samples for culture analysis and ISH tests were collected simultaneously at the onset of fever
    the latter were performed repeatedly. Results Fifty febrile episodes were evaluated. In 24 episodes of fever of unknown origin and 15 episodes of local infection (all negative for blood cultures), ISH tests identified causal bacteria in 21% and 13% of cases, respectively, at the onset of fever. In seven sepsis cases (all positive for blood culture), positive ISH test results at fever onset were achieved in 71%
    for two patients with neutrophil counts of 0/μl and 171/μl, respectively, negative results were obtained. Conclusions This new ISH approach could prove useful for early detection of bacteria in patients with neutropenia and blood culture-negative, with fever of unknown etiology after chemotherapy. Using this method in combination with blood culture, even in cases with extremely low neutrophil counts, might contribute to better management of FN.

    DOI： 10.1016/j.jiac.2016.08.001

    PubMed

  • 発熱を伴う好中球減少症患者の細菌同定に対する23SリボソームRNA遺伝子を標的とするin situハイブリダイゼーションと血液培養との組み合わせアプローチ(Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever)

    Koh Hideo, Aimoto Mizuki, Matsuhisa Akio, Inoue Shin-ichi, Katayama Takako, Okamura Hiroshi, Yoshimura Takuro, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    Journal of Infection and Chemotherapy   22 ( 9-10 )   697 - 703   2016.10（ ISSN:1341-321X ）

    　More details

    化学療法施行中の発熱性好中球減少症(FN)患者において、global bacteria probe(GBプローブ)を用いた新たなin situハイブリダイゼーション法(ISH)の有用性を評価した。患者34例(男18例、女16例、年齢中央値42.5歳)を対象とした。50回の発熱事象を評価した。発熱時におけるISHによる原因菌の特定は原因不明の発熱事象24で21%、局所感染(血液培養陰性)による発熱事象15で13%であった。敗血症7名(血液培養陽性)では発熱時にISH陽性に達したのは71%であった。好中球数0/μLと171/μLの症例では陰性の結果が得られた。この新しいISH法は、化学療法後に好中球減少症と原因不明の発熱を有する血液培養陰性患者における、細菌の早期検出に有用であった。この方法と血液培養との併用は好中球数が極端に低い症例においてでも、FNの良好な管理に寄与する可能性があると考えられた。

  • 発熱を伴う好中球減少症患者の細菌同定に対する23SリボソームRNA遺伝子を標的とするin situハイブリダイゼーションと血液培養との組み合わせアプローチ(Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever) Reviewed

    Koh Hideo, Aimoto Mizuki, Matsuhisa Akio, Inoue Shin-ichi, Katayama Takako, Okamura Hiroshi, Yoshimura Takuro, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    エルゼビア・ジャパン(株) Journal of Infection and Chemotherapy   22 ( 9-10 )   697 - 703   2016.10（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    化学療法施行中の発熱性好中球減少症(FN)患者において、global bacteria probe(GBプローブ)を用いた新たなin situハイブリダイゼーション法(ISH)の有用性を評価した。患者34例(男18例、女16例、年齢中央値42.5歳)を対象とした。50回の発熱事象を評価した。発熱時におけるISHによる原因菌の特定は原因不明の発熱事象24で21%、局所感染(血液培養陰性)による発熱事象15で13%であった。敗血症7名(血液培養陽性)では発熱時にISH陽性に達したのは71%であった。好中球数0/μLと171/μLの症例では陰性の結果が得られた。この新しいISH法は、化学療法後に好中球減少症と原因不明の発熱を有する血液培養陰性患者における、細菌の早期検出に有用であった。この方法と血液培養との併用は好中球数が極端に低い症例においてでも、FNの良好な管理に寄与する可能性があると考えられた。

  • 慢性移植片対宿主病に関連する多発性筋炎におけるTh1、Th2、Th17サイトカインの血漿中動態(Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease) Reviewed

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    (一社)日本内科学会　Internal Medicine   55 ( 16 )   2265 - 2270   2016.08（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は36歳男性で、骨髄異形成症候群のため同種造血細胞移植(allo-HCT)を施行されたが、25日後にグレード3の急性移植片対宿主病(GVHD)を発症した。メチルプレドニゾロン投与により症状は消失したが、allo-HCTから1570日後に机の角に右大腿をぶつけてしまった。大腿が腫脹した後、全身疲労と高熱が出現し、筋肉痛のため歩行不能になったため入院した。筋生検で筋線維の破壊およびCD20陽性B細胞とCD4陽性・CD8陽性T細胞の浸潤が明らかとなり、肝生検では慢性GVHDの所見が確認された。血漿サイトカインプロファイル分析で、Tヘルパー(Th)1およびTh2だけでなくTh17サイトカインの上昇を認めた。プレドニゾロン経口投与により症状は消失した。

  • 慢性移植片対宿主病に関連する多発性筋炎におけるTh1、Th2、Th17サイトカインの血漿中動態(Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease) Reviewed

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    (一社)日本内科学会 Internal Medicine   55 ( 16 )   2265 - 2270   2016.08（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は36歳男性で、骨髄異形成症候群のため同種造血細胞移植(allo-HCT)を施行されたが、25日後にグレード3の急性移植片対宿主病(GVHD)を発症した。メチルプレドニゾロン投与により症状は消失したが、allo-HCTから1570日後に机の角に右大腿をぶつけてしまった。大腿が腫脹した後、全身疲労と高熱が出現し、筋肉痛のため歩行不能になったため入院した。筋生検で筋線維の破壊およびCD20陽性B細胞とCD4陽性・CD8陽性T細胞の浸潤が明らかとなり、肝生検では慢性GVHDの所見が確認された。血漿サイトカインプロファイル分析で、Tヘルパー(Th)1およびTh2だけでなくTh17サイトカインの上昇を認めた。プレドニゾロン経口投与により症状は消失した。

  • 慢性移植片対宿主病に関連する多発性筋炎におけるTh1、Th2、Th17サイトカインの血漿中動態(Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease) Reviewed

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    (一社)日本内科学会 Internal Medicine   55 ( 16 )   2265 - 2270   2016.08（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は36歳男性で、骨髄異形成症候群のため同種造血細胞移植(allo-HCT)を施行されたが、25日後にグレード3の急性移植片対宿主病(GVHD)を発症した。メチルプレドニゾロン投与により症状は消失したが、allo-HCTから1570日後に机の角に右大腿をぶつけてしまった。大腿が腫脹した後、全身疲労と高熱が出現し、筋肉痛のため歩行不能になったため入院した。筋生検で筋線維の破壊およびCD20陽性B細胞とCD4陽性・CD8陽性T細胞の浸潤が明らかとなり、肝生検では慢性GVHDの所見が確認された。血漿サイトカインプロファイル分析で、Tヘルパー(Th)1およびTh2だけでなくTh17サイトカインの上昇を認めた。プレドニゾロン経口投与により症状は消失した。

  • 慢性移植片対宿主病に関連する多発性筋炎におけるTh1、Th2、Th17サイトカインの血漿中動態(Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease)

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    Internal Medicine   55 ( 16 )   2265 - 2270   2016.08（ ISSN:0918-2918 ）

    　More details

    症例は36歳男性で、骨髄異形成症候群のため同種造血細胞移植(allo-HCT)を施行されたが、25日後にグレード3の急性移植片対宿主病(GVHD)を発症した。メチルプレドニゾロン投与により症状は消失したが、allo-HCTから1570日後に机の角に右大腿をぶつけてしまった。大腿が腫脹した後、全身疲労と高熱が出現し、筋肉痛のため歩行不能になったため入院した。筋生検で筋線維の破壊およびCD20陽性B細胞とCD4陽性・CD8陽性T細胞の浸潤が明らかとなり、肝生検では慢性GVHDの所見が確認された。血漿サイトカインプロファイル分析で、Tヘルパー(Th)1およびTh2だけでなくTh17サイトカインの上昇を認めた。プレドニゾロン経口投与により症状は消失した。

  • Lung function score including a parameter of small airway disease as a highly predictive indicator of survival after allogeneic hematopoietic cell transplantation Reviewed

    Nakamae Mika, Yamashita Mariko, Koh Hideo, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakashima Yasuhiro, Hirose Asao, Hino Masayuki, Nakamae Hirohisa

    TRANSPLANT INTERNATIONAL   29 ( 6 )   707 - 714   2016.06（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tri.12779

    PubMed

  • THE ALTERATION OF IMMUNOPROFILE DURING DASATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A PROSPECTIVE OBSERVATIONAL STUDY Reviewed

    Kuno M, Nakamae H, Katayama T, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Nakashima Y, Koh H, Nakane T, Hino M

    HAEMATOLOGICA   101   457 - 457   2016.06（ ISSN:0390-6078 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • THE ALTERATION OF IMMUNOPROFILE DURING DASATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A PROSPECTIVE OBSERVATIONAL STUDY Reviewed

    Kuno M., Nakamae H., Katayama T., Nishimoto M., Hayashi Y., Hirose A., Nakamae M., Nakashima Y., Koh H., Nakane T., Hino M.

    HAEMATOLOGICA   101   457 - 457   2016.06（ ISSN:0390-6078 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Lung function score including a parameter of small airway disease as a highly predictive indicator of survival after allogeneic hematopoietic cell transplantation Reviewed

    Mika Nakamae, Mariko Yamashita, Hideo Koh, Mitsutaka Nishimoto, Yoshiki Hayashi, Takahiko Nakane, Yasuhiro Nakashima, Asao Hirose, Masayuki Hino, Hirohisa Nakamae

    Transplant International   29 ( 6 )   707 - 14   2016.06（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Some studies on the predictive value of determining pulmonary function prior to allogeneic hematopoietic cell transplantation (allo-HCT) have shown a significant association between pulmonary function test (PFT) parameters and pulmonary complications, and mortality. However, the percentage of patients showing abnormalities in pretransplant PFT parameters is low. We comprehensively evaluated the effect of pretransplant PFT parameters, including a marker of small airway disease (ratio of the airflow rate of 50% vital capacity to the airflow rate of 25% vital capacity ((Formula presented.) 50/ (Formula presented.) 25), on outcomes in 206 evaluable patients who underwent allo-HCT at our institute. Notable among the significant parameters in a univariable analysis, (Formula presented.) 50/ (Formula presented.) 25 was the most powerful indicator of survival following allo-HCT (delta-Akaike information criterion [∆AIC] = 12.47, ∆χ2 = 14.47
    P = 0.0001). Additionally, a pretransplant lung function score (pLFS) established by applying three parameters with superior predictive values including (Formula presented.) 50/ (Formula presented.) 25 represented a better discriminating variable for the prediction of survival. Our data demonstrate that a pLFS incorporating a parameter of small airway disease, rather than the parameters of central airway obstruction, may be useful for predicting patient survival following allo-HCT.

    DOI： 10.1111/tri.12779

    PubMed

  • THE ALTERATION OF IMMUNOPROFILE DURING DASATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A PROSPECTIVE OBSERVATIONAL STUDY Reviewed

    Kuno M, Nakamae H, Katayama T, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Nakashima Y, Koh H, Nakane T, Hino M

    HAEMATOLOGICA   101   457 - 457   2016.06（ ISSN:0390-6078 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Lung function score including a parameter of small airway disease as a highly predictive indicator of survival after allogeneic hematopoietic cell transplantation Reviewed

    Mika Nakamae, Mariko Yamashita, Hideo Koh, Mitsutaka Nishimoto, Yoshiki Hayashi, Takahiko Nakane, Yasuhiro Nakashima, Asao Hirose, Masayuki Hino, Hirohisa Nakamae

    Transplant International   29 ( 6 )   707 - 14   2016.06（ ISSN:0934-0874 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Some studies on the predictive value of determining pulmonary function prior to allogeneic hematopoietic cell transplantation (allo-HCT) have shown a significant association between pulmonary function test (PFT) parameters and pulmonary complications, and mortality. However, the percentage of patients showing abnormalities in pretransplant PFT parameters is low. We comprehensively evaluated the effect of pretransplant PFT parameters, including a marker of small airway disease (ratio of the airflow rate of 50% vital capacity to the airflow rate of 25% vital capacity ((Formula presented.) 50/ (Formula presented.) 25), on outcomes in 206 evaluable patients who underwent allo-HCT at our institute. Notable among the significant parameters in a univariable analysis, (Formula presented.) 50/ (Formula presented.) 25 was the most powerful indicator of survival following allo-HCT (delta-Akaike information criterion [∆AIC] = 12.47, ∆χ2 = 14.47
    P = 0.0001). Additionally, a pretransplant lung function score (pLFS) established by applying three parameters with superior predictive values including (Formula presented.) 50/ (Formula presented.) 25 represented a better discriminating variable for the prediction of survival. Our data demonstrate that a pLFS incorporating a parameter of small airway disease, rather than the parameters of central airway obstruction, may be useful for predicting patient survival following allo-HCT.

    DOI： 10.1111/tri.12779

    PubMed

  • Combinational approach using in situ hybridization targeting 23S ribosomal RNA genes and blood cultures for bacterial identification in patients with neutropenia and fever Reviewed

    Koh Hideo, Aimoto Mizuki, Matsuhisa Akio, Inoue Shin-Ichi, Katayama Takako, Okamura Hiroshi, Yoshimura Takuro, Koh Shiro, Nanno Satoru, Nishimoto Mitsutaka, Nakashima Yasuhiro, Hirose Asao, Nakamae Mika, Nakane Takahiko, Hino Masayuki, Nakamae Hirohisa

    JOURNAL OF INFECTION AND CHEMOTHERAPY   22 ( 9-10 )   697 - 703   2016（ ISSN:1341-321X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jiac.2016.08.001

    PubMed

  • Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease Reviewed

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    一般社団法人 日本内科学会　INTERNAL MEDICINE   55 ( 16 )   2265 - 2270   2016（ ISSN:0918-2918 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>We herein describe a case of myelodysplastic syndrome with chronic graft-versus-host disease (cGVHD)-related polymyositis. On approximately day 1,570 post HLA-identical sibling bone marrow transplant, the patient presented with a fever, myalgia and liver dysfunction. A muscle biopsy revealed destruction of the muscle fibers and infiltration of CD20<sup>+</sup> B cells and CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and a liver biopsy confirmed the findings of cGVHD. An analysis of plasma cytokine profiles indicated elevation of not only T-helper (Th)1 and Th2, but also Th17 cytokines. Increases in these cytokines in addition to the invasion of inflammatory cells might be associated with the pathophysiology of cGVHD involving the muscle and liver. </p>

    DOI： 10.2169/internalmedicine.55.6206

    PubMed

    CiNii Article

  • Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    Internal Medicine   55 ( 16 )   2265 - 70   2016（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>We herein describe a case of myelodysplastic syndrome with chronic graft-versus-host disease (cGVHD)-related polymyositis. On approximately day 1,570 post HLA-identical sibling bone marrow transplant, the patient presented with a fever, myalgia and liver dysfunction. A muscle biopsy revealed destruction of the muscle fibers and infiltration of CD20<sup>+</sup> B cells and CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and a liver biopsy confirmed the findings of cGVHD. An analysis of plasma cytokine profiles indicated elevation of not only T-helper (Th)1 and Th2, but also Th17 cytokines. Increases in these cytokines in addition to the invasion of inflammatory cells might be associated with the pathophysiology of cGVHD involving the muscle and liver. </p>

    DOI： 10.2169/internalmedicine.55.6206

    PubMed

    CiNii Article

  • Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease

    Koh Shiro, Koh Hideo, Nakashima Yasuhiro, Katayama Takako, Sakabe Manami, Okamura Hiroshi, Yoshimura Takuro, Nanno Satoru, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakane Takahiko, Nakamae Hirohisa, Ohsawa Masahiko, Hino Masayuki

    Internal Medicine   55 ( 16 )   2265 - 70   2016（ ISSN:0918-2918 ） （ eISSN:13497235 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    <p>We herein describe a case of myelodysplastic syndrome with chronic graft-versus-host disease (cGVHD)-related polymyositis. On approximately day 1,570 post HLA-identical sibling bone marrow transplant, the patient presented with a fever, myalgia and liver dysfunction. A muscle biopsy revealed destruction of the muscle fibers and infiltration of CD20<sup>+</sup> B cells and CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and a liver biopsy confirmed the findings of cGVHD. An analysis of plasma cytokine profiles indicated elevation of not only T-helper (Th)1 and Th2, but also Th17 cytokines. Increases in these cytokines in addition to the invasion of inflammatory cells might be associated with the pathophysiology of cGVHD involving the muscle and liver. </p>

    DOI： 10.2169/internalmedicine.55.6206

    PubMed

    CiNii Article

  • Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakane Takahiko, Nakamae Mika, Koh Hideo, Nishimoto Mitsutaka, Hayashi Yoshiki, Hirose Asao, Nakashima Yasuhiro, Hino Masayuki, Nakamae Hirohisa

    BLOOD   126 ( 23 )   2015.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakane Takahiko, Nakamae Mika, Koh Hideo, Nishimoto Mitsutaka, Hayashi Yoshiki, Hirose Asao, Nakashima Yasuhiro, Hino Masayuki, Nakamae Hirohisa

    BLOOD   126 ( 23 )   2015.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakane Takahiko, Nakamae Mika, Koh Hideo, Nishimoto Mitsutaka, Hayashi Yoshiki, Hirose Asao, Nakashima Yasuhiro, Hino Masayuki, Nakamae Hirohisa

    BLOOD   126 ( 23 )   2015.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakane Takahiko, Nakamae Mika, Koh Hideo, Nishimoto Mitsutaka, Hayashi Yoshiki, Hirose Asao, Nakashima Yasuhiro, Hino Masayuki, Nakamae Hirohisa

    BLOOD   126 ( 23 )   2015.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease Reviewed

    Nishimoto Mitsutaka, Koh Hideo, Hirose Asao, Nakamae Mika, Nakane Takahiko, Hayashi Yoshiki, Okamura Hiroshi, Yoshimura Takuro, Koh Shiro, Nanno Satoru, Nakashima Yasuhiro, Takeshita Toru, Yamamoto Akira, Sakai Yukimasa, Nishida Norifumi, Matsuoka Toshiyuki, Miki Yukio, Hino Masayuki, Nakamae Hirohisa

    EXPERIMENTAL HEMATOLOGY   43 ( 12 )   995 - 1000   2015.12（ ISSN:0301-472X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.exphem.2015.08.002

    PubMed

  • Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease Reviewed

    Mitsutaka Nishimoto, Hideo Koh, Asao Hirose, Mika Nakamae, Takahiko Nakane, Yoshiki Hayashi, Hiroshi Okamura, Takuro Yoshimura, Shiro Koh, Satoru Nanno, Yasuhiro Nakashima, Toru Takeshita, Akira Yamamoto, Yukimasa Sakai, Norifumi Nishida, Toshiyuki Matsuoka, Yukio Miki, Masayuki Hino, Hirohisa Nakamae

    EXPERIMENTAL HEMATOLOGY   43 ( 12 )   995 - 1000   2015.12（ ISSN:0301-472X ） （ eISSN:1873-2399 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    There is no established second-line treatment for steroid-resistant acute graft-versus-host disease (GVHD). We prospectively assessed the safety and efficacy of intra-arterial steroid infusions (IASIs) for steroid-resistant acute gastrointestinal (GI) GVHD and compared the outcomes with those of historical controls at our institution. Nineteen consecutive, allogeneic hematopoietic stem cell transplantation subjects aged 31-67 years (median 52) were enrolled between October, 2008, and November, 2012. Acute GVHD was confirmed by biopsy in all cases. The enrolled patients were treated with infusions of methylprednisolone into the mesenteric arteries and/or gastroduodenal and left gastric arteries. Fourteen consecutive patients who developed steroid-resistant acute GI GVHD between 2001 and 2008 were used as controls. For the primary endpoint at day 28, the overall and complete responses in the IASI group trended higher (79% vs. 42%, p = 0.066) and were significantly higher (63% vs. 21%, p = 0.033) than those in the control group. Although not statistically significant, owing to the small population, the crude day-180-nonrelapse mortality rate was about 20% lower and the day-180-overall-survival rate tended to be higher than the control (11% vs. 29%, p = 0.222; 79% vs. 50%, p = 0.109, respectively). There were no serious IASI-related complications. Our results suggest that IASI can safely provide excellent efficacy for refractory acute GI GVHD without increasing infection-related complications and may improve prognosis. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.

    DOI： 10.1016/j.exphem.2015.08.002

    PubMed

  • HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome Reviewed

    Nakamae Hirohisa, Koh Hideo, Katayama Takako, Nishimoto Mitsutaka, Hayashi Yoshiki, Nakashima Yasuhiro, Nakane Takahiko, Nakamae Mika, Hirose Asao, Hino Masayuki

    EXPERIMENTAL HEMATOLOGY   43 ( 11 )   921 - 929   2015.11（ ISSN:0301-472X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.exphem.2015.07.006

    PubMed

  • HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome Reviewed

    Hirohisa Nakamae, Hideo Koh, Takako Katayama, Mitsutaka Nishimoto, Yoshiki Hayashi, Yasuhiro Nakashima, Takahiko Nakane, Mika Nakamae, Asao Hirose, Masayuki Hino

    EXPERIMENTAL HEMATOLOGY   43 ( 11 )   921 - 929.e1   2015.11（ ISSN:0301-472X ） （ eISSN:1873-2399 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Nonmyeloablative, human leukocyte antigen (HLA) haploidentical, T-cell-replete bone marrow transplantation followed by high-dose posttransplantation cyclophosphamide (PT/Cy) has recently been developed. This transplantation milieu has resulted in favorable outcomes with low transplantation-related mortality, owing to a low incidence of graft-versus-host disease (GVHD), without increased infectious complications. However, the high relapse rate remains a major concern. We therefore performed a prospective pilot study of HLA haploidentical peripheral blood stem cell transplantation (PBSCT) with intensified conditioning, followed by two lower doses of PT/Cy. A total of 20 patients with refractory or poor-prognosis myelodysplastic syndrome (MDS) and leukemia were enrolled in the study. A trend toward a lower incidence of grade III-IV acute GVHD at day 100 in the group receiving 25 mg/kg x 2 doses of PT/Cy, compared with the group receiving 25 mg/kg of PT/Cy (9.1% vs. 33%, p = 0.20), was noted. However, the cumulative incidence of chronic GVHD was low, at 10% irrespective of PT/Cy dose. The number of infused CD34(+) cells significantly correlated with the grade of acute GVHD (p = 0.004). In addition, the occurrence of BK virus hemorrhagic cystitis was significantly more common in the double-dose PT/Cy group (25% vs. 0%, p = 0.043), especially when combined with busulfan. The probability of overall survival at 1 year in the double-dose group tended to be better compared with that in the single-dose group (64% vs. 44%, respectively; p = 0.20). In conclusion, HLA haploidentical, T-cell-replete PBSCT with 25 mg/kg x 2 doses of PT/Cy might be a feasible option for treating high-risk leukemia and MDS. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.

    DOI： 10.1016/j.exphem.2015.07.006

    PubMed

  • HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome Reviewed

    Hirohisa Nakamae, Hideo Koh, Takako Katayama, Mitsutaka Nishimoto, Yoshiki Hayashi, Yasuhiro Nakashima, Takahiko Nakane, Mika Nakamae, Asao Hirose, Masayuki Hino

    EXPERIMENTAL HEMATOLOGY   43 ( 11 )   921 - 929.e1   2015.11（ ISSN:0301-472X ） （ eISSN:1873-2399 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Nonmyeloablative, human leukocyte antigen (HLA) haploidentical, T-cell-replete bone marrow transplantation followed by high-dose posttransplantation cyclophosphamide (PT/Cy) has recently been developed. This transplantation milieu has resulted in favorable outcomes with low transplantation-related mortality, owing to a low incidence of graft-versus-host disease (GVHD), without increased infectious complications. However, the high relapse rate remains a major concern. We therefore performed a prospective pilot study of HLA haploidentical peripheral blood stem cell transplantation (PBSCT) with intensified conditioning, followed by two lower doses of PT/Cy. A total of 20 patients with refractory or poor-prognosis myelodysplastic syndrome (MDS) and leukemia were enrolled in the study. A trend toward a lower incidence of grade III-IV acute GVHD at day 100 in the group receiving 25 mg/kg x 2 doses of PT/Cy, compared with the group receiving 25 mg/kg of PT/Cy (9.1% vs. 33%, p = 0.20), was noted. However, the cumulative incidence of chronic GVHD was low, at 10% irrespective of PT/Cy dose. The number of infused CD34(+) cells significantly correlated with the grade of acute GVHD (p = 0.004). In addition, the occurrence of BK virus hemorrhagic cystitis was significantly more common in the double-dose PT/Cy group (25% vs. 0%, p = 0.043), especially when combined with busulfan. The probability of overall survival at 1 year in the double-dose group tended to be better compared with that in the single-dose group (64% vs. 44%, respectively; p = 0.20). In conclusion, HLA haploidentical, T-cell-replete PBSCT with 25 mg/kg x 2 doses of PT/Cy might be a feasible option for treating high-risk leukemia and MDS. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.

    DOI： 10.1016/j.exphem.2015.07.006

    PubMed

  • Effectiveness of antibacterial prophylaxis with non-absorbable polymyxin B compared to levofloxacin after allogeneic hematopoietic stem cell transplantation Reviewed

    Koh S., Yamada K., Nishimoto M., Hayashi Y., Koh H., Nakashima Y., Nakane T., Hirose A., Nakamae M., Kakeya H., Hino M., Nakamae H.

    TRANSPLANT INFECTIOUS DISEASE   17 ( 5 )   647 - 654   2015.10（ ISSN:1398-2273 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/tid.12416

  • Effectiveness of antibacterial prophylaxis with non-absorbable polymyxin B compared to levofloxacin after allogeneic hematopoietic stem cell transplantation Reviewed

    S. Koh, K. Yamada, M. Nishimoto, Y. Hayashi, H. Koh, Y. Nakashima, T. Nakane, A. Hirose, M. Nakamae, H. Kakeya, M. Hino, H. Nakamae

    TRANSPLANT INFECTIOUS DISEASE   17 ( 5 )   647 - 54   2015.10（ ISSN:1398-2273 ） （ eISSN:1399-3062 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    BackgroundFluoroquinolones are widely used for antibacterial prophylaxis during neutropenia following hematopoietic stem cell transplantation (HSCT). Nevertheless, data are inadequate as to whether fluoroquinolones decrease mortality rate compared with other antibiotics.
    MethodsWe retrospectively compared the efficacy of antibacterial prophylaxis using non-absorbable polymyxin B (PB) (n=106) or systemic levofloxacin (LVFX) (n=140) after allogeneic SCT at our institute between 2004 and 2013.
    ResultsNo significant difference was observed between the 2 groups in the cumulative incidences of failure of prophylaxis (P=0.21), clinically documented infections (P=0.70), or non-relapse mortality within the first 100days after transplantation (P=0.42). With bacteremia, the rate of resistance to LVFX was 82% in the PB group and 100% in the LVFX group (P=0.41). Also, no significant difference was found in overall survival between the 2 groups (P=0.78).
    ConclusionOur results indicate no difference in the effectiveness of antibacterial prophylaxis between systemic antibiotic LVFX and non-absorbable antibiotic PB.

    DOI： 10.1111/tid.12416

    PubMed

  • 初回治療としてCHOP-R療法を選択した縦隔原発大細胞型B細胞性リンパ腫 Reviewed

    田垣内 優美, 西本 光孝, 林 良樹, 幕内 陽介, 久野 雅智, 高桑 輝人, 岡村 浩史, 吉村 卓朗, 康 史朗, 南野 智, 廣瀬 朝生, 中前 美佳, 中嶋 康博, 康 秀男, 中根 孝彦, 中前 博久, 大澤 政彦, 日野 雅之

    「血液診療」編集委員会　血液診療   11 ( 1 )   16 - 20   2015.07

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は43歳、女性。前医にて前縦隔腫瘤を指摘され、胸腺癌の疑いで切除術を施行された。術後病理検査の結果、悪性リンパ腫の診断であった。当院にて精査の結果、縦隔原発大細胞型B細胞性リンパ腫(primary mediastinal large B-cell lymphoma、PMBL)の臨床病期IV期と診断した。初回治療としてCHOP-R療法を選択し、現在3コースまで施行し、経過良好である。PMBLはまれな疾患であり、リスク分類および治療選択に関してはまだ十分に確立されていない。今回我々は若年女性に発症した初発PMBLの1例を経験した。初回治療選択および長期治療戦略に関して文献的考察を加えて報告する。(著者抄録)

  • 初回治療としてCHOP-R療法を選択した縦隔原発大細胞型B細胞性リンパ腫 Reviewed

    田垣内 優美, 西本 光孝, 林 良樹, 幕内 陽介, 久野 雅智, 高桑 輝人, 岡村 浩史, 吉村 卓朗, 康 史朗, 南野 智, 廣瀬 朝生, 中前 美佳, 中嶋 康博, 康 秀男, 中根 孝彦, 中前 博久, 大澤 政彦, 日野 雅之

    「血液診療」編集委員会 血液診療   11 ( 1 )   16 - 20   2015.07

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は43歳、女性。前医にて前縦隔腫瘤を指摘され、胸腺癌の疑いで切除術を施行された。術後病理検査の結果、悪性リンパ腫の診断であった。当院にて精査の結果、縦隔原発大細胞型B細胞性リンパ腫(primary mediastinal large B-cell lymphoma、PMBL)の臨床病期IV期と診断した。初回治療としてCHOP-R療法を選択し、現在3コースまで施行し、経過良好である。PMBLはまれな疾患であり、リスク分類および治療選択に関してはまだ十分に確立されていない。今回我々は若年女性に発症した初発PMBLの1例を経験した。初回治療選択および長期治療戦略に関して文献的考察を加えて報告する。(著者抄録)

  • 初回治療としてCHOP-R療法を選択した縦隔原発大細胞型B細胞性リンパ腫 Reviewed

    田垣内 優美, 西本 光孝, 林 良樹, 幕内 陽介, 久野 雅智, 高桑 輝人, 岡村 浩史, 吉村 卓朗, 康 史朗, 南野 智, 廣瀬 朝生, 中前 美佳, 中嶋 康博, 康 秀男, 中根 孝彦, 中前 博久, 大澤 政彦, 日野 雅之

    「血液診療」編集委員会 血液診療   11 ( 1 )   16 - 20   2015.07

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は43歳、女性。前医にて前縦隔腫瘤を指摘され、胸腺癌の疑いで切除術を施行された。術後病理検査の結果、悪性リンパ腫の診断であった。当院にて精査の結果、縦隔原発大細胞型B細胞性リンパ腫(primary mediastinal large B-cell lymphoma、PMBL)の臨床病期IV期と診断した。初回治療としてCHOP-R療法を選択し、現在3コースまで施行し、経過良好である。PMBLはまれな疾患であり、リスク分類および治療選択に関してはまだ十分に確立されていない。今回我々は若年女性に発症した初発PMBLの1例を経験した。初回治療選択および長期治療戦略に関して文献的考察を加えて報告する。(著者抄録)

  • 初回治療としてCHOP-R療法を選択した縦隔原発大細胞型B細胞性リンパ腫

    田垣内 優美, 西本 光孝, 林 良樹, 幕内 陽介, 久野 雅智, 高桑 輝人, 岡村 浩史, 吉村 卓朗, 康 史朗, 南野 智, 廣瀬 朝生, 中前 美佳, 中嶋 康博, 康 秀男, 中根 孝彦, 中前 博久, 大澤 政彦, 日野 雅之

    血液診療   11 ( 1 )   16 - 20   2015.07

    　More details

    症例は43歳、女性。前医にて前縦隔腫瘤を指摘され、胸腺癌の疑いで切除術を施行された。術後病理検査の結果、悪性リンパ腫の診断であった。当院にて精査の結果、縦隔原発大細胞型B細胞性リンパ腫(primary mediastinal large B-cell lymphoma、PMBL)の臨床病期IV期と診断した。初回治療としてCHOP-R療法を選択し、現在3コースまで施行し、経過良好である。PMBLはまれな疾患であり、リスク分類および治療選択に関してはまだ十分に確立されていない。今回我々は若年女性に発症した初発PMBLの1例を経験した。初回治療選択および長期治療戦略に関して文献的考察を加えて報告する。(著者抄録)

  • Drug interaction and safety profiles of concomitant use of caspofungin and tacrolimus in allogeneic hematopoietic stem cell transplant recipients Reviewed

    Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Hayashi Y, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H

    BONE MARROW TRANSPLANTATION   50   S408 - S408   2015.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin Reviewed

    Nishimoto Mitsutaka, Nakamae Hirohisa, Koh Hideo, Nakamae Mika, Hirose Asao, Hayashi Yoshiki, Nakashima Yasuhiro, Nakane Takahiko, Hino Masayuki

    EXPERIMENTAL HEMATOLOGY   43 ( 3 )   177 - 179   2015.03（ ISSN:0301-472X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.exphem.2014.11.008

    PubMed

  • Drug interaction and safety profiles of concomitant use of caspofungin and tacrolimus in allogeneic hematopoietic stem cell transplant recipients Reviewed

    Nishimoto M., Koh H., Tokuwame A., Makuuchi Y., Kuno M., Takakuwa T., Okamura H., Koh S., Yoshimura T., Nanno S., Hayashi Y., Nakamae M., Hirose A., Nakashima Y., Nakane T., Hino M., Nakamae H.

    BONE MARROW TRANSPLANTATION   50   S408 - S408   2015.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Drug interaction and safety profiles of concomitant use of caspofungin and tacrolimus in allogeneic hematopoietic stem cell transplant recipients Reviewed

    Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Hayashi Y, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H

    BONE MARROW TRANSPLANTATION   50   S408 - S408   2015.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin Reviewed

    Mitsutaka Nishimoto, Hirohisa Nakamae, Hideo Koh, Mika Nakamae, Asao Hirose, Yoshiki Hayashi, Yasuhiro Nakashima, Takahiko Nakane, Masayuki Hino

    EXPERIMENTAL HEMATOLOGY   43 ( 3 )   177 - 9   2015.03（ ISSN:0301-472X ） （ eISSN:1873-2399 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Treatment for steroid-refractory acute graft-versus-host disease (GVHD) has not been established yet. In this article, we report a single-center experience with rabbit antithymocyte globulin (ATG) for the treatment of steroid-refractory acute GVHD. We retrospectively analyzed 11 consecutive patients between December 2009 and December 2013. ATG was given at an initial dose of 1.0 mg/kg for all but one patient with gradual dose escalation while assessing responses. The overall improvement at day 28 was 55% after a median of two treatments (range: 1-5), and a median dose of 3 mg/kg (range: 1.0-11.75 mg/kg) of ATG. Patients with skin (100%, 3/3) and gut (83%, 5/6) responded favorably, whereas the cases with liver involvement showed poor responses (25%, 1/4). The overall survival and transplant-related mortality at 1 year were 55% and 45%, respectively. There were no patients who had developed a posttransplant lymphoproliferative disorder. We suggest that response-guided ATG therapy could be an option for patients with steroid-refractory GVHD, without increasing the incidence of opportunistic infections. Copyright (C) 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.

    DOI： 10.1016/j.exphem.2014.11.008

    PubMed

  • Prognostic Value and Clinical Implication of Serum Ferritin Levels following Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakamae Mika, Nakamae Hirohisa, Koh Shiro, Koh Hideo, Nishimoto Mitsutaka, Nakashima Yasuhiro, Nakane Takahiko, Hirose Asao, Hino Masayuki

    ACTA HAEMATOLOGICA   133 ( 3 )   310 - 316   2015（ ISSN:0001-5792 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000365779

    PubMed

  • Prognostic Value and Clinical Implication of Serum Ferritin Levels following Allogeneic Hematopoietic Cell Transplantation Reviewed

    Mika Nakamae, Hirohisa Nakamae, Shiro Koh, Hideo Koh, Mitsutaka Nishimoto, Yasuhiro Nakashima, Takahiko Nakane, Asao Hirose, Masayuki Hino

    ACTA HAEMATOLOGICA   133 ( 3 )   310 - 6   2015（ ISSN:0001-5792 ） （ eISSN:1421-9662 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Little research has been done on changes in serum ferritin (s-ferritin) levels and clinical implications following allogeneic hematopoietic cell transplantation (HCT). We retrospectively evaluated the correlation of s-ferritin levels after HCT with survival in 203 patients. The s-ferritin level was significantly elevated, with 75% of the patients showing peak levels 90 days after HCT. The level was &gt; 10,000 ng/ml in a total of 43% of the patients, a finding that was associated with febrile neutropenia or infection. The s-ferritin level at day 30 and at 1 year after HCT was significantly associated with prognosis. However, this statistically significant relationship was lost after adjusting for acute-phase reactants. We conclude that hyperferritinemia is very common and the degree of influence of a red blood cell transfusion will vary depending on the phase after HCT. A prospective study is needed to determine if iron load in and of itself contributes to a worse prognosis after HCT. (C) 2014 S. Karger AG, Basel

    DOI： 10.1159/000365779

    PubMed

  • Prognostic Value and Clinical Implication of Serum Ferritin Levels following Allogeneic Hematopoietic Cell Transplantation Reviewed

    Mika Nakamae, Hirohisa Nakamae, Shiro Koh, Hideo Koh, Mitsutaka Nishimoto, Yasuhiro Nakashima, Takahiko Nakane, Asao Hirose, Masayuki Hino

    ACTA HAEMATOLOGICA   133 ( 3 )   310 - 6   2015（ ISSN:0001-5792 ） （ eISSN:1421-9662 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Little research has been done on changes in serum ferritin (s-ferritin) levels and clinical implications following allogeneic hematopoietic cell transplantation (HCT). We retrospectively evaluated the correlation of s-ferritin levels after HCT with survival in 203 patients. The s-ferritin level was significantly elevated, with 75% of the patients showing peak levels 90 days after HCT. The level was &gt; 10,000 ng/ml in a total of 43% of the patients, a finding that was associated with febrile neutropenia or infection. The s-ferritin level at day 30 and at 1 year after HCT was significantly associated with prognosis. However, this statistically significant relationship was lost after adjusting for acute-phase reactants. We conclude that hyperferritinemia is very common and the degree of influence of a red blood cell transfusion will vary depending on the phase after HCT. A prospective study is needed to determine if iron load in and of itself contributes to a worse prognosis after HCT. (C) 2014 S. Karger AG, Basel

    DOI： 10.1159/000365779

    PubMed

  • Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Koh Shiro, Nakamae Hirohisa, Yamada Koichi, Nishimoto Mitsutaka, Hayashi Yoshiki, Koh Hideo, Nakashima Yasuhiro, Nakane Takahiko, Hirose Asao, Nakamae Mika, Kakeya Hiroshi, Hino Masayuki

    BLOOD   124 ( 21 )   2014.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Koh Shiro, Nakamae Hirohisa, Yamada Koichi, Nishimoto Mitsutaka, Hayashi Yoshiki, Koh Hideo, Nakashima Yasuhiro, Nakane Takahiko, Hirose Asao, Nakamae Mika, Kakeya Hiroshi, Hino Masayuki

    BLOOD   124 ( 21 )   2014.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • The V50/V25 Ratio, a Marker of Small Airway Disease, Is Highly Predictive of Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakamae Mika, Nakamae Hirohisa, Yamashita Mariko, Nishimoto Mitsutaka, Hayashi Yoshiki, Koh Hideo, Nakane Takahiko, Nakashima Yasuhiro, Hirose Asao, Hino Masayuki

    BLOOD   124 ( 21 )   2014.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • The V50/V25 Ratio, a Marker of Small Airway Disease, Is Highly Predictive of Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakamae Mika, Nakamae Hirohisa, Yamashita Mariko, Nishimoto Mitsutaka, Hayashi Yoshiki, Koh Hideo, Nakane Takahiko, Nakashima Yasuhiro, Hirose Asao, Hino Masayuki

    BLOOD   124 ( 21 )   2014.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Koh Shiro, Nakamae Hirohisa, Yamada Koichi, Nishimoto Mitsutaka, Hayashi Yoshiki, Koh Hideo, Nakashima Yasuhiro, Nakane Takahiko, Hirose Asao, Nakamae Mika, Kakeya Hiroshi, Hino Masayuki

    BLOOD   124 ( 21 )   2014.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • The V50/V25 Ratio, a Marker of Small Airway Disease, Is Highly Predictive of Survival after Allogeneic Hematopoietic Cell Transplantation Reviewed

    Nakamae Mika, Nakamae Hirohisa, Yamashita Mariko, Nishimoto Mitsutaka, Hayashi Yoshiki, Koh Hideo, Nakane Takahiko, Nakashima Yasuhiro, Hirose Asao, Hino Masayuki

    BLOOD   124 ( 21 )   2014.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Cerebral toxoplasmosis after umbilical cord blood transplantation diagnosed by the detection of anti-toxoplasma specific IgM antibody in cerebrospinal fluid. Reviewed

    Inaba A, Koh H, Nakashima Y, Nishimoto M, Hayashi Y, Okamura H, Inoue A, Nanno S, Nakane T, Shimono T, Nakamae H, Hino M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   55 ( 4 )   456 - 60   2014.04（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • 髄液中特異的IgM抗体が診断に有用であった臍帯血移植後トキソプラズマ脳症 Reviewed

    稲葉 晃子, 康 秀男, 中嶋 康博, 西本 光孝, 林 良樹, 岡村 浩史, 井上 敦司, 南野 智, 中根 孝彦, 下野 太郎, 中前 博久, 日野 雅之

    (一社)日本血液学会-東京事務局 臨床血液   55 ( 4 )   456 - 460   2014.04（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は60歳女性。骨髄異形成症候群に対して,臍帯血移植を施行した。再発消化管急性GVHD(Grade 2)に対してtacrolimus/mPSLによる治療を行っていたところ,day 210に発熱と意識障害を発症し,頭部造影MRI検査で,左視床や基底核,脳幹,皮質下白質にリング状造影効果を認める多発結節影を認めた。髄液と血中の抗トキソプラズマIgM,IgG抗体価はともに上昇しており,特にIgM抗体価は髄液の方が高く,トキソプラズマ脳症と診断した。sulfamethoxazole/trimethoprim合剤内服,clindamycin点滴と抗浮腫治療を開始したところ,症状,画像所見とも改善傾向となり,day 229の血清抗体価は不変であったが,髄液中抗体価は明らかに低下し,軽快退院となった。移植後トキソプラズマ脳症は発症時の確定診断が難しいため,治療の遅れが懸念される致死的合併症であるが,髄液中の特異的IgM抗体測定は早期診断に有用であり,また髄液中抗体価の推移は治療効果を反映する可能性が示唆された。(著者抄録)

  • 髄液中特異的IgM抗体が診断に有用であった臍帯血移植後トキソプラズマ脳症 Reviewed

    稲葉 晃子, 康 秀男, 中嶋 康博, 西本 光孝, 林 良樹, 岡村 浩史, 井上 敦司, 南野 智, 中根 孝彦, 下野 太郎, 中前 博久, 日野 雅之

    (一社)日本血液学会-東京事務局　臨床血液   55 ( 4 )   456 - 460   2014.04（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は60歳女性。骨髄異形成症候群に対して,臍帯血移植を施行した。再発消化管急性GVHD(Grade 2)に対してtacrolimus/mPSLによる治療を行っていたところ,day 210に発熱と意識障害を発症し,頭部造影MRI検査で,左視床や基底核,脳幹,皮質下白質にリング状造影効果を認める多発結節影を認めた。髄液と血中の抗トキソプラズマIgM,IgG抗体価はともに上昇しており,特にIgM抗体価は髄液の方が高く,トキソプラズマ脳症と診断した。sulfamethoxazole/trimethoprim合剤内服,clindamycin点滴と抗浮腫治療を開始したところ,症状,画像所見とも改善傾向となり,day 229の血清抗体価は不変であったが,髄液中抗体価は明らかに低下し,軽快退院となった。移植後トキソプラズマ脳症は発症時の確定診断が難しいため,治療の遅れが懸念される致死的合併症であるが,髄液中の特異的IgM抗体測定は早期診断に有用であり,また髄液中抗体価の推移は治療効果を反映する可能性が示唆された。(著者抄録)

  • Cerebral toxoplasmosis after umbilical cord blood transplantation diagnosed by the detection of anti-toxoplasma specific IgM antibody in cerebrospinal fluid. Reviewed

    Inaba A, Koh H, Nakashima Y, Nishimoto M, Hayashi Y, Okamura H, Inoue A, Nanno S, Nakane T, Shimono T, Nakamae H, Hino M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   55 ( 4 )   456 - 60   2014.04（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    PubMed

  • [Cerebral toxoplasmosis after umbilical cord blood transplantation diagnosed by the detection of anti-toxoplasma specific IgM antibody in cerebrospinal fluid].

    Inaba A, Koh H, Nakashima Y, Nishimoto M, Hayashi Y, Okamura H, Inoue A, Nanno S, Nakane T, Shimono T, Nakamae H, Hino M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   55 ( 4 )   456 - 60   2014.04（ ISSN:0485-1439 ）

    　More details

  • 髄液中特異的IgM抗体が診断に有用であった臍帯血移植後トキソプラズマ脳症 Reviewed

    稲葉 晃子, 康 秀男, 中嶋 康博, 西本 光孝, 林 良樹, 岡村 浩史, 井上 敦司, 南野 智, 中根 孝彦, 下野 太郎, 中前 博久, 日野 雅之

    (一社)日本血液学会-東京事務局 臨床血液   55 ( 4 )   456 - 460   2014.04（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    症例は60歳女性。骨髄異形成症候群に対して,臍帯血移植を施行した。再発消化管急性GVHD(Grade 2)に対してtacrolimus/mPSLによる治療を行っていたところ,day 210に発熱と意識障害を発症し,頭部造影MRI検査で,左視床や基底核,脳幹,皮質下白質にリング状造影効果を認める多発結節影を認めた。髄液と血中の抗トキソプラズマIgM,IgG抗体価はともに上昇しており,特にIgM抗体価は髄液の方が高く,トキソプラズマ脳症と診断した。sulfamethoxazole/trimethoprim合剤内服,clindamycin点滴と抗浮腫治療を開始したところ,症状,画像所見とも改善傾向となり,day 229の血清抗体価は不変であったが,髄液中抗体価は明らかに低下し,軽快退院となった。移植後トキソプラズマ脳症は発症時の確定診断が難しいため,治療の遅れが懸念される致死的合併症であるが,髄液中の特異的IgM抗体測定は早期診断に有用であり,また髄液中抗体価の推移は治療効果を反映する可能性が示唆された。(著者抄録)

  • 髄液中特異的IgM抗体が診断に有用であった臍帯血移植後トキソプラズマ脳症

    稲葉 晃子, 康 秀男, 中嶋 康博, 西本 光孝, 林 良樹, 岡村 浩史, 井上 敦司, 南野 智, 中根 孝彦, 下野 太郎, 中前 博久, 日野 雅之

    臨床血液   55 ( 4 )   456 - 460   2014.04（ ISSN:0485-1439 ）

    　More details

    症例は60歳女性。骨髄異形成症候群に対して,臍帯血移植を施行した。再発消化管急性GVHD(Grade 2)に対してtacrolimus/mPSLによる治療を行っていたところ,day 210に発熱と意識障害を発症し,頭部造影MRI検査で,左視床や基底核,脳幹,皮質下白質にリング状造影効果を認める多発結節影を認めた。髄液と血中の抗トキソプラズマIgM,IgG抗体価はともに上昇しており,特にIgM抗体価は髄液の方が高く,トキソプラズマ脳症と診断した。sulfamethoxazole/trimethoprim合剤内服,clindamycin点滴と抗浮腫治療を開始したところ,症状,画像所見とも改善傾向となり,day 229の血清抗体価は不変であったが,髄液中抗体価は明らかに低下し,軽快退院となった。移植後トキソプラズマ脳症は発症時の確定診断が難しいため,治療の遅れが懸念される致死的合併症であるが,髄液中の特異的IgM抗体測定は早期診断に有用であり,また髄液中抗体価の推移は治療効果を反映する可能性が示唆された。(著者抄録)

  • Cerebral toxoplasmosis after umbilical cord blood transplantation diagnosed by the detection of anti-toxoplasma specific IgM antibody in cerebrospinal fluid. Reviewed

    Inaba A, Koh H, Nakashima Y, Nishimoto M, Hayashi Y, Okamura H, Inoue A, Nanno S, Nakane T, Shimono T, Nakamae H, Hino M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   55 ( 4 )   456 - 60   2014.04（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • DIAGNOSTIC VALUE OF SERUM FERRITIN AND RISK FACTORS FOR HEMOPHAGOCYTIC SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Reviewed

    Nanno S., Koh H., Nakashima Y., Katayama T., Kuno M., Makuuchi Y., Nagasaki J., Takakuwa T., Okamura H., Koh S., Yoshimura T., Nishimoto M., Nakamae M., Hirose A., Nakane T., Nakao Y., Nakamae H., Hino M.

    BONE MARROW TRANSPLANTATION   49   S472 - S473   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • PROMISING OUTCOMES FROM INTRA-ARTERIAL STEROID INFUSIONS IN PATIENTS WITH TREATMENT-RESISTANT ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Reviewed

    Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Nakashima Y, Takeshita T, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M

    BONE MARROW TRANSPLANTATION   49   S278 - S279   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • DIAGNOSTIC VALUE OF SERUM FERRITIN AND RISK FACTORS FOR HEMOPHAGOCYTIC SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Reviewed

    Nanno S, Koh H, Nakashima Y, Katayama T, Kuno M, Makuuchi Y, Nagasaki J, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nishimoto M, Nakamae M, Hirose A, Nakane T, Nakao Y, Nakamae H, Hino M

    BONE MARROW TRANSPLANTATION   49   S472 - S473   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • PROMISING OUTCOMES FROM INTRA-ARTERIAL STEROID INFUSIONS IN PATIENTS WITH TREATMENT-RESISTANT ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Reviewed

    Nishimoto M., Koh H., Nakamae H., Hirose A., Nakamae M., Nakane T., Hayashi Y., Okamura H., Yoshimura T., Koh S., Nanno S., Nakashima Y., Takeshita T., Yamamoto A., Sakai Y., Nishida N., Matsuoka T., Miki Y., Hino M.

    BONE MARROW TRANSPLANTATION   49   S278 - S279   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • DIAGNOSTIC VALUE OF SERUM FERRITIN AND RISK FACTORS FOR HEMOPHAGOCYTIC SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Reviewed

    Nanno S, Koh H, Nakashima Y, Katayama T, Kuno M, Makuuchi Y, Nagasaki J, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nishimoto M, Nakamae M, Hirose A, Nakane T, Nakao Y, Nakamae H, Hino M

    BONE MARROW TRANSPLANTATION   49   S472 - S473   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • PROMISING OUTCOMES FROM INTRA-ARTERIAL STEROID INFUSIONS IN PATIENTS WITH TREATMENT-RESISTANT ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Reviewed

    Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Nakashima Y, Takeshita T, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M

    BONE MARROW TRANSPLANTATION   49   S278 - S279   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • PROMISING OUTCOMES FROM INTRA-ARTERIAL STEROID INFUSIONS IN PATIENTS WITH TREATMENT-RESISTANT ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Reviewed

    Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Nakashima Y, Takeshita T, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M

    BONE MARROW TRANSPLANTATION   49   S278 - S279   2014.03（ ISSN:0268-3369 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Cerebral toxoplasmosis after umbilical cord blood transplantation diagnosed by the detection of anti-toxoplasma specific IgM antibody in cerebrospinal fluid Reviewed

    INABA Akiko, KOH Hideo, NAKASHIMA Yasuhiro, NISHIMOTO Mitsutaka, HAYASHI Yoshiki, OKAMURA Hiroshi, INOUE Atsushi, NANNO Satoru, NAKANE Takahiko, SHIMONO Taro, NAKAMAE Hirohisa, HINO Masayuki

    The Japanese Society of Hematology, Rinsho Ketsueki   55 ( 4 )   456 - 460   2014（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Cerebral toxoplasmosis is a rare, potentially fatal, complication of hematopoietic cell transplantation. Early definitive diagnosis is very difficult and it may be associated with a poor prognosis. Herein, we describe a 60-year-old woman who developed cerebral toxoplasmosis after cord blood transplantation for myelodysplastic syndrome. During treatment with tacrolimus and methylprednisolone for relapsed grade 2 acute gut GVHD, fever and disturbance of consciousness occurred on day 210. Brain MRI showed multiple ring-enhancing nodular lesions in the thalamus, basal ganglia, brainstem, and subcortical white matter. Cerebrospinal fluid (CSF) assessment revealed elevations of both anti-to-xoplasma IgM and IgG, which were also elevated in serum, but no evidence of other infections or malignancies. Notably, the IgM level was higher in the CSF than in serum. Thus, cerebral toxoplasmosis was diagnosed. Soon after administration of oral sulfamethoxazole/trimethoprim and intravenous clindamycin in combination with short-term dexamethasone for the cerebral edema, her symptoms and signs began to improve. On day 229, both IgM and IgG titers in CSF had clearly decreased but remained essentially constant in serum. She was discharged without clinically significant neurological disorders. This case suggests that CSF specific anti-toxoplasma IgM titers might be useful for early diagnosis of cerebral toxoplasmosis after transplantation.

    DOI： 10.11406/rinketsu.55.456

    CiNii Article

  • Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies Reviewed

    Aimoto Mizuki, Yamane Takahisa, Shiomoto Kazumasa, Sakamoto Chikahiko, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Takeoka Yasunobu, Hirose Asao, Nakamae Mika, Hagihara Kiyoyuki, Terada Yoshiki, Nakao Yoshitaka, Nakamae Hirohisa, Hino Masayuki, Miyata Shigeki

    INTERNATIONAL JOURNAL OF HEMATOLOGY   98 ( 4 )   472 - 477   2013.10（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-013-1427-4

    PubMed

  • 急性骨髄性白血病における血小板輸血不応状態は抗血小板第4因子/ヘパリン複合体抗体の吸光度と相関する(Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies) Reviewed

    Aimoto Mizuki, Yamane Takahisa, Shiomoto Kazumasa, Sakamoto Chikahiko, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Takeoka Yasunobu, Hirose Asao, Nakamae Mika, Hagihara Kiyoyuki, Terada Yoshiki, Nakao Yoshitaka, Nakamae Hirohisa, Hino Masayuki, Miyata Shigeki

    (一社)日本血液学会 International Journal of Hematology   98 ( 4 )   472 - 477   2013.10（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    66歳女性。10日前に発熱および上気道症状が出現し、他院にて肺炎および急性骨髄性白血病(AML)と診断され、当院に転院となった。血小板輸血を行うも血小板数低値が持続し、ヒト白血球抗原(HLA)適合血小板輸血、副腎皮質ステロイド投与、高用量免疫グロブリン静注を行っても血小板輸血不応状態は改善しなかった。へパリン起因性血小板減少症の可能性を考慮し、9日目にヘパリンフラッシュを中止、ELISA法にて抗血小板第4因子(PF4)/ヘパリン複合体抗体を測定したところ、吸光度(OD)は2.1と高値を示した。21日目(ヘパリンフラッシュ中止12日後)に血小板輸血不応状態は消散し、AMLに対する化学療法を開始した。2コース実施後に完全寛解が得られたが、地固め療法実施下で再発をきたし死亡した。その後の検討で、抗PF4/ヘパリン複合体抗体のOD値の漸減と、OD値が1.0未満へ至ったときに血小板輸血不応状態が消散していた。

  • 急性骨髄性白血病における血小板輸血不応状態は抗血小板第4因子/ヘパリン複合体抗体の吸光度と相関する(Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies) Reviewed

    Aimoto Mizuki, Yamane Takahisa, Shiomoto Kazumasa, Sakamoto Chikahiko, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Takeoka Yasunobu, Hirose Asao, Nakamae Mika, Hagihara Kiyoyuki, Terada Yoshiki, Nakao Yoshitaka, Nakamae Hirohisa, Hino Masayuki, Miyata Shigeki

    (一社)日本血液学会　International Journal of Hematology   98 ( 4 )   472 - 477   2013.10（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    66歳女性。10日前に発熱および上気道症状が出現し、他院にて肺炎および急性骨髄性白血病(AML)と診断され、当院に転院となった。血小板輸血を行うも血小板数低値が持続し、ヒト白血球抗原(HLA)適合血小板輸血、副腎皮質ステロイド投与、高用量免疫グロブリン静注を行っても血小板輸血不応状態は改善しなかった。へパリン起因性血小板減少症の可能性を考慮し、9日目にヘパリンフラッシュを中止、ELISA法にて抗血小板第4因子(PF4)/ヘパリン複合体抗体を測定したところ、吸光度(OD)は2.1と高値を示した。21日目(ヘパリンフラッシュ中止12日後)に血小板輸血不応状態は消散し、AMLに対する化学療法を開始した。2コース実施後に完全寛解が得られたが、地固め療法実施下で再発をきたし死亡した。その後の検討で、抗PF4/ヘパリン複合体抗体のOD値の漸減と、OD値が1.0未満へ至ったときに血小板輸血不応状態が消散していた。

  • Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies Reviewed

    Mizuki Aimoto, Takahisa Yamane, Kazumasa Shiomoto, Chikahiko Sakamoto, Yasuhiro Nakashima, Hideo Koh, Takahiko Nakane, Yasunobu Takeoka, Asao Hirose, Mika Nakamae, Kiyoyuki Hagihara, Yoshiki Terada, Yoshitaka Nakao, Hirohisa Nakamae, Masayuki Hino, Shigeki Miyata

    International Journal of Hematology   98 ( 4 )   472 - 477   2013.10（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    A small number of reports have described cases of heparin-induced thrombocytopenia complicating hematological disorders with impaired platelet production. We describe the case of a 66-year-old woman with acute myeloid leukemia who exhibited unexplained refractoriness to platelet transfusion, while receiving heparin flushes, and was found to have anti-platelet factor 4 (PF4)/heparin antibodies with high optical density (OD) values (&gt
    2 units) detected by an enzyme-linked immunosorbent assay. After cessation of heparin flushes, her refractoriness to platelet transfusion resolved. We retrospectively confirmed that the OD values for anti-PF4/heparin antibodies declined gradually
    refractoriness to platelet transfusion resolved when the OD values fell below 1.0 units. Given the absence of any other evident explanation for this phenomenon, and the correlation between the OD values for anti-PF4/heparin antibodies and the efficacy of platelet transfusions, we conclude that the patient's refractoriness to platelet transfusion was most likely caused by anti-PF4/heparin antibodies that had platelet-activating properties. © 2013 The Japanese Society of Hematology.

    DOI： 10.1007/s12185-013-1427-4

    PubMed

  • 急性骨髄性白血病における血小板輸血不応状態は抗血小板第4因子/ヘパリン複合体抗体の吸光度と相関する(Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies) Reviewed

    Aimoto Mizuki, Yamane Takahisa, Shiomoto Kazumasa, Sakamoto Chikahiko, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Takeoka Yasunobu, Hirose Asao, Nakamae Mika, Hagihara Kiyoyuki, Terada Yoshiki, Nakao Yoshitaka, Nakamae Hirohisa, Hino Masayuki, Miyata Shigeki

    (一社)日本血液学会 International Journal of Hematology   98 ( 4 )   472 - 477   2013.10（ ISSN:0925-5710 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    66歳女性。10日前に発熱および上気道症状が出現し、他院にて肺炎および急性骨髄性白血病(AML)と診断され、当院に転院となった。血小板輸血を行うも血小板数低値が持続し、ヒト白血球抗原(HLA)適合血小板輸血、副腎皮質ステロイド投与、高用量免疫グロブリン静注を行っても血小板輸血不応状態は改善しなかった。へパリン起因性血小板減少症の可能性を考慮し、9日目にヘパリンフラッシュを中止、ELISA法にて抗血小板第4因子(PF4)/ヘパリン複合体抗体を測定したところ、吸光度(OD)は2.1と高値を示した。21日目(ヘパリンフラッシュ中止12日後)に血小板輸血不応状態は消散し、AMLに対する化学療法を開始した。2コース実施後に完全寛解が得られたが、地固め療法実施下で再発をきたし死亡した。その後の検討で、抗PF4/ヘパリン複合体抗体のOD値の漸減と、OD値が1.0未満へ至ったときに血小板輸血不応状態が消散していた。

  • 急性骨髄性白血病における血小板輸血不応状態は抗血小板第4因子/ヘパリン複合体抗体の吸光度と相関する(Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies)

    Aimoto Mizuki, Yamane Takahisa, Shiomoto Kazumasa, Sakamoto Chikahiko, Nakashima Yasuhiro, Koh Hideo, Nakane Takahiko, Takeoka Yasunobu, Hirose Asao, Nakamae Mika, Hagihara Kiyoyuki, Terada Yoshiki, Nakao Yoshitaka, Nakamae Hirohisa, Hino Masayuki, Miyata Shigeki

    International Journal of Hematology   98 ( 4 )   472 - 477   2013.10（ ISSN:0925-5710 ）

    　More details

    66歳女性。10日前に発熱および上気道症状が出現し、他院にて肺炎および急性骨髄性白血病(AML)と診断され、当院に転院となった。血小板輸血を行うも血小板数低値が持続し、ヒト白血球抗原(HLA)適合血小板輸血、副腎皮質ステロイド投与、高用量免疫グロブリン静注を行っても血小板輸血不応状態は改善しなかった。へパリン起因性血小板減少症の可能性を考慮し、9日目にヘパリンフラッシュを中止、ELISA法にて抗血小板第4因子(PF4)/ヘパリン複合体抗体を測定したところ、吸光度(OD)は2.1と高値を示した。21日目(ヘパリンフラッシュ中止12日後)に血小板輸血不応状態は消散し、AMLに対する化学療法を開始した。2コース実施後に完全寛解が得られたが、地固め療法実施下で再発をきたし死亡した。その後の検討で、抗PF4/ヘパリン複合体抗体のOD値の漸減と、OD値が1.0未満へ至ったときに血小板輸血不応状態が消散していた。

  • [PD-1 expressing T cells in leukemia]. Reviewed

    Nakashima Y, Minato N

    [Rinsho ketsueki] The Japanese journal of clinical hematology   53 ( 5 )   515 - 20   2012.05（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    PubMed

  • [PD-1 expressing T cells in leukemia]. Reviewed

    Nakashima Y, Minato N

    [Rinsho ketsueki] The Japanese journal of clinical hematology   53 ( 5 )   515 - 20   2012.05（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • [PD-1 expressing T cells in leukemia]. Reviewed

    Nakashima Y, Minato N

    [Rinsho ketsueki] The Japanese journal of clinical hematology   53 ( 5 )   515 - 20   2012.05（ ISSN:0485-1439 ）

    　More details

    Publishing type：Research paper (scientific journal)  

  • Clinical Significance of 4C8 Antigen Expression on Acute Leukemic Cells and Neutrophils Reviewed

    Nakashima Yasuhiro

    Osaka City University, The journal of the Osaka City Medical Center   59   11 - 16   2010.06（ ISSN:03864103 ）

    　More details

    Publishing type：Research paper (scientific journal)   Kind of work：Single Work  

    CiNii Article

  • 急性白血病細胞および好中球における4C8抗原発現の臨床的意義の検討 Reviewed

    中嶋 康博

    大阪市医学会　大阪市医学会雑誌   59 ( 1-2 )   11 - 16   2010.06（ ISSN:0386-4103 ）

    　More details

    Publishing type：Research paper (scientific journal)   Kind of work：Single Work  

    【目的】4C8抗原は健常人の末梢リンパ球、単球および好酸球において高い発現が認められる一方、好中球では発現しない。本論文では様々な病態での4C8抗原の発現、とりわけ顆粒球系細胞での発現の臨床的意義を検討する。【対象と方法】白血病株および急性白血病細胞における4C8抗原の発現を検討した。対象は9例の急性リンパ性白血病(acute lymphoblastic leukemia;ALL)患者および18例の急性骨髄性白血病(acute myeloblastic leukemia;AML)で、検体は末梢血もしくは骨髄液を使用した。4C8抗原の発現はフローサイトメーターならびにWestern Blot法により検出した。さらに9例の感染症患者と20例の慢性腎不全血液透析患者の末梢好中球における4C8抗原の発現を、健常人の好中球と比較検討した。【結果】4C8抗原の発現は、単球性白血病細胞株であるTHP-1にのみ発現し、他の細胞株では認められなかった。ALL患者の白血病細胞では全例に4C8抗原の発現を認めたのに対し、AMLではFrench-American-British(FAB)分類のM2、M3の患者において4C8抗原は発現していなかった。Western blotの結果、フローサイトメーターで4C8抗原を発現していた白血病症例では、全例において末梢血単球細胞と同様の、80kDaのタンパク発現を認めた。感染症患者および慢性腎不全血液透析患者の末梢血好中球の4C8抗原陽性率は、健常人の好中球に比較し、共に有意に高値であった。【結論】抗4C8抗体は急性白血病における補助診断の一つとして有用であると考えられた。また、何らかの刺激が加わるような病態では、健常人の末梢好中球においても発現が亢進すると考えられた。(著者抄録)

  • 急性白血病細胞および好中球における4C8抗原発現の臨床的意義の検討

    中嶋 康博

    大阪市医学会雑誌   59 ( 1-2 )   11 - 16   2010.06（ ISSN:0386-4103 ）

    　More details

    【目的】4C8抗原は健常人の末梢リンパ球、単球および好酸球において高い発現が認められる一方、好中球では発現しない。本論文では様々な病態での4C8抗原の発現、とりわけ顆粒球系細胞での発現の臨床的意義を検討する。【対象と方法】白血病株および急性白血病細胞における4C8抗原の発現を検討した。対象は9例の急性リンパ性白血病(acute lymphoblastic leukemia;ALL)患者および18例の急性骨髄性白血病(acute myeloblastic leukemia;AML)で、検体は末梢血もしくは骨髄液を使用した。4C8抗原の発現はフローサイトメーターならびにWestern Blot法により検出した。さらに9例の感染症患者と20例の慢性腎不全血液透析患者の末梢好中球における4C8抗原の発現を、健常人の好中球と比較検討した。【結果】4C8抗原の発現は、単球性白血病細胞株であるTHP-1にのみ発現し、他の細胞株では認められなかった。ALL患者の白血病細胞では全例に4C8抗原の発現を認めたのに対し、AMLではFrench-American-British(FAB)分類のM2、M3の患者において4C8抗原は発現していなかった。Western blotの結果、フローサイトメーターで4C8抗原を発現していた白血病症例では、全例において末梢血単球細胞と同様の、80kDaのタンパク発現を認めた。感染症患者および慢性腎不全血液透析患者の末梢血好中球の4C8抗原陽性率は、健常人の好中球に比較し、共に有意に高値であった。【結論】抗4C8抗体は急性白血病における補助診断の一つとして有用であると考えられた。また、何らかの刺激が加わるような病態では、健常人の末梢好中球においても発現が亢進すると考えられた。(著者抄録)

  • PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia. Reviewed

    Shimatani K, Nakashima Y, Hattori M, Hamazaki Y, Minato N

    Proceedings of the National Academy of Sciences of the United States of America   106 ( 37 )   15807 - 12   2009.09（ ISSN:0027-8424 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1073/pnas.0908805106

    PubMed

  • PD-1(+) memory phenotype CD4(+) T cells expressing C/EBP alpha underlie T cell immunodepression in senescence and leukemia Reviewed

    Kenichiro Shimatani, Yasuhiro Nakashima, Masakazu Hattori, Yoko Hamazaki, Nagahiro Minato

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   106 ( 37 )   15807 - 15812   2009.09（ ISSN:0027-8424 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Although altered T cell function plays a part in immunosenescence, the mechanisms remain uncertain. Here we identify a bona fide age-dependent PD-1(+) memory phenotype (MP) CD4(+) T cell sub-population that hardly proliferates in response to T cell receptor (TCR) stimulation and produces abundant osteopontin at the cost of typical T cell lymphokines. These T cells demonstrate impaired repopulation in Rag2(-/-) mice, but a homeostatic proliferation in gamma-ray-irradiated mice. These T cells also reveal a unique molecular signature, including a strong expression of C/EBP alpha normally expressed in myeloid-lineage cells, with diminished c-Myc and cyclin D1. Transduction of Cebpa in regular CD4(+) T cells inhibited the TCR-mediated proliferation with c-Myc and cyclin D1 repression and caused a striking activation of Spp1 encoding osteopontin along with concomitant repression of T cell lymphokine genes. Although these T cells gradually increase in number with age and become predominant at the senescent stage in normal mice, the generation is robustly accelerated during leukemia. In both conditions, their predominance is associated with the diminution of specific CD4(+) T cell response. The results suggest that global T cell immunodepression in senescence and leukemia is attributable to the increase in PD-1(+) MP CD4(+) T cells expressing C/EBP alpha.

    DOI： 10.1073/pnas.0908805106

  • PD-1(+) memory phenotype CD4(+) T cells expressing C/EBP alpha underlie T cell immunodepression in senescence and leukemia Reviewed

    Kenichiro Shimatani, Yasuhiro Nakashima, Masakazu Hattori, Yoko Hamazaki, Nagahiro Minato

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   106 ( 37 )   15807 - 15812   2009.09（ ISSN:0027-8424 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Although altered T cell function plays a part in immunosenescence, the mechanisms remain uncertain. Here we identify a bona fide age-dependent PD-1(+) memory phenotype (MP) CD4(+) T cell sub-population that hardly proliferates in response to T cell receptor (TCR) stimulation and produces abundant osteopontin at the cost of typical T cell lymphokines. These T cells demonstrate impaired repopulation in Rag2(-/-) mice, but a homeostatic proliferation in gamma-ray-irradiated mice. These T cells also reveal a unique molecular signature, including a strong expression of C/EBP alpha normally expressed in myeloid-lineage cells, with diminished c-Myc and cyclin D1. Transduction of Cebpa in regular CD4(+) T cells inhibited the TCR-mediated proliferation with c-Myc and cyclin D1 repression and caused a striking activation of Spp1 encoding osteopontin along with concomitant repression of T cell lymphokine genes. Although these T cells gradually increase in number with age and become predominant at the senescent stage in normal mice, the generation is robustly accelerated during leukemia. In both conditions, their predominance is associated with the diminution of specific CD4(+) T cell response. The results suggest that global T cell immunodepression in senescence and leukemia is attributable to the increase in PD-1(+) MP CD4(+) T cells expressing C/EBP alpha.

    DOI： 10.1073/pnas.0908805106

  • Essential role of Rap signal in pre-TCR-mediated beta-selection checkpoint in alphabeta T-cell development. Reviewed

    Kometani K, Moriyama M, Nakashima Y, Katayama Y, Wang SF, Yamasaki S, Saito T, Hattori M, Minato N

    Blood   112 ( 12 )   4565 - 73   2008.12（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2008-06-164517

    PubMed

  • Essential role of Rap signal in pre-TCR-mediated beta-selection checkpoint in alpha beta T-cell development Reviewed

    Kohei Kometani, Masaki Moriyama, Yasuhiro Nakashima, Yoshinori Katayama, Shu-Fang Wang, Sho Yamasaki, Takashi Saito, Masakazu Hattori, Nagahiro Minato

    BLOOD   112 ( 12 )   4565 - 4573   2008.12（ ISSN:0006-4971 ） （ eISSN:1528-0020 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    We demonstrate that lck promoter-driven conditional expression of transgenic SPA-1, a Rap GTPase-activation protein, causes a profound defect of alpha beta T-cell development at the CD4/CD8 double-negative (DN) stage due to enhanced cell death without affecting gamma delta T-cell development. The effect was specific to the DN stage, because CD4 promoter-driven SPA-1 expression hardly affected T-cell development. Rap1A17, a dominant-negative Rap mutant, interfered with the generation of double-positive (DP) cells from Rag2(-/-) fetal thymocytes in vitro in the presence of anti-CD3 epsilon antibody and Notch ligand. Rap GTPases were activated in a DN cell line by the expression of self-oligomerizing CD3 (CD8:CD3 epsilon chimera), which substituted autonomous pre-T-cell receptor (TCR) signal, inducing CD69 expression and CD25 down-regulation. Reciprocally, expression of C3G, a Rap guanine nucleotide exchange factor, in both normal and Rag2(-/-) DN cells markedly enhanced Notch-dependent generation and expansion of DP cells without additional anti-CD3 epsilon antibody, thus bypassing pre-TCR. Defective alpha beta T-cell development in the conditional SPA-1-transgenic mice was restored completely by introducing a p53(-/-) mutation. These results suggest that endogenous Rap GTPases downstream of pre-TCR play an essential role in rescuing pre-T cells from the p53-mediated checkpoint response, thus allowing Notch-mediated expansion and differentiation. (Blood. 2008; 112: 4565-4573)

    DOI： 10.1182/blood-2008-06-164517

  • Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. Reviewed

    Wang SF, Aoki M, Nakashima Y, Shinozuka Y, Tanaka H, Taniwaki M, Hattori M, Minato N

    Blood   111 ( 5 )   2878 - 86   2008.03（ ISSN:0006-4971 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2007-07-103119

    PubMed

▼display all

MISC

▼display all

Presentations

▼display all

Grant-in-Aid for Scientific Research

  • PTCyによる造血細胞移植の国際標準化に向けて：抗腫瘍効果を効果的に誘導するには?

    Grant-in-Aid for Scientific Research(C)  2027

  • PTCyによる造血細胞移植の国際標準化に向けて：抗腫瘍効果を効果的に誘導するには?

    Grant-in-Aid for Scientific Research(C)  2026

  • meniscal regeneration by endogenous mobilization and transplantation of Muse cells

    Grant-in-Aid for Scientific Research(C)  2026

  • PTCyによる造血細胞移植の国際標準化に向けて：抗腫瘍効果を効果的に誘導するには?

    Grant-in-Aid for Scientific Research(C)  2025

  • meniscal regeneration by endogenous mobilization and transplantation of Muse cells

    Grant-in-Aid for Scientific Research(C)  2025

  • PTCyによる造血細胞移植の国際標準化に向けて：抗腫瘍効果を効果的に誘導するには?

    Grant-in-Aid for Scientific Research(C)  2024

  • meniscal regeneration by endogenous mobilization and transplantation of Muse cells

    Grant-in-Aid for Scientific Research(C)  2024

▼display all

Charge of on-campus class subject

  • 分子生物学検査

    2018     Undergraduate